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Fungi are pathogenic to plants, humans, and animals, and secondary 
metabolites produced by fungi are implicated in these interactions. As part of an 
interdisciplinary project to identify the chemical and genomic differences between 
pathogenic and non-pathogenic fungi, this research identified the chemical differences 
among Aspergillus section Fumigati. During the research, eight fungal strains were 
grown under three different temperatures, and 13 different media types were evaluated 
for their chemical diversity. Chemical studies resulted in 30 secondary metabolites and a 
variety of chemometric comparisons. The characterized secondary metabolites were 
compared between strains using several different methodologies, including 
chemometrics, dereplication, and biosynthetic gene clusters. These comparisons shed 
light on how secondary metabolites affect pathogenicity in Aspergillus section Fumigati. 
Bioinformatic analysis of the genome of Aspergillus fischeri predicted the presence of 48 
biosynthetic gene clusters, yet only 5 classes of secondary metabolites were identified 
by chemical characterization. Interaction-driven secondary metabolite discovery (i.e., co-
culturing) was used to activate silent biosynthetic gene clusters. This methodology was 
utilized successfully by co-culturing A. fischeri and Xylaria flabelliformis, which produces 
the FDA-approved antifungal drug griseofulvin; to activate secondary metabolites not 
observed when the two fungi were grown in monoculture. The co-culture resulted in the 
characterization of a novel scaffold with cytotoxic activity. 
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Fungi are morphologically, phylogenetically, and chemically diverse with 
estimates ranging from 2 to 5 million species.1, 2 They naturally grow in a broad range of 
environments, such as soil, rhizospheres, plants, and human fluids and tissues.3, 4 This 
environmental diversity leads to a high chemical diversity, which fungi can 
biosynthetically produce and jettison into their environment.5 These chemicals are known 
as secondary metabolites, which are small molecular weight compounds that are not 
necessary for growth and reproduction but are likely biosynthesized for self-protection 
and to gain an ecological advantage.6, 7  
Fungi produce a wide range of secondary metabolites, such as mycotoxins, 
pigments, and antibiotics.6-8 Secondary metabolite biosynthesis is encoded by 
biosynthetic gene clusters,9-12 these gene clusters encode for several pathways, such as 
polyketide synthase (PKSs), non-ribosomal peptide synthases (NRPSs), as well as 
pathways that lead to terpenes.10, 12, 13 With recent advances in the next generation 
sequencing of fungal genomes, secondary metabolites can now be linked to their 
biosynthetic gene clusters at least for those clusters which are known to produce a 
product(s).14-19 Fungi are pathogenic to plants, humans and animals, and secondary 
metabolites produced by fungi are implicated in these interactions.17, 20-22 
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Aspergillus fumigatus is a common sporulating fungus found in the environment. 
Healthy individuals exposed to A. fumigatus will have little to no symptoms while people 
with compromised immune systems are at a greater risk of life-threatening 
altercations.23, 24 Aspergillus fumigatus infections can range from mild to severe. The 
most severe and life threatening is invasive aspergillosis, which commonly only affects 
immunocompromised individuals (weakened immune systems).25 Aspergillus fumigatus 
has many traits that enable it to become an invasive human pathogen, these traits are 
known as “cards of virulence.26” Some of these “cards of virulence” are secondary 
metabolites that allow A. fumigatus to protect itself from the host immune response, 
impair the host immune system, or acquire key nutrients.20, 27-33 Some of the important 
secondary metabolites are gliotoxin which helps A. fumigatus evade the host immune 
response;34, 35 fumitremorgin which inhibits the breast cancer resistance protein;36 
fumagillin which causes epithelial cell damage37, 38 and impairs the function of 
neutrophils;39, 40 and pseurotin which inhibits immunoglobulin E.41  
In the family Aspergillaceae, section Fumigati, A. fischeri and A. 
oerlinghausenensis are perceived as the closest relative to A. fumigatus. Yet, A. fischeri 
and A. oerlinghausenensis are rarely seen to cause aspergillosis, the main divergence in 
their genomes is in the genes that encode for secondary metabolite biosynthesis.42 For 
example, ~85% of the non-secondary metabolism genes are conserved between A. 
fumigatus and A. fischeri including 48/49 genes known to be involved in virulence.16, 22 
However, only 10/33 of A. fumigatus biosynthetic gene clusters are conserved in A. 
fischeri.16 It is important to gain insights into the underlying cause of this difference in 
pathogenicity. Secondary metabolites gene cluster seem to be the most divergent and 
seem to play a key role in virulence.16 Thus, it is essential to understand how chemical 
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diversity of secondary metabolites produced by these closely related yet diverse 
genotypes contributes to the evolution of a deadly pathogen. 
Genome studies have shown that fungi have a rich diversity of secondary 
metabolite pathways, but the genes and gene clusters in these biosynthetic pathways, 
and their secondary metabolite products, are largely unknown.13, 43-50 With so much 
unknown biosynthetic potential, there is a pressing need to uncover ways to turn on 
secondary metabolite biosynthesis in fungi, potentially uncovering new chemical 
diversity. Interaction-driven secondary metabolite discovery (i.e. co-culturing) has been 
used to activate these silent biosynthetic gene clusters.15, 51-56 It works by mimicking the 
complex environments in which fungi naturally interact.3, 4, 29 Co-culturing can cause 
stress for nutrients and space on both fungi, and it could accelerate the activation of 
unique secondary metabolites that may give a survival edge to the fungus.3, 57-61 
However, under standard laboratory conditions, fungi have been shown to produce only 
a fraction of their potential secondary metabolites,10, 18, 43, 47-49 but not other silent 
secondary metabolites, which are hypothesized to be active in the context of ‘fighting’ 
with another organism. Therefore, the strategy of co-culturing two fungi in a controlled 
environment can be a practical application for undiscovered secondary metabolites 
through interspecies crosstalk.43 These fungi are confined to a space with limited 
nutrients and territory, which will cause them to interact by mostly two ways: 1) the 
inhibition of one fungus, or 2) one fungus will use up all the resources, which will make 
them not available for the other fungus, essentially causing it to stress.62 Such 
experimental studies shed light on the biological roles of secondary metabolites in fungi 
as well as increase knowledge of fungal chemical diversity. 
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The accurate characterization of secondary metabolites is important since they 
play a key role in a variety of different biological functions. Secondary metabolite 
characterization is primarily done through the determination of the molecular formula 
(mass spectrometry) and the interpretation of a suite of NMR experiments.63-68 During 
the structure elucidation process many factors can lead to the assignment of an incorrect 
structure,69-71 with some of the most common being double bonds72-76 and a change in 
functional group locations.77, 78 There is the need for the development of orthogonal 
techniques to either assign or verify the de novo structure elucidation of secondary 
metabolites. In 2008,79 ozone-induced dissociation mass spectrometry (OzID-MS) was 
introduced into the field of lipidomics to identify the location of double bonds.80-85 The 
mechanism of OzID-MS is based on the fundamentals of the ozonolysis reaction and 
takes place in the gas phase inside a mass spectrometer.86 This results in a predictable 
cleavage pattern that accurately pinpoints the location of double bonds, which can serve 
as an orthogonal structure elucidation tool.79, 80, 82, 85 Identification of the absolute 
configuration of secondary metabolites also plays a key role in biological function.87 
There are several traditional methods to probe the relative/absolute configuration of 
natural products, such as, total synthesis,88-90 X-ray crystallography,91-94 Mosher’s ester 
method,95, 96 Marfey’s reagent,97, 98 NOESY/ROSEY NMR,64 and ECD (Electric Circular 
Dichroism).99, 100 While all these methods provide accurate results, not all secondary 
metabolites are created equal and there is need for the development and use of new 
methods. GIAO NMR and optical rotation calculations have been shown to accurately 
provide the absolute configuration of a broad range of natural products, by calculating 
the 1H and 13C NMR data and the [α]D.101-111 
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This dissertation represents part of the findings of my research, which studies the 
secondary metabolism of Ascomycota fungi. Specific focus includes understanding the 
chemical difference between pathogenic and non-pathogenic fungi; co-culturing fungi to 
increase chemical diversity, as a source of biologically active novel scaffolds, and 
development of techniques to aid in the structure elucidation of secondary metabolites.  
This dissertation includes chapters devoted to the isolation, characterization, 
chemometric analysis, and biological assessment of secondary metabolites from 
Ascomycota fungi for the understanding of how secondary metabolites differ between 
related species. So far, 9 strains have been genetically and chemically characterized, 
with more than 30 compounds identified from several different environmental conditions.  
Chapters 2-4 presents the understanding the secondary metabolites produced by 
section Fumigati fungi and how they are chemically and genetically related. The optimal 
growth media for secondary metabolite production in Aspergillus fischeri (NRRL 181) 
was identified to be oatmeal, and ten secondary metabolites (3 new and 7 known) were 
characterized and compared to A. fumigatus secondary metabolism (Chapter 2). 
Gliotoxin was identified to be biosynthesized from A. fischeri (NRRL 181) when grown at 
37°C on Czapek Dox agar and 5% blood agar (Chapter 3).  
Three A. fumigatus strains, (Af293, CEA10, CEA17), three A. fischeri (NRRL 
181, NRRL 4161, NRRL 4585) and one strain of A. oerlinghausenensis (CBS 139183) 
were grown at three different temperatures (23°C, 30°C, 37°C). These strains were 
chemically characterized and chemometrics was preformed to compare the chemical 
variation across section Fumigati (Chapter 4).  
6 
Chapters 5 and 6 focused on co-culturing A. fischeri with Xylaria flabelliformis 
(formally known as Xylaria cubensis) to induce secondary metabolites not seen under 
traditional laboratory conditions. The fungi were paired due to the antifungal ability of X. 
flabelliformis and their genetic tractability. Aspergillus fischeri produces a suite of 
mycotoxins whereas X. flabelliformis produces the FDA approved antifungal griseofulvin. 
When these fungi were paired both had to adapt to their new surrounding and this led to 
the activation of silent biosynthetic gene clusters. During this interspecific interaction 18 
secondary metabolites were characterized. The spatial location of these metabolites 
during mono and co-culture was obtained to understand how these fungi chemically 
respond to environmental cues (Chapter 5). One novel secondary metabolite with 
cytotoxic activities was described (Chapter 6) 
Chapters 7 and 8 focus on the development of new techniques that aid in the 
structure elucidation of secondary metabolites. Ozone-Induced Dissociation Mass 
Spectrometry (OzID-MS) was utilized for the identification of double bond placement in 
secondary metabolites. Four known metabolites were used as a test case to confirm the 
accuracy of OzID-MS on secondary metabolites. One new secondary metabolite was 
identified, and this method was used orthogonally to confirm the structure as a pure 
compound, in the context of an extract, and in situ. (Chapter 7). NMR and optical rotation 
calculations were used to determine the absolute configuration of secondary 
metabolites, where traditional methods were unsuccessful. These methods enabled the 
identification of absolute configuration of four new bioactive bislactones were 
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Aspergillus fischeri is closely related to Aspergillus fumigatus, the major cause of 
invasive mold infections. Even though A. fischeri is commonly found in diverse 
environments, including hospitals, it rarely causes invasive disease. Why A. fischeri 
causes less human disease than A. fumigatus is unclear. A comparison of A. fischeri 
and A. fumigatus for pathogenic, genomic, and secondary metabolic traits revealed 
multiple differences in pathogenesis-related phenotypes. We observed that A. fischeri 
NRRL 181 is less virulent than A. fumigatus strain CEA10 in multiple animal models of 
disease, grows slower in low oxygen environments, and is more sensitive to oxidative 
stress. Strikingly, the observed differences for some traits are of the same order of 
magnitude as those previously reported between A. fumigatus strains. In contrast, 
similar to what has previously been reported, the two species exhibit high genomic 
similarity; ~90% of the A. fumigatus proteome is conserved in A. fischeri, including 48/49 
genes known to be involved in A. fumigatus virulence. However, only 10/33 A. fumigatus 
biosynthetic gene clusters (BGCs) likely involved in secondary metabolite production are 
conserved in A. fischeri and only 13/48 A. fischeri BGCs are conserved in A. fumigatus. 
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Detailed chemical characterization of A. fischeri cultures grown on multiple substrates 
identified multiple secondary metabolites, including two new compounds and one never 
before isolated as a natural product. Additionally, an A. fischeri deletion mutant of laeA, 
a master regulator of secondary metabolism, produced fewer secondary metabolites and 
in lower quantities, suggesting that regulation of secondary metabolism is at least 
partially conserved. These results suggest that the non-pathogenic A. fischeri possesses 
many of the genes important for A. fumigatus pathogenicity but is divergent with respect 
to its ability to thrive under host-relevant conditions and its secondary metabolism. 
Aspergillus fumigatus is the primary cause of aspergillosis, a devastating 
ensemble of diseases associated with severe morbidity and mortality worldwide. A. 
fischeri is a close relative of A. fumigatus, but is not generally observed to cause human 
disease. To gain insights into the underlying causes of this remarkable difference in 
pathogenicity, we compared two representative strains (one from each species) for a 
range of pathogenesis-relevant biological and chemical characteristics. We found that 
disease progression in multiple A. fischeri mouse models was slower and caused less 
mortality than A. fumigatus. Remarkably, the observed differences between A. fischeri 
and A. fumigatus strains examined here closely resembled those previously described 
for two commonly studied A. fumigatus strains, AF293 and CEA10. A. fischeri and A. 
fumigatus exhibited different growth profiles when placed in a range of stress-inducing 
conditions encountered during infection, such as low levels of oxygen and the presence 
of chemicals that induce the production of reactive oxygen species. We also found that 
the vast majority of A. fumigatus genes known to be involved in virulence are conserved 
in A. fischeri, whereas the two species differ significantly in their secondary metabolic 
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pathways. These similarities and differences that we report here are the first step toward 
understanding the evolutionary origin of a major fungal pathogen. 
Aspergillosis is a major cause of human morbidity and mortality, resulting in over 
200,000 life-threatening infections each year worldwide, and is primarily caused by the 
filamentous fungus Aspergillus fumigatus.112 Multiple virulence traits related to Invasive 
Aspergillosis (IA) are known for A. fumigatus, including growth at human body 
temperature and in low oxygen conditions, the ability to acquire micronutrients such as 
iron and zinc in limiting environments, and the production of a diverse set of secondary 
metabolites.112 
Growth at human body temperature is a key trait for the survival of A. fumigatus 
inside mammalian hosts and may have arisen through adaptation to the warm 
temperatures present in decaying compost piles, one of the organism’s ecological 
niches.113-115 The primary route of A. fumigatus colonization and infection is through the 
lung, where oxygen levels have been observed to be as low as 2/3 of atmospheric 
pressure during infection. A successful response to this hypoxic environment is required 
for fungal pathogenesis.116, 117 Moreover, A. fumigatus produces a diverse set of small, 
bioactive molecules, known as secondary metabolites, which are biosynthesized in 
pathways that are often encoded by Biosynthetic Gene Clusters (BGCs).10 Some of 
these secondary metabolites and their regulators have been shown to contribute to 
disease in mouse models.11, 18, 20 Furthermore, a master regulator of secondary 
metabolism, laeA, is required for full virulence in IA mouse model studies.118, 119  
Species closely related to A. fumigatus are also capable of causing disease, but 
they are rarely observed in the clinic.112, 120-122 For example, A. fischeri is the closest 
evolutionary relative to A. fumigatus for which a genome has been sequenced,123, 124 but 
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it is rarely reported to cause human disease.112 Recent evolutionary genomic analyses 
suggest that A. fischeri and A. fumigatus last shared a common ancestor approximately 
4 million years ago (95% credible interval: 2 – 7 million years ago).124 Why A. fischeri-
mediated disease is less common than A. fumigatus-mediated disease remains an open 
question. Non-mutually exclusive possibilities include differences in ecological 
abundance, lack of species-level diagnosis of disease-causing strains in the clinic, and 
innate differences in pathogenicity and virulence between the two species. 
Previous studies have suggested that the difference in the frequencies with 
which the two species cause disease is unlikely to be solely due to ecological factors, as 
both can be isolated from a variety of locales, including soils, fruits, and hospitals.125-127 
For example, approximately 2% of the fungi isolated from the respiratory intensive care 
unit at Beijing Hospital were A. fischeri compared to approximately 23% of fungal 
species identified as A. fumigatus.127 While A. fischeri is easily isolated from a variety of 
environments, only a few cases of human infections have been reported.128-131 
Furthermore, numerous recent epidemiological studies from multiple countries that used 
state-of-the-art molecular typing methods were able to identify several rarely isolated 
pathogenic species closely related to A. fumigatus, such as A. lentulus and A. 
udagawae, as the source of 10-15% of human infections but did not identify A. fischeri in 
any patient sample.120, 121, 132-134  
If ecological factors and lack of precision in species identification do not 
convincingly explain why A. fischeri is non-pathogenic and A. fumigatus is pathogenic, 
other factors must be responsible. An initial genomic comparison between strains of A. 
fumigatus, A. fischeri, as well as the more distantly related Aspergillus clavatus identified 
818 genes that were A. fumigatus-specific.123 These genes were enriched for functions 
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associated with carbohydrate transport and catabolism, secondary metabolite 
biosynthesis, and detoxification,123 raising the possibility that the observed differences in 
pathogenicity observed between A. fischeri and A. fumigatus have a molecular basis. 
To gain further insight into why A. fischeri-mediated disease is less abundant 
than A. fumigatus-mediated disease, we took a multi-pronged approach to investigate 
phenotypic, genomic, and chemical differences between A. fischeri strain NRRL 181 and 
A. fumigatus strain CEA10. We observed that while A. fischeri is able to cause fatal 
disease in multiple animal models, its disease progression and response to multiple 
host-relevant stresses is markedly reduced when compared to A. fumigatus CEA10. We 
also found that while the two organisms’ genomes are in general very similar, the sets of 
secondary metabolite pathways in each of them exhibit a surprisingly low level of 
overlap. Examination of the secondary metabolite profile of A. fischeri identified both 
previously isolated as well as novel compounds. Finally, construction of a mutant A. 
fischeri strain that lacked the laeA gene, a master regulator of secondary metabolism, 
and examination of its chemical profile suggested that LaeA-mediated regulation of 
secondary metabolism in A. fischeri closely resembles that of A. fumigatus. These 
results begin to reveal the molecular differences between A. fischeri and A. fumigatus 
related to fungal pathogenesis and suggest that a functional evolutionary genomic 
comparison between pathogenic and non-pathogenic species closely related to A. 







A. fischeri is Less Virulent Than A. fumigatus in Multiple Animal Models of 
Invasive Pulmonary Aspergillosis (IPA). In contrast to A. fumigatus-mediated disease, 
only a handful of cases of invasive fungal infections have been reported to be caused by 
A. fischeri.128-131 Given this contrast, we utilized two immunologically distinct murine IPA 
models to assess differences in pathogenicity and virulence between the two species. In 
a leukopenic murine model, A. fischeri NRRL 181 was significantly less virulent than A. 
fumigatus CEA10, in a dose dependent manner (Figure 1A). Using an inoculum of 1x105 
conidia, A. fischeri was completely attenuated in virulence, with 100% murine survival by 
day 15 post-fungal challenge. In contrast, inoculation with A. fumigatus resulted in 100% 
murine mortality by day 15 (Figure 1A). Using a higher dose (2x106) of conidia, both 
strains caused 90% mortality by day 14; however, the disease progression was 
markedly different. 80% of mice inoculated with A. fumigatus succumbed to infection by 
day 4, whereas in mice inoculated with A. fischeri, mortality started occurring on day 5, 
and then one or two mice succumbed each day until day 14 (Figure 1A). Thus, despite 
the similar overall mortality at higher fungal challenge doses, A. fischeri is substantially 
less virulent than A. fumigatus in a leukopenic murine IPA model.  
To better understand what is happening in vivo during disease progression with 
A. fischeri NRRL 181 and A. fumigatus CEA10, we performed histological analyses on 
lungs from the leukopenic model 3 days post inoculation. Histological sections were 
stained with Gomori methenamine silver (GMS) to visualize fungal burden and with 
hematoxylin and eosin (H&E) stain to visualize host related pathology (Figure 1C). 
Leukopenic mice inoculated with A. fumigatus had an overall greater number of fungal 
lesions per animal than mice inoculated with A. fischeri. These A. fumigatus lesions 
13 
contained a greater amount of fungus, which coincided with increased tissue necrosis 
surrounding the lesions. There was also a greater number of A. fumigatus lesions with 
fungi invading from the larger airways into the lung parenchyma. Meanwhile, the A. 
fischeri lesions were largely maintained within the larger airways. A striking difference 
between the lesions caused by the two species was in the appearance of the hyphae of 
the two species, where A. fischeri filaments were much shorter than those of A. 
fumigatus. We hypothesize that in the leukopenic mouse, A. fischeri is unable to grow as 
well as A. fumigatus, resulting in smaller and fewer fungal lesions, shorter fungal 




Figure 1. A. fischeri is Significantly Less Virulent than A. fumigatus in Multiple Murine 
Models of Invasive Pulmonary Aspergillosis. A) Cumulative survival of mice inoculated 
with 1x105 (gray) or 2x106 (black) conidia in a leukopenic model of IPA. For the 1x105 
inoculations, 10 mice were infected per group and for the 2x106 inoculations, 12 mice 
were infected per group. For each PBS control, 4 mice were inoculated. *p=0.0098 by 
Log-Rank test, p=0.0002 by Gehan-Breslow-Wilcoxon test. B) Cumulative survival of 
mice inoculated with 2x106 conidia in a steroid model of IPA. n=12/group, 4/PBS. 
*p=<0.0001 by Log-Rank and Gehan-Breslow-Wilcoxon tests. C) Histological sections 
from 3 days post inoculation in a leukopenic (left) and steroid (right) model of IPA 
stained with H&E and GMS. Images were acquired at 100x. D) Cumulative survival of G. 
mellonella larvae inoculated with 1x106 (gray) or 1x109 (black) conidia. 10 larvae were 
used per condition in all assays. Survival curves for A. fischeri and A. fumigatus were 
significantly different (p<0.003) in both Log-Rank and Gehan-Breslow-Wilcoxon tests for 
both inoculums. 
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As the patient population at risk for IA continues to change and grow,135 we next 
tested a non-leukopenic, triamcinolone (steroid)-induced immune suppression model 
and observed a significant reduction in virulence of A. fischeri compared to A. fumigatus 
(p<0.0001 by Log-Rank and Gehan-Breslow-Wilcoxon tests). All mice inoculated with A. 
fumigatus succumbed to infection by day 4; however, similar to the leukopenic model, 
mice inoculated with A. fischeri had significantly slower disease progression as 
monitored by Kaplan-Meier analyses (Figure 1B).  
Histological analyses were also carried out on lungs from the steroid model 3 
days post fungal inoculation (Figure 2C). Overall, mice inoculated with A. fischeri in the 
steroid model had similar numbers of fungal lesions as those inoculated with A. 
fumigatus, but the lesions caused by the two species were phenotypically distinct (Figure 
1C). In larger terminal bronchioles infected with A. fumigatus, there was greater fungal 
growth per lesion, and the growth was observed throughout the bronchiole itself, 
extending well into the lumen. These lesions were accompanied by substantial 
granulocytic inflammation and obstructed the airways surrounding the hyphae (Figure 
1C). In the lesions containing A. fischeri, the fungal growth was contained to the 
epithelial lining of the bronchioles. This pattern of growth was accompanied by 
inflammation at the airway epithelia, leaving the airway lumen largely unobstructed 
(Figure 1C). The lack of airway obstruction during A. fischeri infection and reduced 
inflammation may contribute to the reduced virulence compared to A. fumigatus in this 
murine model. 
Although the distribution of the fungal lesions varied, there was still significant 
fungal growth in the steroid immunosuppressed mice infected with A. fischeri, 
suggesting that A. fischeri is capable of growing within the immune compromised murine 
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host. Indeed, we tested the growth rate of A. fischeri and A. fumigatus in lung 
homogenate as a proxy for growth capability within the nutrient environment of the host 
and observed no difference between the two strains (Figure 6). These experiments show 
that in multiple models of fungal disease, A. fischeri is less virulent than A. fumigatus 
even though it is able to grow within the immune compromised murine lung. 
We observed similar pathogenicity and virulence results when using the Galleria 
mellonella insect larvae model of aspergillosis (Figure 1D). Both low (1x106 conidia) and 
high (1x109 conidia) inoculum experiments showed significant differences between the 
disease progression of A. fischeri (slower) and A. fumigatus (faster) in this insect model 
of fungal pathogenicity. 
 
 
Figure 2. A. fischeri is Unable to Thrive Under Suboptimal Metabolic Conditions at 37C. 
1x103 conidia were point inoculated on each plate, then plates were incubated at 37C in 
normoxia (N; ~21% oxygen, 5%CO2) or hypoxia (H; 0.2% O2, 5%CO2); colony diameter 
was measured every 24 hours. Mean and SEM of triplicates. CAA – Casamino acids; 
GMM – glucose minimal media. 
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When Compared to A. fumigatus, A. fischeri Differs in its Response to 
Several Host-Relevant Stresses. Our in vivo experiments suggested that the lower 
virulence of A. fischeri is not the result of an inability to grow within the host per se. 
Therefore, we hypothesized that A. fischeri is unable to mitigate stresses encountered in 
the host as effectively as its close evolutionary relative, A. fumigatus. Nutrient fluctuation 
is a stress encountered in vivo during A. fumigatus infection,136 and to assess 
differences in metabolic plasticity between the two species, we measured the two 
organisms’ growth on media supplemented with glucose, fatty acids (Tween-80), or 
casamino acids. Because low oxygen tension is a significant stress encountered during 
infection,116 and recently, fitness in low oxygen has been correlated to virulence of A. 
fumigatus,137 we measured growth of both species at 37C in both normoxic (ambient 
air) and hypoxia-inducing (0.2% O2, 5% CO2) conditions. In normoxia with glucose, fatty 
acids (Tween-80), or casamino acids supplied as the carbon source, radial growth of A. 
fischeri was reduced when compared to A. fumigatus (Figure 2). However, on rich media 
both organisms grew equally well (Figure 2). We also observed a slower growth rate of 
A. fischeri compared to A. fumigatus in the first 16 hours of culture in liquid media 
supplied with glucose at 37C. At 30C, A. fischeri grew the same as, or better than, A. 
fumigatus except on Tween-80 where A. fumigatus had a slight advantage (Figure 7). 
Also, A. fischeri grew substantially worse than A. fumigatus when grown at 44C (Figure 
7), a temperature rarely observed in the patient but easily observed in compost piles. To 
determine relative fitness in hypoxic liquid environments, we measured the ratio of 
biomass in liquid culture in ambient air (normoxia) versus hypoxic (0.2% O2, 5%CO2) 
conditions. A. fischeri showed significantly lower fitness in hypoxic conditions, with about 
an 8.5-fold lower biomass than A. fumigatus (Figure 3A). These data suggest that A. 
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fischeri is less fit than A. fumigatus at 37C and in low oxygen conditions, both of which 
have been shown to impact fungal virulence. 
 
 
Figure 3. A. fischeri is More Susceptible to Multiple Host-Relevant Stresses Than A. 
fumigatus. A) Fitness ratio of A. fumigatus or A. fischeri during hypoxic vs normoxic 
growth (measured as the dry weight of cultures). Data represent mean and SEM of 
biological triplicates; ***p=0.0006 by Student’s t-test. B) Growth inhibition of strains 
grown on 1% lactate minimal media with 0.1% 2-deoxyglucose (2-DG) under a range of 
low oxygen conditions. C) A. fumigatus and A. fischeri were grown in the presence of the 
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cell wall perturbing agent Congo Red (0.5mg/mL), the oxidative stressor Menadione (20 
µM), or the chitin perturbing agent Calcofluor White (CFW, 25µg/mL). Plates were grown 
for 96 hours at 37°C and 5% CO2. For all plates except Congo Red and its GMM control, 
1x103 spores were plated. For Congo Red and the control GMM plate 1x105 spores were 
plated. Student’s t-test was performed where *: p<0.05, **: p<0.01. D) Strains were 
grown for 48 h at 37°C in liquid complete medium supplemented with increasing 
concentrations of hydrogen peroxide. 
 
Metabolic flexibility, or the ability for an organism to utilize multiple carbon 
sources simultaneously, has been suggested to provide a fitness advantage to Candida 
albicans during in vivo growth.138 Metabolic flexibility can be characterized using the 
glucose analog, 2-deoxyglucose (2-DG), in combination with an alternative carbon 
source available in vivo, such as lactate. 2-DG triggers carbon catabolite repression, 
which shuts down alternative carbon utilization pathways. However, in C. albicans this 
shut down is delayed and growth occurs on lactate with 2-DG.138, 139 We tested the 
metabolic flexibility of both A. fumigatus and A. fischeri and observed that while both 
species can grow in the presence of 2-DG on lactate, the growth inhibition of A. fischeri 
is higher (~60%) than that of A. fumigatus (~35%; Figure 3B). Even under low oxygen 
conditions (5% and 2%), A. fumigatus maintains this metabolic flexibility except under 
extremely low oxygen conditions (0.2%), whereas A. fischeri shows even greater 
inhibition at all oxygen tensions of 5% or below. These data suggest that while both 
species exhibit some level of metabolic flexibility, A. fumigatus appears more 
metabolically flexible under a wider range of conditions than A. fischeri. 
Next, we measured the susceptibility of A. fischeri to oxidative stress, cell wall 
stress, and antifungal drugs as they are stresses that are encountered during infection 
and treatment.140 Interestingly, we observed that A. fischeri is more resistant to the 
intracellular oxidative stress agent menadione than A. fumigatus but more susceptible to 
the external oxidative stress agent hydrogen peroxide (Figure 3CD). As the in vivo levels 
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of inflammation caused by the two species appeared different, we indirectly tested for 
differences in cell wall pathogen-associated molecular patterns using the cell wall 
perturbing agents Congo Red and Calcofluor White. A. fumigatus was significantly more 
resistant to both agents than A. fischeri (Figure 3C), suggesting differences in the 
response to cell wall stress or in the composition and organization of the cell wall 
between the two species. These differences are likely important for host immune cell 
recognition and interaction, which in turn influences pathology and disease outcome.  
Lastly, A. fischeri showed enhanced resistance relative to A. fumigatus for three 
of the four antifungal drugs tested (Table 2.1), consistent with previous experiments.42 
Overall, our phenotypic data show that the response of A. fischeri to host-related 
stresses and antifungals is substantially different from that of A. fumigatus. Furthermore, 
our results suggest that increased growth capability of A. fumigatus in low oxygen and in 
high temperatures are two important attributes that likely contribute to its pathogenic 
potential compared to A. fischeri. 
 











A. fumigatus 0.7 0.8 5 0.09 
A. fischeri 2.4 > 4 > 24 0.06 
 
 
The Proteomes of A. fumigatus and A. fischeri are Highly Similar, but Their 
Secondary Metabolic Pathways Show Substantial Divergence. The large differences 
in virulence and virulence-related traits we observed between A. fumigatus and A. 
fischeri led us to investigate the genotypic differences that could be responsible. To 
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describe the genomic similarities and differences between A. fumigatus and A. fischeri, 
we determined how many orthologous proteins and how many species-specific proteins 
were present in each genome using a Reciprocal Best BLAST Hit approach.141 We 
identified 8,737 proteins as being shared between the two species (Figure 8), 
representing 88% and 84% of the A. fumigatus and A. fischeri proteomes, respectively, 
and 1,684 A. fischeri-specific proteins (16% of its proteome) and 1,189 A. fumigatus-
specific proteins (12% of its proteome). These results are similar to what had previously 
been reported in an early analysis of the A. fischeri genome.123  
To narrow our search for genes that are absent in A. fischeri but are important for 
A. fumigatus disease, we compiled a list of 49 A. fumigatus genes considered to be 
involved in virulence (Table 2.3) based on two previously published articles142, 143 and 
extensive literature searches of our own. We observed that all but one of these 
virulence-associated genes were also present in A. fischeri, a surprising finding 
considering the substantial differences observed between the two species in our animal 
models of infection. The virulence-associated gene not present in A. fischeri is pesL 
(Afu6g12050), a non-ribosomal peptide synthase that is essential for the synthesis of the 
secondary metabolite fumigaclavine C and required for virulence in the Galleria model of 
A. fumigatus infection.144  
Since the only previously described A. fumigatus virulence-associated gene not 
present in the A. fischeri genome (i.e. pesL) is involved in secondary metabolism and a 
previous study suggested that secondary metabolism is not conserved between these 
two species,145 we investigated the differences between the repertoire of secondary 
metabolic pathways present in A. fumigatus and A. fischeri. Using the program 
antiSMASH,146 we identified 598 genes distributed amongst 33 BGCs in A. fumigatus 
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(Table 2.4) and 786 genes spread out over 48 BGCs in A. fischeri (Table 2.5). Of these 
598 A. fumigatus genes, 407 (68%) had an orthologous gene that was part of an A. 
fischeri BGC. This level of conservation of BGC genes (68%) is much lower than the 
amount of conservation observed for the rest of the proteome (88%), illustrating the 
rapid rate at which fungal metabolic pathways evolve.147, 148 
 
 
Figure 4. Biosynthetic Gene Clusters (BGCs) of A. fumigatus and A. fischeri Show 
Substantial Evolutionary Divergence. Predicted BGCs are shown in the inner track, are 
alternatively colored dark and light gray, and their size is proportional to the number of 
genes in them. Black ticks on the exterior of the cluster track indicate genes that 
possess an ortholog in the other species but are not in a BGC in the second species. 
White dots indicate species-specific clusters. Solid bars on the exterior correspond to the 
chromosome on which the BGCs below them reside. Genes are connected to their 
orthologs in the other species with dark lines if >90% of the BGC genes in A. fumigatus 
are conserved in the same BGC in A. fischeri. Lighter lines connect all other orthologs 
that are present in both species’ sets of BGCs. Image was made using Circos version 
0.69-4.149 
 
We next directly compared the BGCs of the two organisms. An A. fumigatus 
BGC was considered conserved in A. fischeri if ≥ 90% of its genes were also present in 
an A. fischeri BGC and vice versa. We found that only 10 / 33 A. fumigatus BGCs are 
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conserved in A. fischeri and only 13 / 48 A. fischeri BGCs are conserved in A. fumigatus 
(Figure 4), a finding consistent with previous results145 and the low conservation of 
individual secondary metabolic genes between the two species. While only 10 A. 
fumigatus BGCs were conserved in A. fischeri, many other BGCs contained one or more 
orthologs of genes in A. fischeri BGCs.  
Only one BGC (Cluster 18) was completely A. fumigatus-specific. Interestingly, 
our previous examination of the genomes of 66 A. fumigatus strains showed that this 
BGC was a “jumping cluster”, as it was found to be present in only 5 strains and to 
reside in three distinct genomic locations.148 Conversely, there are 10 A. fischeri-specific 
BGCs that do not have orthologs in BGCs in A. fumigatus. One of these BGCs is 
responsible for making helvolic acid [a gene cluster known to be absent from the A. 
fumigatus strain CEA10 but present in strain Af293],148 but the other 9 have not been 
biochemically connected to any metabolite. 
All the genes required for the production of the mycotoxin gliotoxin are located in 
a BGC in A. fischeri (Figure 9), and are in fact similar to their A. fumigatus orthologs,150 
even though A. fischeri is not known to produce this mycotoxin.151 Both the gliotoxin and 
acetylaszonalenin BGCs are adjacent to one another in the A. fischeri genome (Figure 
9). In A. fumigatus, the gliotoxin BGC is immediately next to what appears to be a 
truncated version of the acetylaszonalenin BGC that lacks portions of the nonribosomal 
peptide synthase and acetyltransferase genes as well as the entire indole 
prenyltransferase gene required for acetylaszonalenin production. The close proximity of 
these two BGCs is noteworthy, as it is similar to previously reported “super clusters” in 
A. fumigatus and A. fumigatus-related strains.152 These super clusters have been 
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hypothesized to be “evolutionary laboratories” that may give rise to new compounds and 
pathways.148 
Isolation and Characterization of Three New Compounds from A. fischeri. 
The relatively low level of conservation of BGCs we observed between A. fumigatus and 
A. fischeri led us to characterize the secondary metabolites produced by A. fischeri 
(Figure 10).96, 153-156 The one strain-many compounds (OSMAC) approach was used to 
alter the secondary metabolites being biosynthesized in order to produce a diverse set of 
molecules.157-160 Depending on the media on which it was grown, A. fischeri produced as 
few as 4 (Yeast Extract Soy Peptone Dextrose Agar - YESD) or as many as 10 
compounds (Oatmeal Agar – OMA) (Figure 11). These results showed that culture 
media influences the biosynthesis of secondary metabolites in A. fischeri, a 
phenomenon observed in many other fungi.158, 161  
To characterize the peaks of interest we observed when A. fischeri was grown on 
OMA, we increased the size of our fungal cultures; doing so yielded seven previously 
isolated compounds (sartorypyrone A (1), aszonalenin (4), acetylaszonalenin (5), 
fumitremorgin A (6), fumitremorgin B (7), verruculogen (8), and the C-11 epimer of 
verruculogen TR2 (9)) and three newly biosynthesized secondary metabolites 
(sartorypyrone E (2), 14-epi-aszonapyrone A (3), and 13-O-fumitremorgin B (10). Two of 
the secondary metabolites were new compounds (2 and 3) and one was a new natural 
product (10)) (Figure 5B). The structures for all 10 compounds were determined using a 
set of spectroscopic (1 and 2D NMR) and spectrometric techniques (HRMS). Our data 
for sartorypyrone A (1),162 aszonalenin (4),163, 164 acetylaszonalenin (5),162, 165 
fumitremorgin A (6),166, 167 fumitremorgin B (7),19, 168, 169 verruculogen (8),170, 171 and the C-
11 epimer of verruculogen TR2 (9)171 correlated well with literature values (Figures 13, 
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14, 20-25). The structures of 14-epi-aszonapyrone A (3), and 13-O-prenyl fumitremorgin 
B (10) were fully characterized in this study; the structure elucidation of sartorypyrone E 
(2) is ongoing and will be reported in detail in a forthcoming manuscript.  
The structures of compounds 1 - 10 were determined using a set of 
spectroscopic (1 and 2D NMR) and spectrometric techniques (HRMS), where the data 
for sartorypyrone A (1)162, aszonalenin (4)163, 164, acetylaszonalenin (5)162, 165, 
fumitremorgin A (6)166, 167, fumitremorgin B (7)19, 168, 169, verruculogen (8)170, 171, and 11-
epimer of verruculogen TR-2 (9)171, compared favorably to the literature. 
14 – epi-aszonapyrone A (3) (3.2mg) was obtained as a white solid. Its formula was 
C28H40O5 based on the HRESIMS data, indicating nine degrees of unsaturation. Analysis 
of the 1H and 13C NMR data indicated the structure to be a cyclic diterpenoid, with a di-
substituted fully-unsaturated δ-lactone. The 1H and 13C data were similar to those of 
aszonapyrone A 162. Whereas there are slight differences around the C-14 chiral center, 
the 1H shifts for C-14, C-15, and C-26 were shifted. However, the 1D and 2D NMR 
(Figure 30) data confirmed the planar structure to be the same as aszonapyrone A, this 
could indicate the inversion of the stereocenter. Through Nuclear Overhauser Effects 
Spectroscopy (NOESY) there were no correlations between the 1Hs on C-14 and C-15 
with those at C-25. Although the lack of correlations does not confirm the switch in 
stereochemistry, this combined with the 1D NMR shifts and 2D correlations, leads the 
absolute configuration of 14 – epi-aszonapyrone A at the C-14 position to be the S 
configuration (Figures 15-19). 
13-O-prenyl-fumitremorgin B (10) (1.22mg) was obtained as a white solid. Its 
formula was C32H41N3O5, on the basis of the HRESIMS, indicating 14 degrees of 
unsaturation. Analysis of the 1H, 13C NMR, and CD data indicated the structure to be 
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similar to that of the fumitremorgin class of secondary metabolites 19, 166-169. The chemical 
shifts of the similarities between fumitremorgin A 167 and B 169 are conserved in 10, other 
than the loss of the peroxide ring from fumitremorgin A, and the addition of a prenyl 
group in fumitremorgin B. The 1H and 13C data of 13-O-prenyl-fumitremorgin B was 
highly similar to that of fumitremorgin B other than the addition of the prenylated O at 
position 13. The Heteronuclear Multiple Bond Correlation spectroscopy (HMBC) 
correlations (Figure 30) of H2-31 to C-13 and H1-13 to C-31 connected the prenyl group 
to C-13 (Figures 26-29). In 2012, the activity of the gene ftmPT3 from the gene cluster 
that produces the fumitremorgin-type alkaloids was explored 19. It was expressed in E. 
coli and assayed with fumitremorgin B and the desired product was 13-O-prenyl-
fumitremorgin B. This proved that ftmPT3 prenylates the hydroxyl at the C-13; however, 
this secondary metabolite has never been isolated naturally. Only the 1H NMR was 
obtained, and the assignment was based on previously isolated analogues; however, it 
has for the first time been isolated naturally from A. fischeri. The absolute configuration 
of compound 10 was determined by Circular Dichroism (CD) (Figure 31) and found to be 
identical to fumitremorgin B. 
Since four secondary metabolites (5-8) from A. fischeri had also been reported 
from A. fumigatus (Table 2.2), we hypothesized that the mechanisms A. fischeri employs 
to regulate its secondary metabolism would also be similar to those used by A. 
fumigatus. To test this hypothesis, we constructed a deletion mutant of laeA in A. fischeri 
(Figure 12). LaeA is a master regulator of secondary metabolism in A. fumigatus and a 
variety of other fungi (67-69). Both the wild type and ΔlaeA strains of A. fischeri were 
subjected to LC-MS analysis. The chromatographic profile of ΔlaeA showed mass data 
that corresponded to sartorypyrone A (1), sartorypyrone E (2), 14-epi-aszonapyrone A 
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(3), aszonalenin (4), acetylaszonalenin (5), fumitremorgin A (6), verruculogen (8), and 
the C-11 epimer of verruculogen TR2 (9). However, the relative abundance of 
compounds present was very low compared to the wild type (Figure 5C). Fumitremorgin 
B (7) and 13-O-prenyl-fumitremorgin B (10) were not produced by the laeA mutant at 
all. 
 
Table 2.2. Secondary metabolites isolated from A. fischeri that have been reported from 
A. fumigatus 
 
Secondary Metabolites A. fischeri A. fumigatus 
sartorypyrone A (1) + - 
sartorypyrone E (2) + - 
14-epi-aszonapyrone A (3) + - 
aszonalenin (4) + - 
acetylaszonalenin (5) + + 
fumitremorgin A (6) + + 
fumitremorgin B (7) + + 
verruculogen (8) + + 
C-11 epimer of verruculogen TR2 (9) + _ 





A. fumigatus is a major human fungal pathogen, yet its close relative A. fischeri is 
rarely an agent of human disease. A number of traits that contribute to the virulence of 
A. fumigatus have been characterized, but their distribution and potential role in A. 
fischeri-mediated disease is largely unknown. In this study, we thoroughly characterized 
A. fischeri (strain NRRL 181) and compared it to A. fumigatus (strain CEA10) for multiple 
disease-relevant biological and chemical differences. Our data shows that A. fischeri can 
grow in a mammalian host but is much less fit and causes a disease progression quite 
different than that observed during A. fumigatus infections (Figures 1 and 2). Future 
studies will be needed to determine if these differences between A. fischeri NRRL 181 
and A. fumigatus CEA10 are conserved across a range of A. fischeri and A. fumigatus 
isolates. 
Further investigations revealed that secondary metabolic genes are much less 
conserved than genes in the rest of the genome (Figure 8), and a chemical analysis of 
A. fischeri resulted in the identification of both previously identified and new compounds 
(Figure 5). While the BGCs producing secondary metabolites in A. fischeri and A. 
fumigatus appear to be quite different, our data suggest that a master regulator of 
secondary metabolism in A. fumigatus (laeA) possesses a similar role in A. fischeri 
(Figure 5C). This is consistent with previous observations that the global regulation of 
secondary metabolism is conserved but that the underlying BGCs are not, suggesting 
that the regulatory circuit involved in Aspergillus secondary metabolism has undergone 
extensive regulatory rewiring.147 Our analyses are the first to infer the occurrence of 






Figure 5. Secondary Metabolite Production in A. fischeri. A) Compounds isolated from 
A. fischeri: (1) sartorypyrone A, (2) sartorypyrone E, (3) 14-epimer aszonapyrone A, (4) 
aszonalenin, (5) acetylaszonalenin, (6) fumitremorgin A, (7) fumitremorgin B, (8) 
verruculogen, (9) C-11 epimer verruculogen TR2, and (10) 13-O-prenyl-fumitremorgin B. 
The color coding indicates which putative class the molecule belongs to; e.g., terpenes, 
PKS, or NRPS. B) Top, Aspergillus fischeri was initially grown on rice for two weeks and 
then extracted using methods outlined in Figure S5. The rice culture yielded compounds 
1, 4, and 5. Middle, A. fischeri was grown on multigrain Cheerios for two weeks, which 
yielded compounds 1 and 4-9. Bottom, A. fischeri on Quaker oatmeal for two weeks. All 
compounds that were previously isolated in rice and multigrain cheerios cultures in 
addition to three new compounds (2, 3, and 10) were found in the oatmeal culture. All 
pictures depict fungi growing in 250 mL Erlenmeyer flasks; left panel indicates top view, 
while the right panel shows bottom view. All chromatographic profiles have been 
normalized to the highest μAU value. C) A. fischeri WT and laeA were grown on solid 
breakfast oatmeal for two weeks and extracted using organic solvents as indicated 
previously. The crude de-sugared and de-fatted extracts were run using UPLC-MS at a 
concentration of 2 mg/mL with 5 L being injected for analysis.  The chromatographic 
profiles were normalized to the highest μAU value. Mass spec analysis indicated the 
presence of secondary metabolites 1–10 within the wild type, and only 1-6, 8, and 9 




In order to cause disease, a microbe must be able to respond to the set of 
diverse and stressful environments presented by its host. Based on our data, A. fischeri 
strain NRRL 181 is unable to respond to many of these stresses as well as A. fumigatus 
CEA10 (Figures 2-3). We hypothesize that this inability to thrive under stress contributes 
to the varying disease progressions observed during our animal model experiments 
(Figure 1). Some or all of the genetic determinants responsible for this discrepancy in 
stress response and virulence could reside in the ~1,200 A. fumigatus-specific genes we 
identified (Figure 8); alternatively, some of the ~1,700 A. fischeri-specific genes we 
identified may inadvertently facilitate control of A. fischeri in a mammalian host. An 
additional explanation for the discrepancy in stress response is that A. fumigatus has 
evolved more efficient regulatory circuits than A. fischeri that allow it to cope with more 
stringent conditions that are observed in the host. 
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Even though more than 10% of the genes in each species lack an ortholog in the 
other species, only ~2% (1/49) of previously identified genetic determinants of virulence 
in A. fumigatus are not conserved in A. fischeri (Table 2.3). This result, and our 
observation that many of the pathways of secondary metabolism are quite different 
between A. fischeri and A. fumigatus, support a multifactorial model of A. fumigatus 
virulence24, 173, 174 and suggest a need to investigate virulence on multiple levels of 
biological complexity. In order to cause disease in a host, A. fumigatus (and other 
species closely related to it) must adhere and germinate in the lung,24 survive inherently 
stressful conditions presented by host environments (ex. severe lack of metals and 
oxygen),116, 175, 176 and modulate or endure actions of the host immune system.177 Given 
the diversity of these activities, it is unlikely that single genes or pathways will be 
responsible for the totality of A. fumigatus-derived disease, even though many genes in 
the genome have not yet been characterized for their role in pathogenicity. We 
hypothesize that multiple pathways (including those involved in secondary metabolism) 
have changed during the evolution of A. fischeri and A. fumigatus, resulting in their 
differing ability to cause disease.  
As mentioned, an important caveat to our experiments is that we only analyzed a 
single, representative strain from each species, and further studies are needed to 
determine how typical these observed trait and genomic differences are across multiple 
strains from each species. Several recent studies have identified a wide variety of 
differences between A. fumigatus strains, which have in turn been shown to contribute to 
physiological differences, including but not limited to secondary metabolism and 
virulence.24, 137, 146, 174 While the genome of only one isolate of A. fischeri has so far been 
sequenced123 and the organism has only been reported to cause human disease a few 
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times,128-131 it would be of great interest to compare patient-derived and environment-
derived isolates at the genomic, phenotypic, and chemical levels. Although it appears 
that clinical and environmental isolates do not stem from separate lineages in A. 
fumigatus,178 whether this is also the case for largely non-pathogenic species, such as A. 
fischeri, or for rarely isolated pathogenic species, such as A. lentulus or A. udagawae, 
remains largely unknown. 
Our mouse infection studies revealed that A. fischeri strain NRRL 181 was less 
virulent than A. fumigatus strain CEA10 in both leukopenic and steroid-induced immune 
suppression models of disease. The difference in disease outcome in the steroid model 
closely matches what was observed in comparisons of two A. fumigatus strains, CEA10 
and Af293.137 It is intriguing that the difference between pathogenic (A. fumigatus 
CEA10) and non-pathogenic (A. fischeri NRRL 181) species in disease outcomes in this 
model is similar to that between two clinically derived pathogenic strains (A. fumigatus 
CEA10 and Af293). Interestingly, Kowalski et al. did not observe any statistically 
significant difference in disease progression between CEA10 and Af293 in the 
leukopenic model, whereas we found that A. fischeri is less virulent in this second 
murine model of disease (Figure 1). These strain-, species-, and infection model-specific 
differences in disease outcomes are consistent with our hypothesis that A. fumigatus 
virulence is a complex genetic trait and highlight the need for further studies using wider 
sets of strains, species, and virulence-related traits.  
A. fumigatus and A. fischeri are members of Aspergillus section Fumigati, a clade 
that includes multiple closely related species, some of which are pathogens (e.g., A. 
fumigatus, A. lentulus, and A. udagawae) and some of which are considered non-
pathogens (e.g., A. fischeri, A. aureolus, and A. turcosus).112, 151, 179, 180 The ability to 
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cause disease in humans appears to have either arisen or been lost (or both) multiple 
times independently during the evolution of this lineage, as pathogenic species are 
spread throughout the phylogeny.124, 181 A broader, phylogenetically-informed 
comparison of pathogenic and non-pathogenic species in section Fumigati would 
provide far greater resolution in identifying (or dismissing) factors and pathways that may 
contribute or prevent the ability of these organisms to cause disease. Also, leveraging 
the diversity of section Fumigati would give researchers a better understanding of the 
nature and evolution of human fungal pathogenesis as the appreciation for the health 
burden caused by fungi increases.182 
Materials and Methods 
Strains and Growth Media. A. fischeri strain NRRL 181 was acquired from the 
ARS Culture Collection (NRRL). A. fumigatus strain CEA10 (CBS 144.89) was obtained 
from the Westerdijk Fungal Biodiversity Institute (CBS). All strains were grown on 
glucose minimal media (GMM) from conidial glycerol stocks stored at -80C. All strains 
were grown in the presence of white light at 37C. Conidia were collected in 0.01% 
Tween-80 and enumerated with a hemocytometer.  
Murine Virulence Studies. For the chemotherapeutic (leukopenic) murine 
model, outbred CD-1 female mice (Charles River Laboratories, Raleigh, NC, USA), 6-8 
weeks old, were immunosuppressed with intraperitoneal (i.p.) injections of 150 mg/kg 
cyclophosphamide (Baxter Healthcare Corporation, Deerfield, IL, USA) 48 hours before 
and 72 hours after fungal inoculation, along with subcutaneous (s.c.) injections of 40 
mg/kg Kenalog-10 (triamcinolone acetonide, Bristol-Myer Squibb, Princeton, NJ, USA) 
24 hours before and 6 days after fungal inoculation. For the murine triamcinolone model 
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outbred CD-1 female mice, 6-8 weeks old, were treated with 40 mg/kg Kenalog-10 by 
s.c. injection 24 hours prior to fungal inoculation. 
Unless otherwise noted, conidial suspensions of 2x106 conidia were prepared in 
40 L sterile PBS and administered to mice intranasally while under isoflourine 
anesthesia. Mock mice were given 40 L PBS. Mice were monitored three times a day 
for signs of disease for 14 or 18 days post-inoculation. Survival was plotted on Kaplan-
Meir curves and statistical significance between curves was determined using Mantel-
Cox Log-Rank and Gehan Breslow-Wilcoxon tests. Mice were housed in autoclaved 
cages at 4 mice per cage with HEPA filtered air and autoclaved food and water available 
at libitum. 
Galleria mellonella Virulence Studies. G. mellonella larvae were obtained by 
breeding adult moths.183 G. mellonella larvae of a similar size were selected 
(approximately 275–330 mg) and kept without food in glass containers (Petri dishes) at 
37°C in darkness for 24 h prior to use. A. fumigatus and A. fischeri conidia were 
obtained by growing on YAG media for 2 days. The conidia were harvested in PBS and 
filtered through Miracloth (Calbiochem). The concentration of conidia was estimated by 
using a hemocytometer and were resuspended at a concentration of 2.0 x 108 
conidia/ml. The viability of the conidia was determined by incubating on YAG media at 
37°C for 48 hours. Inoculum (5 µl) of conidia from both strains were used to investigate 
the virulence of A. fumigatus and A. fischeri against G. mellonella. Ten G. mellonella in 
the final (sixth) instar larval stage of development were used per condition in all assays. 
The control group was the larvae inoculated with 5 μl of PBS to observe the killing due to 
physical trauma. The inoculation was performed by using a Hamilton syringe (7000.5KH) 
and injecting 5 μl into the haemocel of each larva via the last left proleg. After, the larvae 
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were incubated in a glass container (Petri dishes) at 37ºC in the dark. Larval killing was 
scored daily. Larvae were considered dead by presenting the absence of movement in 
response to touch. 
Histopathology. Outbred CD-1 mice, 6-8 weeks old, were immunosuppressed 
and intranasally inoculated with 2x106 conidia as described above for the 
chemotherapeutic and corticosteroid murine models. Mice were sacrificed 72 hours post 
inoculation. Lungs were perfused with 10% buffered formalin phosphate before removal, 
then stored in 10% buffered formalin phosphate until embedding. Paraffin embedded 
sections were stained with haematoxylin and eosin (H&E) and Gömöri methenamine 
silver (GMS). Slides were analyzed microscopically with a Zeiss Axioplan 2 imaging 
microscope (Carl Zeiss Microimaging, Inc. Thornwood, NY, USA) fitted with a Qimiging 
RETIGA-SRV Fast 1394 RGB camera. Analysis was performed in Phylum Live 4 
imaging software. 
Ethics Statement. We carried out our mouse studies in strict accordance with 
the recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Research Council (Council, 1996). The mouse experimental protocol was 
approved by the Institutional Animal Care and Use Committee (IACUC) at Dartmouth 
College (Federal-Wide Assurance Number: A3259-01). 
Growth Assays. Radial growth was quantified by point inoculation of 1x103 
conidia in 2 L on indicated media; plates were incubated at 37C in normoxia (~21% 
O2, 5% CO2) or hypoxia (0.2% O2, 5% CO2). Colony diameter was measured every 24 
hours for 4 days and reported as the average of three biological replicates per strain. 
For 2-DG experiments, 1x103 conidia in 2 L were spotted on 1% lactate minimal 
media with or without 0.1% 2-deoxyglucose (2-DG; Sigma, D8375). Plates were 
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incubated for 3 days at 37C in normoxia or hypoxia with 5% CO2. Percent inhibition was 
calculated by dividing radial growth on 2-DG plates by the average radial growth of 
biological triplicates on plates without 2-DG. 
Fungal biomass was quantified by measuring the dry weight of fungal tissue from 
5x107 conidia grown in 100 mL liquid GMM shaking at 200 rpm for 48 hours in normoxia 
(~21% O2) and hypoxia (0.2% O2, 5% CO2). Liquid biomass is reported as the average 
of three biological replicates per strain. Hypoxic conditions were maintained using an 
INVIVO2 400 Hypoxia Workstation (Ruskinn Technology Limited, Bridgend, UK) with a 
gas regulator and 94.8% N2. 
Liquid growth curves were performed with conidia adjusted to 2x104 conidia in 20 
L 0.01% Tween-80 in 96-well dishes, then 180 L of media (GMM or lung homogenate) 
was added to each well. Plates were incubated at 37C for 7 hours, then Abs405 
measurements were taken every 10 minutes for the first 16 hours of growth with 
continued incubation at 37C. Lung homogenate media was prepared as follows: lungs 
were harvested from healthy CD-1 female mice (20-24 g) and homogenized through a 
100 M cell strainer in 2 mL PBS/lung. Homogenate was diluted 1:4 in sterile PBS, spun 
down to remove cells, then filter sterilized through 22 M PVDF filters. 
Cell Wall and Oxidative Stresses. Congo Red (0.5 mg/mL), Menadione (20 
µM), or calcofluor white (CFW, 25 µg/mL) were added to GMM plates.  1x103 conidia 
(Calcofluor white and Menadione) or 1x105 conidia (Congo Red) were point inoculated 
and plates were incubated for 96 hours at 37°C with 5% CO2. 
Orthology Determination and Analyses. Genomes for A. fumigatus CEA10 
and A. fischeri NRRL 181 were downloaded from NCBI (Accession numbers of 
GCA_000150145.1 and GCF_000149645.1, respectively). To identify putative 
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orthologous genes between A. fischeri and A. fumigatus, a reciprocal best BLAST hit 
(RBBH) approach was used. We blasted the proteome of A. fischeri to A. fumigatus and 
vice versa using an e-value cutoff of 10-3 and then filtered for RBBHs according to 
bitscore.184 A pair of genes from each species was considered orthologous if their best 
blast hit was to each other. Species-specific and orthologous protein sets were 
visualized using version 3.0.0 of eulerAPE.185 
Biosynthetic Gene Cluster (BGC) Prediction and Analyses. Version 4.2.0 of 
antiSMASH146 was used with its default settings to identify BGCs. Orthologous cluster 
genes were identified using our RBBH results and visualized using version 0.69 of 
Circos.149 Chromosomes were identified for A. fischeri NRRL1 and A. fumigatus CEA10 
using NUCMER186 and chromosomal sequences from A. fumigatus strain AF293 from 
NCBI (Accession number GCA_000002655.1). Syntenic clusters were visualized using 
easyfig version 2.2.2.187 
Secondary Metabolite Extraction and Identification. Secondary metabolites 
were extracted from A. fischeri using techniques well established in the Natural Products 
literature.188, 189 This was done by adding a 1:1 mixture of CHCl3:CH3OH and left to 
shake overnight. The resulting slurry was partitioned twice, first with a 4:1:5 
CHCl3:CH3OH:H2O solution, with the organic layer drawn off and evaporated to dryness 
in vaccuo, and secondly, reconstituting 1:1:2 CH3CN:CH3OH:hexanes, where the 
organic layer was drawn off and evaporated to dryness. The extract then underwent 
chromatographic separation (flash chromatography and HPLC) using varied gradient 
systems.  
Growth on Petri Dish. Aspergillus fischeri strain NRRL 181 was maintained in 
the laboratory on potato dextrose agar (PDA; Difco). For the chemical analysis of A. 
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fischeri in Petri dishes different types of media, such as (1) synthetic, and (2) semi-
synthetic were made. Some media were prepared with antibiotics (Streptomycin and 
Penicillin G (ab); 250 mg added in 1L after media sterilization); Potato Dextrose Agar + 
ab + Balsa wood (PDA + Balsa; Difco), PDA + ab (Difco), PDA and cheerios (Difco and 
General Mills), Oatmeal Agar (OMA; Difco), Sabouraud Agar (SDA; Difco), Peptone 
Yeast Glucose Agar (PYG; 1.25 g soy peptone, 1.25 g yeast extract, 5 g D-glucose, 1 L 
H2O), Czapek Yeast Agar (CYA; 50 g Czapek mixture, 5 g yeast extract, 1 L H2O), and 
Yeast Extract Soy Peptone Dextrose Agar (YESD; 20 g soy peptone, 20 g dextrose, 5 g 
yeast extract, 1 L H2O).  A small piece of agar plug  (~0.5 cm2) from a fresh culture 
grown on potato dextrose agar was cut from the leading edge of 2-week old colony from 
A. fischeri and was used to inoculate eight different types of agar media, respectively. 
The Petri plates were then incubated at room temperature until the cultures showed 
formation of conidia (sporulation), which would indicate completion of initial growth 
phase (~2 weeks), thus corresponding to the production of secondary metabolites. 
 Growth on Solid-State Fermentation for Isolation and Structural 
Elucidation of Secondary Metabolites. Aspergillus fischeri was grown on three 
different types of solid-state fermentation media, rice 96, 153-156, multigrain cheerios 190, 
and oatmeal. To initiate growth on grain or cereal based media, we first prepared a seed 
culture of the fungus. As outlined above a small square of agar along with the fungal 
mycelium was cut out aseptically from the leading edge of a 2-week old culture growing 
on potato dextrose agar media and transferred to a sterile falcon tube with 10 ml of 
YESD liquid media for seed culture. The liquid YESD cultures were grown for three days 
on an orbital shaker (100 rpm) at room temperature, and then they were used to 
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inoculate three different types of solid fermentation media, which was prepared as 
outlined below.    
Solid-state fermentation using rice [(1:1 commercial white rice (variety: Calrose 
Botan; 5 g) and (variety: Sona Masoori; 5 g)] was prepared by adding 10 g rice into a 
250 mL Erlenmeyer flask with 20 mL of DI-H2O, then autoclaved at 221 °C for 30 min. 
Cheerios breakfast cereal (multigrain variety) was prepared using 7g of cheerios 
(enough to cover the bottom surface area of a 250 mL Erlenmeyer flask) and autoclaved 
at 221 °C for 30 min, without any DI-H2O. Finally, Oatmeal cereal media (Old fashioned 
breakfast Quaker oats) was made by adding 10 g oatmeal to a 250 mL Erlenmeyer flask 
with 15-17 mL of DI-H2O, then autoclaved at 221 °C for 30 min. All fermentation cultures 
were incubated statically at room temperature for 14 days before chemical analysis.  
For chemical analysis, cultures of A. fischeri were not grown on liquid media because 
previous studies in our laboratory suggested that solid media yield a larger quantity of 
secondary metabolites.159  
Solid Media Extraction. To each of the solid fermentation cultures of Aspergillus 
fischeri, 60 mL of 1:1 CHCl3-CH3OH were added, and the cultures were chopped using a 
spatula and left to shake overnight (~ 16 hrs.). The resulting slurries were vacuum 
filtered, and to the filtrate was added 90 mL of CHCl3 and 150 mL of DI H2O.  This 4:1:5 
CHCl3:CH3OH:H2O solution was partitioned in a separatory funnel, and the organic layer 
was drawn off and evaporated to dryness in vacuo. This sample was then reconstituted 
with 100 mL 1:1 CH3CN : CH3OH and 100 mL of hexanes and partitioned. The defatted 
organic layer was evaporated to dryness.  
Isolation. The defatted extract was then dissolved in CHCl3, absorbed onto celite 
545 (Acros Organics, celite 545), and fractioned by normal phase flash chromatography 
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using a gradient of hexane-CHCl3-CH3OH at an 18 mL/min flow rate and 90.0 column 
volumes over 24.0 min to produce five fractions. Fraction 1 was purified further via 
preparative HPLC using a gradient system 20:80 to 100:0 of CH3CN-H2O with 0.1% 
formic acid over 30 min at a flow rate of 16.9 mL/min to yield seven subfractions. 
Subfractions 1, 2, 3, 4, 5, and 6 yielded compounds 8 (0.85 mg), 4 (0.82 mg), 7(0.51 
mg), 6 (1.13 mg), 1 (2.88 mg), and 3 (3.20 mg), which eluted at approximately 6.9, 7.7, 
8.9, 13.2, 17.0, and 24.4 min, respectively. Fraction 3 was purified further via preparative 
HPLC using the same gradient system to yield ten subfractions. Subfractions 2, 3, 4, and 
5 yielded compounds 10 (1.20 mg), 9 (1.73 mg), 2 (1.17 mg), and 5 (3.2 mg), which 
eluted at approximately 8.2, 9.3, 17.2, and 24.4 min respectively.  
Agar Plate Extraction. Each agar plate culture of A. fischeri was chopped 
thoroughly and added to a scintillation vial, then 10 mL of 1:1 CHCl3-CH3OH were 
added. The cultures were shaken vigorously on a vortex for a few minutes, and then let 
to sit for four hours. The cultures were then filtered, and the supernatant was collected. 
The supernatant was then subjected to LC-MS analysis. 
General Experimental Procedures. Optical rotation data were obtained using a 
Rudolph Research Autopol III polarimeter (Rudolph Research Analytical). UV was 
carried out on a Varian Cary 100 Bio UV−vis spectrophotometer (Varian Inc.) Circular 
Dichroism (CD) was carried out on an Olis DSM 17 ECD spectrophotometer (Olis, Inc.) 
The NMR data were collected using either a JEOL ECS-400 spectrometer, which was 
equipped with a JEOL normal geometry broadband Royal probe, and a 24-slot 
autosampler, and operated at 400 MHz for 1H and 100 MHz for 13C, or a JEOL ECA-500 
spectrometer operating at 500 MHz for 1H and 125 MHz for 13C (Both from JEOL USA, 
Inc.), or an Agilent 700 MHz spectrometer (Agilent Technologies), equipped with a 
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cryoprobe, operating at 700 MHz for 1H and 175 MHz for 13C. HRMS experiments 
utilized either a Thermo LTQ Orbitrap XL mass spectrometer or a Thermo QExactive 
Plus (Thermo Fisher Scientific); both were equipped with an electrospray ionization 
source. A Waters Acquity UPLC (Waters Corp.) was utilized for both mass 
spectrometers, using a BEH C18 column (1.7 m; 50 mm x 2.1 mm) set to a column 
temperature of 40oC and a flow rate of 0.3 mL/min. The mobile phase consisted of a 
linear gradient of CH3CN-H2O (acidified with 0.1% formic acid), starting at 15% CH3CN 
and increasing linearly to 100% CH3CN over 8 min, with a 1.5 min hold before returning 
to the starting condition. The HPLC separations were performed with an Atlantis T3 C18 
semi-preparative (5 m; 10 x 250 mm) and preparative (5 m; 19 x 250 mm) columns, at 
a flow rate of 4.6 mL/min and 16.9 mL/min, respectively, with a Varian Prostar HPLC 
system equipped with a Prostar 210 pumps and a Prostar 335 photodiode array detector 
(PDA), with the collection and analysis of data using Galaxie Chromatography 
Workstation software. Flash chromatography was performed on a Teledyne ISCO 
Combiflash Rf 200 and monitored by both ELSD and PDA detectors. 
Construction of the A. fischeri laeA Mutant. The gene replacement cassettes 
were constructed by ‘‘in vivo’’ recombination in S. cerevisiae as previously described.191, 
192 Approximately 2.0 kb from the 5’-UTR and 3’-UTR flanking regions of the targeted 
ORF were selected for primer design. The primers pRS NF010750 5´fw (5´-
GTAACGCCAGGGTTTTCCCAGTCACGACGCAGTCTAACGCTGGGCCCTTCC-3´) 
and pRS NF010750 3´rv (5´-
GCGGTTAACAATTTCTCTCTGGAAACAGCTACGGCGTTTGACGGCACAC-3´) 
contained a short homologous sequence to the Multicloning site (MCS) of the plasmid 
pRS426. Both the 5’- and 3’-UTR fragments were PCR-amplified from A. fischeri 
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genomic DNA (gDNA). The prtA gene, conferring resistance to pyrithiamine, which was 
placed within the cassette as a dominant marker, was amplified from the pPRT1 plasmid 
by using the primers prtA NF010750 5´rv (5´-
GTAATCAATTGCCCGTCTGTCAGATCCAGGTCGAGGAGGTCCAATCGG-3´) and prtA 
NF010750 3´fw (5´-
CGGCTCATCGTCACCCCATGATAGCCGAGATCAATCTTGCATCC-3´). The deletion 
cassette was generated by transforming each fragment along with the plasmid pRS426, 
cut with BamHI/EcoRI, into the S. cerevisiae strain SC94721 using the lithium acetate 
method.193 The DNA from the transformants was extracted by the method described by 
Goldman et al..194 The cassette was PCR-amplified from these plasmids utilizing 
TaKaRa Ex Taq™ DNA Polymerase (Clontech Takara Bio) and used for A. fisheri 
transformation according to the protocol described by Malavazi and Goldman.192 
Southern blot and PCR analyses were used to demonstrate that the cassette had 
integrated homologously at the targeted A. fischeri locus. Genomic DNA from A. fischeri 
was extracted by grinding frozen mycelia in liquid nitrogen and then gDNA was extracted 
as previously described.192 Standard techniques for manipulation of DNA were carried 
out as described.195 For Southern blot analysis, restricted chromosomal DNA fragments 
were separated on 1% agarose gel and blotted onto Hybond N+ nylon membranes (GE 
Healthcare). Probes were labeled using [α-32P]dCTP using the Random Primers DNA 
Labeling System (Life Technologies). Labeled membranes were exposed to X-ray films, 
which were scanned for image processing. Southern blot and PCR schemes are shown 
in Figure 12. 
Secondary Metabolite Information. Compound 3 (14 – epi-aszonapyrone A): 
white solid; [α]D20 = +43 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 293 (3.16), 221 (3.00) 
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nm; 1H and 13C NMR data, see Table 2.3; HRESIMS [M + H] + 457.2941 (calculated for 
C28H41O5, 457.2948). 
Compound 10 (13-O-prenyl-fumitremorgin B): white solid; [α]D20 = +19 (c 0.09, 
MeOH); UV (MeOH) λmax (log ε) 293 (2.99), 277 (3.01), 232 (3.26) nm; 1H and 13C NMR 
data, see Table 2.4; HRESIMS [M + H] + 548.3103 (calculated for C32H42N3O5, 
548.3118). 
Supplementary Data 
Table 2.3. 1H (700 MHz) and 13C (175 MHz) NMR Data in CDCl3 for 14 – epi-
aszonapyrone A (3). 
 
Position δH  δC Mult (J in Hz) 
1 1.03, 1.69 38.3 m 
2 1.35, 1.62 23.8 m 
3 4.49 81.1 dd (11.7, 4.7) 
4  37.9  
5 0.91 55.5 dd (12.3, 2.2) 
6 1.43, 1.63 18.8 m 
7 1.32, 2.04 40.3 m 
8  40.8  
9 1.08 60.0 m 
10  37.6  
11 1.68 23.7 m 
12 1.99 38.3 td (12.8, 5.0) 
 2.39  ddd (12.5, 3.7, 2.2) 
13  151.4  
14 2.15 55.9 m 
15 2.48 18.6 dd (15.2, 9.2) 
 2.72  dd (15.5, 2.4) 
16  103.5  
17  166.1  
19  160.0  
20 5.80 100.8 s 
21  165.0  
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22 0.85 16.6 s 
23 0.84 28.1 s 
24 0.83 16.4 s 
25 0.75 15.1 s 
26 4.87, 4.98 106.8 s 
27 2.16 19.8 s 
1’  171.3  
2’ 2.05 21.5 s 
 
Table 2.4. 1H (700 MHz) and 13C (175 MHz) NMR Data in CDCl3 for 13-O-prenyl-
fumitremorgin B (10). 
 
Position δH  δC Mult (J in Hz) 
2   131.3 
 
3 6.05 48.1 dd (10.1, 1.0) 
5   171.6 
 
6 4.63 59.1 dd (9.6, 7.4) 
7 2.15 28.9 m 
 2.42  dtd (13.3, 6.9, 2.4) 
8 2.03 23.2 m 


















16 7.65 120.6 dd (8.7, 0.5) 










21 4.53 41.9 m 





24 1.84 18.4 d (1.2) 
25 1.68 25.7 d (1.5) 






28 1.96 18.5 d (1.3) 
29 1.61 25.8 d (1.3) 
30 3.85 55.9 s 
31 4.74 69.5 dd (11.1, 7.0)  
 5.03  m 





34 1.81 18.6 m 
35 1.81 26.0 m 
12 - OH 4.42   s 
 
Table 2.5. HRESIMS Table of Compounds 1-10 
 







sartorypyrone A (1) 
C28H40O5 
457.2940 457.2949 [M+H]+ -1.9 
14-epi-aszonapyrone A (3) 
C28H40O5 
457.2941 457.2949 [M+H]+ -1.6 
aszonalenin (4) 
C23H23N3O2 
374.1856 374.1863 [M+H]+ -1.9 
acetylaszonalenin (5) 
C25H25N3O3 
416.1961 416.1969 [M+H]+ -1.8 
fumitremorgin A (6) 
C32H41N3O7 
580.3001 580.3017 [M+H]+ -2.8 
fumitremorgin B (7) 
C27H33N3O5 
480.2482 480.2493 [M+H]+ -2.3 
verruculogen (8) 
C27H33N3O7 
512.2386 512.2391 [M+H]+ -1.0 
C-11 epimer of verruculogen TR-2 
(9) 
C22H27N3O6 
430.1961 430.1973 [M+H]+ -2.7 
13-O-prenyl-fumitremorgin B (10) 
C32H41N3O5 




Figure 6. A. fumigatus Grows Slower Than A. fischeri in Glucose Minimal Media (GMM), 
but at the Same Speed as A. fischeri in Lung Homogenate Media. A. fumigatus CEA10 
or A. fischeri NRRL181 were cultured in flat-bottom 96 well plates at 2x104 conidia per 
well. Conidia were added in a 20 µL of 0.01% Tween-80 and media was carefully 
pipetted over the inoculum into each well. Lung homogenate was generated according to 
(29). Plates were incubated for 7 hours at 37C before measurements at 405 nm were 
taken every 10 min.  Mean and SEM of eight technical replicates; data is representative 





Figure 7. A. fischeri and A. fumigatus Exhibit Similar Growth Patterns at 30C but Not at 
44C. A-D) 1x103 conidia were point inoculated on each plate, plates were then 
incubated at 30C in normoxia (~21% oxygen, 5%CO2); colony diameter was measured 
every 24 hours. Mean and SEM of triplicates. Tween-80 – 1% Tween-80 provided as 
sole carbon source; CAA – Casamino acids; GMM – glucose minimal media. E) Error 
bars indicate standard deviations between biological duplicates (**P-value < 0.005 in a 
paired, equal variance Student t-test). 
 
 
Figure 8. The Genomes of A. fumigatus and A. fischeri are Largely Similar, but Their 
Secondary Metabolic Pathways are Quite Divergent. Left, Venn diagram showing the 
sets of A. fischeri-specific proteins, shared orthologous proteins, and A. fumigatus-
specific proteins encoded in each genome.  Numbers below each species name indicate 
the total number of proteins encoded in that genome. Right, Venn diagram showing the 
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sets of A. fischeri-specific BGC proteins, shared BGC proteins, and A. fumigatus-specific 
BGC proteins. Numbers below each species name indicate the total number of BGC 
proteins encoded in that genome. In each diagram, circles are proportional to the 
number of proteins they contain. 
 
 
Figure 9. The Acetylaszonalenin and Gliotoxin Biosynthetic Gene Clusters in A. 
fumigatus and A. fischeri are Located Immediately Next to One Another. The portions of 
Clusters 37 and 25 from A. fischeri and A. fumigatus, respectively, that are known to 
contain the previously characterized acetylaszonalenin196 and gliotoxin150 BGCs is 
shown. Genes colored in shades of green are involved in the acetylaszonalenin 
biosynthetic pathway. Dark green, anaPS (nonribosomal peptide synthase). Light green, 
anaAT (acetyltransferase). Green, anaPT (prenyltransferase). Orange, gliotoxin 
biosynthetic genes. Gray arrow, syntenic gene in both species not involved in gliotoxin 
synthesis. Sequences that are similar to one another (based on blastn scores) are 
marked by gray parallelograms. Image was made using EasyFig version 2.2.2.187 
 
 
Figure 10. A Custom Chemical Analysis Protocol was Developed for Studying the 
Metabolites Produced by A. fischeri. Approximately 60 mL of 1:1 CH3OH:CH3Cl was 
added to cultures of Aspergillus fischeri grown on solid-state fermentation for two weeks. 
The cultures were then chopped thoroughly with a large scalpel and shaken for 16 hours 
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using an orbital shaker. The liquid culture was then vacuum filtered and concentrated 
using 90 mL CH3Cl and 150 mL water and transferred into a separatory funnel. The 
organic (bottom) layer was drawn off and evaporated to dryness. The dried, de-sugared 
extract was reconstituted in 100 mL of 1:1 CH3OH:CH3CN and 100 mL of hexane. The 
biphasic solution was shaken vigorously and transferred to a separatory funnel. The 
CH3OH:CH3CN layer was evaporated to dryness under vacuum, producing a de-fatted 
extract. The extract was then subdivided into several peaks or fractions using flash 
chromatography. The subfractions were further separated using HPLC until pure 
compounds were isolated. The pure compounds were subjected to UPLC-MS analysis to 
establish the molecular formula and fragmentation patterns. Finally, pure compounds 




Figure 11. A. Fischeri Produces Different Numbers of Metabolites, Depending on the 
Media it is Grown on. Base peak chromatograms as measured by LC-MS, illustrating 
how the chemistry profiles varied based on growth conditions. PDA + ab was used as 
the chemical control to observe the differences in the secondary metabolites, due to it 
being the media that A. Fischeri is stored. There were overall no chemical differences 
observed between the different variations of PDA media. Each peak (which indicates 
different chemical entities) was observed in the three PDA variations, albeit at fluctuating 
intensities. SDA, PYG, and YESD produced the majority of the peaks observed in PDA, 
but it also lacked some observed peaks, indicating that these growth conditions were not 
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chemically favored. CYA produced the majority of the peaks, as well as an additional 
peak that was observed at a much lower intensity in PDA. However, this peak was 
similarly observed in OMA. OMA produced similar peaks to those observed in PDA, but 
with higher intensity. Due to this, OMA was selected to further study. The gray boxes 




Figure 12. Southern Blot Confirms Construction of the laeA Mutant. A 1kb probe 
recognizes a single DNA band (~4.4kb) in the wild type strain and a single DNA band 




Figure 13. UPLC analysis of compounds 1-10, arranged from Top to Bottom. 
 
Figure 14. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 
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Figure 15. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 
















Figure 19. NOESY spectrum of 14-epimer of aszonapyrone A (3), CDCl3, 700 MHz 
 
 




Figure 21. 1H NMR spectrum (500 MHz, Top) and 13C NMR spectrum (125 MHz, 




Figure 22. 1H NMR spectrum (500 MHz, Top) and 13C NMR spectrum (125 MHz, 




Figure 23. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 




Figure 24. 1H NMR spectrum (500 MHz, Top) and 13C NMR spectrum (125 MHz, 




Figure 25. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 




Figure 26. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 


















Figure 30. Key COSY and HMBC data for 14-epi-aszonapyrone A (3) and 13-O-prenyl-




      
14-epi-aszonapyrone A (3)                   13-O-prenyl-fumitremorgin B (10) 
 = HMBC correlations  = COSY correlations 
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GLIOTOXIN, A KNOWN VIRULENCE FACTOR IN THE MAJOR HUMAN PATHOGEN 
ASPERGILLUS FUMIGATUS, IS ALSO BIOSYNTHESIZED BY THE NON-
PATHOGENIC RELATIVE A. Fischeri 
 
Sonja L. Knowles, Matthew E. Mead, Lilia Pereira Silva, Huzefa A. Raja, Jacob L. 




Aspergillus fumigatus is a major opportunistic human pathogen. Multiple traits 
contribute to A. fumigatus pathogenicity, including its ability to produce specific 
secondary metabolites, such as gliotoxin. Gliotoxin is known to inhibit the host immune 
response, and genetic mutants that inactivate gliotoxin biosynthesis (or secondary 
metabolism in general) attenuate A. fumigatus virulence. The genome of A. Fischeri, a 
very close non-pathogenic relative of A. fumigatus, contains a biosynthetic gene cluster 
that exhibits high sequence similarity to the A. fumigatus gliotoxin cluster. However, A. 
Fischeri is not known to produce gliotoxin. To gain further insight into the similarities and 
differences between the major pathogen A. fumigatus and the non-pathogen A. Fischeri, 
we examined whether A. Fischeri strain NRRL 181 biosynthesizes gliotoxin and whether 
its production, and of secondary metabolites more generally, influence its virulence 
profile. We found that A. Fischeri biosynthesizes gliotoxin in the same conditions as A. 
fumigatus. However, whereas loss of laeA, a master regulator of secondary metabolite 
production, including gliotoxin, has been previously shown to reduce the virulence of 
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A. fumigatus, we found that laeA loss (and loss of secondary metabolite production) in A. 
Fischeri does not influence its virulence. These results suggest that LaeA-regulated 
secondary metabolites are virulence factors in the genomic and phenotypic background 
of the major pathogen A. fumigatus but are much less important in the background of the 
non-pathogen A. Fischeri. We submit that understanding the observed spectrum of 
pathogenicity across closely related pathogenic and non-pathogenic Aspergillus species 
will require detailed characterization of their biological, chemical, and genomic 
similarities and differences. 
Aspergillus fumigatus is a major opportunistic fungal pathogen of humans but 
most of its close relatives are non-pathogenic. Why is that so? This important, yet largely 
unanswered, question can be addressed by examining how A. fumigatus and its non-
pathogenic close relatives are similar or different with respect to virulence-associated 
traits. We investigated whether Aspergillus fischeri, a non-pathogenic close relative of A. 
fumigatus, can produce gliotoxin, a mycotoxin known to contribute to A. fumigatus 
virulence. We discovered that the non-pathogenic A. Fischeri produces gliotoxin under 
the same conditions as the major pathogen A. fumigatus. However, we also discovered 
that, in contrast to what has been previously observed in A. fumigatus, loss of secondary 
metabolite production in A. Fischeri does not alter its virulence. Our results are 
consistent with the “cards of virulence” model of opportunistic fungal disease, where the 
ability to cause disease stems from the combination (“hand”) of individual virulence 




Figure 32. Aspergillus fischeri Biosynthesizes Gliotoxin When Grown in Conditions That 
Induce A. fumigatus Gliotoxin Biosynthesis. A. Chemical structure of gliotoxin. B. The 
genome of the non-pathogenic species A. Fischeri strain NRRL 18116, 123 contains a 
biosynthetic gene cluster homologous to the gliotoxin cluster in the major pathogen A. 
fumigatus strain Af293.150, 197, 198 Arrows indicate genes and the direction in which they 
are transcribed. Red – regulation, Purple – decoration, Orange – backbone biosynthesis, 
Blue – transport, Green – resistance. Homologous genes are connected by gray 
parallelograms. C – I. Chromatograms demonstrating the biosynthesis of gliotoxin in A. 
Fischeri when grown on Czapek-Dox Agar (CDA) or blood agar at 37°C. Each sample 
(dried organic extract in MeOH at a concentration of 0.2 mg/mL) was analyzed by 
UHPLC-HRESIMS, and the data are presented as extracted ion chromatograms (XIC) 
using the protonated mass of gliotoxin (C13H15N2O4S2; [M+H]+ = 327.0473) and a window 
of ± 5.0 ppm. C. Analysis of the gliotoxin standard (in MeOH at a concentration of 0.01 
mg/mL). D. A. fumigatus grown on CDA at 37°C. E. A. fumigatus grown on blood agar at 
37°C. F. A. Fischeri grown on CDA incubated at 37°C. G. A. Fischeri grown on blood 
agar incubated at 37°C. H. A. Fischeri grown on CDA at room temperature (RT). I. A. 
Fischeri grown on blood agar at RT. The retention time (3.30 min) and accurate mass 
(327.0473 ± 5.0 ppm) data confirm the biosynthesis of gliotoxin by A. Fischeri in panels 
F and G. NL: Normalization Level (i.e., base peak intensity; the larger the NL value the 
better the signal to noise ratio). 
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Aspergillus fumigatus is a major fungal pathogen responsible for hundreds of 
thousands of infections and deaths each year.199, 200 Several secondary metabolites 
biosynthesized by A. fumigatus have been shown to be required for disease.27 For 
example, gliotoxin (Figure 32A), a secondary metabolite that belongs to the 
epipolythiodioxopiperazine (ETP) class of mycotoxins,150, 197, 198 can be detected in the 
sera of patients with invasive aspergillosis201 and is known to inhibit the host immune 
response.27 When the gliP gene, which encodes the essential non-ribosomal peptide 
synthetase of the gliotoxin biosynthetic gene cluster, is deleted from A. fumigatus, the 
mutant strain does not biosynthesize gliotoxin and exhibits attenuated virulence in a non-
neutropenic murine model of aspergillosis.34, 35, 202 Similarly, deletion of laeA, a positive 
regulator of several A. fumigatus secondary metabolites, including gliotoxin, also 
reduces virulence.119, 203 These results suggest that gliotoxin, as well as other secondary 
metabolites, contribute to A. fumigatus virulence.27 
Even though A. fumigatus is a major pathogen, its closest relatives are non-
pathogenic.16, 181, 204 For example, the closely related species Aspergillus fischeri has 
been identified as the cause of only a handful of clinical cases129, 131 and is not 
considered pathogenic. Detailed comparisons of virulence in diverse murine and 
invertebrate models of fungal disease have shown that A. Fischeri is much less virulent 
than A. fumigatus.16 It is important to emphasize here that in diverse animal models of 
aspergillosis, especially when high inoculums of spores are administered, non-
pathogens can sometimes cause disease, as we have observed in previous experiments 
with A. Fischeri; however, in all such cases non-pathogens exhibit lower levels of 
virulence than pathogens.16 
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Despite their significant differences in ability to cause fungal disease, a recent 
examination of known genetic contributors to virulence revealed that nearly all genes 
known to contribute to A. fumigatus disease are also present in A. Fischeri.16 For 
example, both species appear to contain laeA, and deletion of the laeA gene in either 
species is known to reduce biosynthesis of secondary metabolites,16, 205 suggesting that 
the gene’s function is conserved. Similarly, both species appear to contain intact 
gliotoxin biosynthetic gene clusters (Figure 32B); however, gliotoxin production has been 
shown in A. fumigatus and a few other closely related species,151 but not in A. Fischeri.16, 
151 These data raise two questions: Is A. Fischeri capable of biosynthesizing gliotoxin? 
And if it is, how does production of gliotoxin, and secondary metabolites more generally, 
influence its virulence profile?  
Results 
A. Fischeri, a Non-Pathogenic Relative of the Major Pathogen A. fumigatus, 
Can Also Biosynthesize Gliotoxin. To test whether A. Fischeri biosynthesizes 
gliotoxin, we examined the chemical profile of a standard of gliotoxin and extracts of A. 
fumigatus strain Af293, and A. Fischeri strain NRRL 181 via UHPLC–HRESIMS (ultra-
high-performance liquid chromatography–high-resolution electrospray ionization mass 
spectrometry). We collected three sets of data, specifically chromatographic retention 
time, high resolution mass spectrometry data, and tandem mass spectrometry 
fragmentation patterns. Analysis of a gliotoxin standard (Figure 32C) showed that it 
elutes at 3.30 min, with an accurate mass of 327.0464 Da (2.8 ppm) and has key 
fragments of 263.1 Da and 245.1 Da, in accord with values reported in the literature.206  
We next analyzed A. fumigatus strain Af293, which we used as a positive control, 
since it is known to biosynthesize gliotoxin.151 When A. fumigatus was grown on Czapek-
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Dox Agar (CDA) at 37°C (Figure 32D), a peak with the same retention time (3.30 min), 
HRESIMS spectrum, MS/MS spectrum, and accurate mass of 327.0463 (3.1ppm) was 
noted (Figures 34 and 35). We also detected gliotoxin production, albeit in lower 
abundance, when we cultured A. fumigatus on 5% blood agar at 37°C (Figure 32E). In 
contrast, we did not observe gliotoxin production when we grew A. fumigatus on oatmeal 
agar at 37°C (Figure 36). 
To test whether A. Fischeri biosynthesized gliotoxin, we grew strain NRRL 181 
on the same media and temperature conditions as A. fumigatus. When A. Fischeri was 
grown on CDA at 37°C, we observed a peak with the same retention time (Figure 32F), 
HRESIMS spectrum (Figure 37), and MS/MS spectrum as that of A. fumigatus (Figure 
38), indicating gliotoxin biosynthesis in A. Fischeri. Similarly, we detected gliotoxin 
production in lower abundance when we grew A. Fischeri on 5% blood agar at 37oC 
(Figure 32G). In contrast, we did not observe gliotoxin production when we grew A. 
Fischeri on CDA or on 5% blood agar at room temperature (Figures 32H and 32I, 
respectively) or on oatmeal agar at 37oC (Figure 36). These results demonstrate that: a) 
the non-pathogen A. Fischeri biosynthesizes similar quantities of gliotoxin in the same 
conditions that induce gliotoxin biosynthesis in the major pathogen A. fumigatus, and b) 
similar to what has been previously observed in A. fumigatus,207, 208 both growth medium 
and temperature influence gliotoxin biosynthesis in A. Fischeri. 
laeA, a Master Regulator of Secondary Metabolism and A. fumigatus 
Virulence Factor, is Not a Virulence Factor in A. Fischeri. To test whether the 
regulation of secondary metabolite production contributes to the virulence profile of A. 
Fischeri, we deleted the endogenous copy of laeA from A. Fischeri and infected larvae of 
the moth Galleria mellonella, a well-established invertebrate model of fungal disease,183 
74 
with the resulting mutant strain. The use of G. mellonella larvae is an appropriate model 
for our study for two reasons. First, because our previous work revealed consistent 
virulence profile differences between wild-type (WT) strains of A. Fischeri and A. 
fumigatus in two difference murine models and in G. mellonella moth larvae 16. Second, 
because infection of G. mellonella larvae with A. fumigatus is known to induce gliotoxin 
biosynthesis.209 We infected asexual spores (conidia) at two different concentrations and 
compared the survival curves between the ΔlaeA and the WT strain of A. Fischeri 
(Figure 33). At both concentrations, our experiments showed that moth larval survival 
was not significantly different between the ΔlaeA and the WT strains.  
 
 
Figure 33. Deletion of the Master Regulator laeA in A. Fischeri Does Not Alter its 
Virulence. Cumulative survival of moth (Galleria mellonella) larvae inoculated with 5 x 
105 (left) or 1 x 106 (right) asexual spores or conidia of either the ΔlaeA mutant or the 
wild-type (WT) A. Fischeri NRRL 181 strain. Comparisons of moth cumulative survival 
when infected with either ΔlaeA or WT strain revealed no statistically significant 
differences at spore concentrations of 5 x 105 (left) or 1 x 106 (right) (p-value = 0.91 and 




Importantly, the ΔlaeA strain of A. Fischeri NRRL 181 is known to exhibit reduced 
production of secondary metabolites in diverse conditions in a manner consistent with 
the gene’s role as a master regulator of secondary metabolism.16 To confirm that the 
ΔlaeA strain does not produce gliotoxin, we analyzed it using the same chemical 
methods that showed production of gliotoxin in the WT strain following growth on CDA or 
5% blood agar at 37oC. In contrast to the WT strain (Figures 32F and 32G), we did not 
observe gliotoxin production in the ΔlaeA strain (Figure 36). Whereas loss of laeA and 
secondary metabolite – including gliotoxin – production has been previously shown to 
reduce the virulence of the major pathogen A. fumigatus,119, 203 our results suggest that 
loss of laeA and secondary metabolite production16 in A. Fischeri does not influence its 
virulence.  
In contrast to the attenuation of A. fumigatus virulence observed in the ΔlaeA119, 
203 and ΔgliP34, 35, 202 strains, deletion or overexpression of gliZ, the transcriptional 
regulator of the gliotoxin biosynthetic cluster, does not alter the virulence of A. 
fumigatus.210 Dissecting the effect of gliotoxin in A. Fischeri virulence through the 
construction of ΔgliZ and ΔgliP mutants in multiple animal models would be an 
interesting follow-up experiment, especially given that A. fumigatus ΔlaeA strains have 
been previously shown to produce a lower, but considerable, amount of gliotoxin in vivo 
during murine infection.210 However, given that deletion of laeA does not alter A. Fischeri 
virulence (Figure 33), the expectation would be that specific inactivation of the gliotoxin 





Materials and Methods 
Fungal Strains. Aspergillus fischeri strain NRRL 181 was obtained from ARS 
Culture Collection (NRRL).16 A. fumigatus strain Af293 was also utilized as a positive 
control.211  
Growth Conditions. All strains were maintained on potato dextrose agar (PDA; 
Difco). To establish individual cultures, an agar square along with fungal mycelium was 
cut out aseptically from the leading edge of the culture and transferred onto blood agar 
(tryptic soy agar with 5% sheep’s blood; Hardy Diagnostics), Czapek-Dox agar (CDA; 
Difco), or oatmeal agar (OMA; Difco). All cultures at 37°C were maintained in an 
incubator (VWR International) in the dark over four days. All cultures at room 
temperature (RT; ~22°C) were kept for two weeks under 12h light/dark cycles. A. 
Fischeri was grown on CDA (RT and 37°C), blood agar (RT and 37°C), and OMA 
(37°C). A. fumigatus was grown on CDA (37°C), blood agar (37°C), and OMA (37°C). 
Extraction. To evaluate the biosynthesis of gliotoxin in these fungal strains, 
cultures were extracted with organic solvents and analyzed by mass spectrometry (see 
below). The agar plates were extracted by spraying the fungal mycelium with MeOH, 
chopping it with a spatula, and transferring the contents to a scintillation vial. Acetone 
(~15 ml) was then added to the scintillation vial, and the resulting slurry was vortexed 
vigorously for approximately 3 min before steeping for 4 h at RT. Subsequently, the 
mixture was filtered and the resulting extract was dried under a stream of nitrogen gas. 
UHPLC-HRESIMS Analysis. High-resolution electrospray ionization mass 
spectrometry (HRESIMS) experiments utilized a Thermo LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific), equipped with an electrospray ionization 
source. This was coupled to an Acquity ultra-high-performance liquid chromatography 
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(UHPLC) system (Waters Corp.), using a flow rate of 0.3 ml/min and a BEH C18 column 
(2.1 mm x 50 mm, 1.7 μm) that was operated at 40°C. The mobile phase consisted of 
CH3CN–H2O (Fischer Optima LC-MS grade; both acidified with 0.1% formic acid). The 
gradient began at 15% CH3CN and increased linearly to 100% CH3CN over 8 mins, 
where it was held for 1.5 mins before returning to starting conditions to re-equilibrate.  
Extracts were analyzed in the positive ion mode, scanning over a mass range of 
m/z 100 to 2,000 at a resolving power of 30,000. The spray voltage, source capillary, 
and tube lens voltages were set to 4.0 kV, 20 V, and 100 V, respectively, with a nitrogen 
sheath gas set to 30 arb and capillary temperature at 300°C. The fragmentation patterns 
(i.e., MS/MS data) were obtained by using an inclusion list containing the mass of 
gliotoxin ([M+H]+ = 327.047 m/z), with an isolation window of 2 Da and collision energy 
of 35%. The extracts and gliotoxin standard (Cayman Chemical Company) were 
prepared at a concentration of 0.2 mg/ml and 0.01 mg/ml, respectfully; both were 
dissolved in MeOH with an injection volume of 3 μl. To eliminate the possibility for 
sample carryover, two blanks (MeOH) were injected between every sample injection and 
the gliotoxin standard was analyzed at the end of the run. 
Virulence Studies Using an Invertebrate Model of Fungal Disease (Galleria 
mellonella).  These experiments were performed as previously described.16 Briefly, 
larvae of the moth G. mellonella were obtained by breeding adult moths183 and selecting 
larvae that were similar in size (~275–330 mg). Prior to use, all larvae were kept for 24 
hours in glass petri dishes in darkness at 37°C. Asexual spores (conidia) of ΔlaeA 
mutant or the wild-type (WT) A. Fischeri were obtained by growing the organism on a 
yeast extract-agar-glucose (YAG) medium for 2 days. Conidia were harvested in PBS 
and filtered through Miracloth (Calbiochem). Conidial concentration was estimated using 
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a hemocytometer and conidial viability was assessed through incubation on YAG 
medium at 37°C for 48 h. 
For infection assays, ten G. mellonella larvae in the final (sixth) instar larval stage 
of development were used per condition. Each larva in the test group was infected with a 
5 μl inoculum of conidia from the ΔlaeA mutant of A. Fischeri (at either a 5 x 105 spores / 
μl or a 1 x 106 spores / μl concentration), whereas each larva in the control group was 
inoculated with the same concentration of the WT strain of A. Fischeri. All inoculations 
were done using a Hamilton syringe (7000.5KH). All injections were performed at the 
hemocoel of each larva via the last left proleg. Following inoculation, all larvae were 
incubated in glass petri dishes in darkness at 37°C. Larval killing was scored daily. 
Larvae were considered dead by if they did not move in response to touch. 
Conclusion 
 In this study, we show for the first time that A. Fischeri – when grown in 
conditions known to induce gliotoxin production in A. fumigatus – can biosynthesize 
gliotoxin (Figure 32). Furthermore, we show that an A. Fischeri mutant that lacks a 
master regulatory gene of secondary metabolism (laeA) does not alter the pathogenic 
potential of A. Fischeri (Figure 33). Thus, it appears that secondary metabolites are 
virulence factors in the genomic and phenotypic background of the pathogen A. 
fumigatus but that they are much less important for virulence in the genomic background 
of the non-pathogen A. Fischeri. These results provide support for the “cards of 
virulence” model of opportunistic fungal disease 212, where the ability to cause disease 
stems from the combination (“hand”) of individual virulence factors (“cards”). We 
hypothesize that while A. Fischeri possesses the “cards” for gliotoxin production and 
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secondary metabolism regulation, its cumulative “hand” is thankfully not a winner when it 





Figure 34. The mass spectra of gliotoxin in A. fumigatus grown on CDA and blood agar 
at 37°C verify the biosynthesis of gliotoxin by cultures of A. fumigatus on both CDA and 
blood agar at 37oC. Data are presented as mass to charge ratios (m/z). A. The isotopic 
pattern of the standard gliotoxin. B. The isotopic pattern of gliotoxin observed in A. 
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fumigatus grown on CDA at 37oC. C. The isotopic pattern of gliotoxin observed in A. 




Figure 35. The fragmentation pattern (i.e., MS/MS data) of gliotoxin in A. fumigatus 
grown on CDA and blood agar at 37°C verify the biosynthesis of gliotoxin in both the 
CDA and blood agar growths of A. fumigatus at 37oC. A.  The fragmentation pattern of 
the gliotoxin standard (263.1 and 245.1). B. The fragmentation pattern of gliotoxin 
observed in A. fumigatus grown on CDA incubated at 37oC. C. The fragmentation 




Figure 36. Base peak chromatograms of the gliotoxin standard, A. fumigatus grown on 
OMA at 37°C, A. Fischeri grown on OMA at 37°C, ΔlaeA A. Fischeri grown on CDA at 
37°C, and ΔlaeA A. Fischeri grown on blood agar at 37°C show that some media do not 
induce gliotoxin biosynthesis. Additionally, a negative control was analyzed (Panel C), to 
confirm that the observation of gliotoxin biosynthesis (Figure 32) was genuine and not 
simply due to system carryover. Each sample (0.2 mg/mL) was analyzed by UHPLC-
HRESIMS, and the data are presented as extracted ion chromatograms (XIC) using the 
protonated mass of gliotoxin (C13H15N2O4S2; [M+H]+ = 327.0473) and a window of ± 5.0 
ppm. A. Analysis of the gliotoxin standard (0.01 mg/mL). B. A. fumigatus grown on OMA 
incubated at 37°C. C. A. Fischeri grown on OMA incubated at 37°C. D. ΔlaeA A. Fischeri 





Figure 37. The mass spectra of gliotoxin in A. Fischeri verify the biosynthesis of gliotoxin 
by cultures of A. Fischeri on both CDA and blood agar at 37oC. The data are presented 
as mass to charge ratios (m/z). A. The isotopic pattern of the standard gliotoxin. B. 
Isotopic pattern of gliotoxin observed in A. Fischeri grown on CDA at 37oC. C. Isotopic 




Figure 38. The fragmentation patterns (i.e., MS/MS data) of gliotoxin in A. Fischeri 
further verify the biosynthesis of gliotoxin by cultures of A. Fischeri in both the CDA and 
blood agar at 37oC. A.  Fragmentation pattern of the gliotoxin standard (263.1 and 
245.1). B. Fragmentation pattern of gliotoxin observed in A. Fischeri grown on CDA 
incubated at 37oC. C. Fragmentation pattern of gliotoxin observed in A. Fischeri grown 




VARIATION AMONG BIOSYNTHETIC GENE CLUSTERS, SECONDARY 
METABOLITE PROFILES, AND CARDS OF VIRULENCE ACROSS ASPERGILLUS 
FUMIGATUS AND CLOSE NONPATHOGENIC RELATIVES 
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Aspergillus fumigatus is a major human pathogen. In contrast, Aspergillus 
fischeri and the recently described Aspergillus oerlinghausenensis, the two species most 
closely related to A. fumigatus, are not known to be pathogenic. Some of the genetic 
determinants of virulence (or “cards of virulence”) that A. fumigatus possesses are 
secondary metabolites that impair the host immune system, protect from host immune 
cell attacks, or acquire key nutrients. To examine whether secondary metabolism-
associated cards of virulence vary between these species, we conducted extensive 
genomic and secondary metabolite profiling analyses of multiple A. fumigatus, one A. 
oerlinghausenensis, and multiple A. fischeri strains. We identified two cards of virulence 
(gliotoxin and fumitremorgin) shared by all three species and three cards of virulence 
(trypacidin, pseurotin, and fumagillin) that are variable. For example, we found that all 
species and strains examined biosynthesized gliotoxin, which is known to contribute to 
virulence, consistent with the conservation of the gliotoxin biosynthetic gene cluster 
(BGC) across genomes. For other secondary metabolites, such as fumitremorgin, a 
modulator of host biology, we found that all species produced the metabolite but that 
there was strain heterogeneity in its production within species. Finally, species differed in
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 their biosynthesis of fumagillin and pseurotin, both contributors to host tissue damage 
during invasive aspergillosis. A. fumigatus biosynthesized fumagillin and pseurotin, while 
A. oerlinghausenensis biosynthesized fumagillin and A. fischeri biosynthesized neither. 
These biochemical differences were reflected in sequence divergence of the intertwined 
fumagillin/pseurotin BGCs across genomes. These results delineate the similarities and 
differences in secondary metabolism-associated cards of virulence between a major 
fungal pathogen and its nonpathogenic closest relatives, shedding light onto the genetic 
and phenotypic changes associated with the evolution of fungal pathogenicity. 
Fungal diseases impose a clinical, economic, and social burden on humans.213-
215 Fungi from the genus Aspergillus are responsible for a considerable fraction of this 
burden, accounting for more than 250,000 infections annually with high mortality rates.199 
Aspergillus infections often result in pulmonary and invasive diseases that are 
collectively termed aspergillosis. Among Aspergillus species, Aspergillus fumigatus is 
the primary etiological agent of aspergillosis.23  
Even though A. fumigatus is a major pathogen, its closest relatives are not 
considered pathogenic.16, 216, 217 Numerous studies have identified genetic determinants 
that contribute to A. fumigatus pathogenicity, such as the organism’s ability to grow well 
at higher temperatures and in hypoxic conditions.113, 142, 218, 219 Genetic determinants that 
contribute to pathogenicity could be conceived as analogous to individual “cards” of a 
“hand” (set of cards) in a card game – that is, individual determinants are typically 
insufficient to cause disease but can collectively do so.26  
Aspergillus fumigatus biosynthesizes a cadre of secondary metabolites and 
several metabolites could be conceived as “cards” of virulence because of their 
involvement in impairing the host immune system, protecting the fungus from host 
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immune cell attacks, or acquiring key nutrients.20, 27-33 For example, the secondary 
metabolite gliotoxin has been shown in A. fumigatus to inhibit the host immune 
response.34, 35 Other secondary metabolites implicated in virulence include: 
fumitremorgin, which inhibits the activity of the breast cancer resistance protein;36 
verruculogen, which modulates the electrophysical properties of human nasal epithelial 
cells;220 trypacidin, which is cytotoxic to lung cells and inhibits phagocytosis;221, 222 
pseurotin, which inhibits immunoglobulin E;41 and fumagillin which causes epithelial cell 
damage37 and impairs the function of neutrophils.39, 40  
By extension, the metabolic pathways responsible for the biosynthesis of 
secondary metabolites could also be conceived as components of these secondary 
metabolism-associated “cards” of virulence. Genes in these pathways are typically 
organized in contiguous sets termed biosynthetic gene clusters (BGCs).10 BGCs are 
known to evolve rapidly, and their composition can differ substantially across species 
and strains.11, 12, 143, 147, 148, 223-225 For example, even though A. fumigatus contains 33 
BGCs and A. fischeri contains 48 BGCs, only 10 of those BGCs appear to be shared 
between the two species.16 Interestingly, one of the BGCs that is conserved between A. 
fumigatus and A. fischeri is the gliotoxin BGC and both species have been shown to 
biosynthesize the secondary metabolite, albeit at different amounts.226 These results 
suggest that the gliotoxin “card” is part of a winning “hand” that facilitates virulence only 
in the background of the major pathogen A. fumigatus and not in that of the 
nonpathogen A. fischeri.226 
To date, such comparisons of BGCs and secondary metabolite profiles among A. 
fumigatus and closely related nonpathogenic species have been few and restricted to 
single strains.16, 226 However, genetic and phenotypic heterogeneity among strains of a 
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single species is an important consideration when studying Aspergillus pathogenicity.33, 
137, 227-233 Examination of multiple strains of A. fumigatus and close relatives—including 
the recently described closest known relative of A. fumigatus, A. oerlinghausenensis, 
whose virulence has yet to be examined but which is not thought to be a human 
pathogen42 and has never been associated with human infections—will increase our 
understanding of the A. fumigatus secondary metabolism-associated “cards” of 
virulence. 
To gain insight into the genomic and chemical similarities and differences in 
secondary metabolism among A. fumigatus and nonpathogenic close relatives, we 
characterized variation in BGCs and secondary metabolites produced by A. fumigatus 
and nonpathogenic close relatives. To do so, we first sequenced and assembled A. 
oerlinghausenensis CBS 139183T as well as A. fischeri strains NRRL 4585 and NRRL 
4161 and analyzed them together with four A. fumigatus and three additional A. fischeri 
publicly available genomes. We also characterized the secondary metabolite profiles of 
three A. fumigatus, one A. oerlinghausenensis, and three A. fischeri strains. We 
observed both variation and conservation among species- and strain-level BGCs and 
secondary metabolites. We found that the biosynthesis of the secondary metabolites 
gliotoxin and fumitremorgin, which are both known to interact with mammalian cells,27, 36, 
234, 235 as well as their BGCs, were conserved among pathogenic and nonpathogenic 
strains. Interestingly, we found only A. fischeri strains, but not A. fumigatus strains, 
biosynthesized verruculogen, which changes the electrophysical properties of human 
nasal epithelial cells.220 Similarly, we found that both A. fumigatus and A. 
oerlinghausenensis biosynthesized fumagillin and trypacidin, whose effects include 
broad suppression of the immune response system and lung cell damage,39-41, 221 but A. 
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fischeri did not. Taken together, these results reveal that nonpathogenic close relatives 
of A. fumigatus also produce some, but not all, of the secondary metabolism-associated 
cards of virulence known in A. fumigatus. Further investigation of the similarities and 
differences among A. fumigatus and close nonpathogenic relatives may provide 
additional insight into the “hand of cards” that enabled A. fumigatus to evolve into a 
deadly pathogen. 
Results 
Conservation and Diversity of Biosynthetic Gene Clusters Within and 
Between Species. We sequenced and assembled A. oerlinghausenensis CBS 139183T 
and A. fischeri strains NRRL 4585 and NRRL 4161. Together with publicly available 
genomes, we analyzed 10 Aspergillus genomes (five A. fischeri strains; four A. 
fumigatus strains; one A. oerlinghausenensis strain; see Methods). We found that the 
newly added genomes were of similar quality to other publicly available draft genomes 
(average percent presence of BUSCO genes: 98.80 ± 0.10%; average N50: 451,294.67 
± 9,696.11; Figure 45). We predicted that A. oerlinghausenensis CBS 139183T, A. 
fischeri NRRL 4585, and A. fischeri NRRL 4161 have 10,044, 11,152 and 10,940 genes, 
respectively, numbers similar to publicly available genomes. Lastly, we inferred the 
evolutionary history of the 10 Aspergillus genomes using a concatenated matrix of 3,041 
genes (5,602,272 sites) and recapitulated species-level relationships as previously 
reported (Houbraken et al. 2016). Relaxed molecular clock analyses suggested that A. 
oerlinghausenensis CBS 139183T diverged from A. fumigatus approximately 3.9 (6.4 – 
1.3) million years ago and that A. oerlinghausenensis and A. fumigatus split from A. 
fischeri approximately 4.5 (6.8 – 1.7) million years ago (Figures 39A and 46). 
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Examination of the total number of predicted BGCs revealed that A. fischeri has 
the largest BGC count. Among A. fumigatus, A. oerlinghausenensis, and A. fischeri, we 
predicted an average of 35.75 ± 2.22, 40, 50.80 ± 2.17 BGCs, respectively, and found 
they spanned diverse biosynthetic classes (e.g., polyketides, non-ribosomal peptides, 
terpenes, etc.) (Figure 39B). Network-based clustering of BGCs into cluster families (or 
groups of homologous BGCs) resulted in qualitatively similar networks when we used 
moderate similarity thresholds (or edge cut-off values; Figure 47A). Using a (moderate) 
similarity threshold of 0.5, we inferred 88 cluster families of putatively homologous BGCs 
(Figure 39C).  
Examination of BGCs revealed extensive presence and absence polymorphisms 
within and between species. We identified 17 BGCs that were present in all 10 
Aspergillus genomes including the hexadehydroastechrome (HAS) BGC (cluster family 
311 or CF311), the neosartoricin BGC (CF61), and other putative BGCs likely encoding 
unknown products (Figure 47B). In contrast, we identified 18 BGCs found in single 
strains, which likely encode unknown products. Between species, similar patterns of 
broadly present and species-specific BGCs were observed. For example, we identified 
18 BGCs that were present in at least one strain across all species; in contrast, A. 
fumigatus, A. oerlinghausenensis, and A. fischeri had 16, 8, and 27 BGCs present in at 
least one strain but absent from the other species, respectively. These results suggest 




Figure 39. Diverse Genetic Repertoire of Biosynthetic Gene Clusters and Extensive 
Presence and Absence Polymorphisms Between and Within Species. (A) Genome-scale 
phylogenomic analysis confirms A. oerlinghausenensis is the closest relative to A. 
fumigatus. Relaxed molecular clock analyses suggest A. fumigatus, A. 
oerlinghausenensis, and A. fischeri diverged from one another during the Neogene 
geologic period. Bipartition support is depicted for internodes that did not have full 
support. (B) A. fumigatus harbors the lowest number of BGCs compared to its two 
closest relatives. (C) Network-based clustering of BGCs into cluster families reveal 
extensive cluster presence and absence polymorphisms between species and strains. 
Cluster family identifiers are depicted on the x-axis; the number of strains represented in 
a cluster family are shown on the y-axis; the colors refer to a single strain from each 
species. Genus and species names are written using the following abbreviations: Afum: 
A. fumigatus; Aoer: A. oerlinghausenensis; Afis: A. fischeri. Classes of BGCs are written 
using the following abbreviations: NRPS: nonribosomal peptide synthetase; T1PKS: type 
I polyketide synthase; Hybrid: a combination of multiple BGC classes. 
 
Examination of shared BGCs across species revealed A. oerlinghausenensis 
CBS139183T and A. fischeri shared more BGCs with each other than either did with A. 
fumigatus. Surprisingly, we found ten homologous BGCs between A. oerlinghausenensis 
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CBS 139183T and A. fischeri but only three homologous BGCs shared between A. 
fumigatus and A. oerlinghausenensis CBS 139183T (Figures 40A and 47C) even though 
A. oerlinghausenensis is more closely related to A. fumigatus than to A. fischeri (Figure 
39A). BGCs shared by A. oerlinghausenensis CBS 139183T and A. fischeri were 
uncharacterized while BGCs present in both A. fumigatus and A. oerlinghausenensis 
CBS 139183T included those that encode fumigaclavine and fumagillin/pseurotin. Lastly, 
to associate each BGC with a secondary metabolite in A. fumigatus Af293, we cross 
referenced our list with a publicly available one.148 Importantly, all known A. fumigatus 
Af293 BGCs were represented in our analyses. 
At the level of gene families, there were few species-specific gene families in A. 
oerlinghausenensis (Figure 40B). A. oerlinghausenensis CBS 139183T has only eight 
species-specific gene families, whereas A. fischeri and A. fumigatus have 1,487 and 548 
species-specific gene families, respectively. Examination of the best BLAST hits of the 
eight species-specific gene families suggest that most are hypothetical or 
uncharacterized fungal genes. To determine if the eight A. oerlinghausenensis CBS 
139183T specific gene families were an artifact of using a single representative strain, 
we conducted and additional ortholog clustering analysis using a single strain of A. 
fischeri (NRRL 181), a single strain of A. fumigatus (Af293), or a single strain of each 
species (CBS 139183, NRRL 181, Af293). When using a single strain of A. fischeri or A. 
fumigatus, there were 23 or six gene families unique to each species, respectively. 
Therefore, the low number of A. oerlinghausenensis-specific gene families likely stems 




Figure 40. Aspergillus oerlinghausenensis Shares More Gene Families and BGCs With 
A. fischeri Than A. fumigatus. (A) Euler diagram showing species-level shared BGCs. 
(B) Euler diagram showing species-level shared gene families. In both diagrams, A. 
oerlinghausenensis shares more gene families or BGCs with A. fischeri than A. 
fumigatus despite a closer evolutionary relationship. The Euler diagrams show the 
results for the species-level comparisons, which may be influenced by the unequal 
numbers of strains used for the three species; strain-level comparisons of BGCs and 
gene families can be found in Figures 39C and 48, respectively. 
 
Despite a closer evolutionary relationship between A. oerlinghausenensis and A. 
fumigatus, we found A. oerlinghausenensis shares more gene families with A. fischeri 
than with A. fumigatus (685 and 109, respectively) suggestive of extensive gene loss in 
the A. fumigatus stem lineage. Lastly, we observed strain heterogeneity in gene family 
presence and absence within both A. fumigatus and A. fischeri (Figure 48). For example, 
the largest intersection that does not include all A. fischeri strains is 493 gene families, 
which were found in all but one strain, NRRL 181. For A. fumigatus, the largest 
intersection that does not include all strains is 233 gene families, which were shared by 
strains Af293 and CEA10. 
Within and Between Species Variation in Secondary Metabolite Profiles of 
A. fumigatus and its Closest Relatives. To gain insight into variation in secondary 
metabolite profiles within and between species, we profiled A. fumigatus strains Af293, 
CEA10, and CEA17 (a pyrG1/URA3 derivative of CEA10), A. fischeri strains NRRL 181, 
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NRRL 4585, and NRRL 4161, and A. oerlinghausenensis CBS 139183T for secondary 
metabolites. Specifically, we used three different procedures, including the isolation and 
structure elucidation of metabolites, where possible, followed by two different metabolite 
profiling procedures that use mass spectrometry techniques. Altogether, we isolated and 
characterized 19 secondary metabolites; seven from A. fumigatus, two from A. 
oerlinghausenensis, and ten from A. fischeri (Figure 49). These products encompassed 
a wide diversity of secondary metabolite classes, such as those derived from polyketide 
synthases, non-ribosomal peptide-synthetases, terpene synthases and mixed 
biosynthesis enzymes.  
To characterize the secondary metabolites biosynthesized that were not 
produced in high enough quantity for structural identification through traditional isolation 
methods, we employed “dereplication” mass spectrometry protocols specific to natural 
products research on all tested strains at both 30°C and 37°C (Figure 52).188, 236-238 We 
found that most secondary metabolites were present across strains of the same species 
(Table 4.3 and Table 4.4); for example, monomethylsulochrin was isolated from A. 
fumigatus Af293, but through metabolite profiling, its spectral features were noted also in 
A. fumigatus strains CEA10 and CEA17. We identified metabolites that were 
biosynthesized by only one species; for example, pseurotin A was solely present in A. 
fumigatus strains. Finally, we found several secondary metabolites that were 
biosynthesized across species, such as fumagillin, which was biosynthesized by A. 
fumigatus and A. oerlinghausenensis, and fumitremorgin B, which was biosynthesized 
by strains of both A. oerlinghausenensis and A. fischeri. Together, these analyses 
suggest that closely related Aspergillus species and strains exhibit variation both within 
as well as between species in the secondary metabolites produced.  
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To further facilitate comparisons of secondary metabolite profiles within and 
between species, we used the 1,920 features (i.e., unique m/z – retention time pairs) 
that were identified from all strains at all temperatures (Figure 41A), to perform 
hierarchical clustering (Figure 41B) and Principal Components Analysis (PCA) (Figure 
50). Hierarchical clustering at 37°C and 30°C indicated the chromatogram of A. 
oerlinghausenensis CBS 139183T is more similar to the chromatogram of A. fischeri than 
to that of A. fumigatus. PCA results were broadly consistent with the clustering results, 
but suggested that A. oerlinghausenensis was just as similar to A. fischeri strains as it 
was to A. fumigatus strains. This difference likely stems from the fact that hierarchical 
clustering is a total-evidence approach whereas PCA captures most but not all variance 
in the data (e.g., the two principal components in Figures 50B and 50C capture 84.6% of 
the total variance). PCA analysis revealed greater variation in secondary metabolite 
production at 30°C compared to 37°C (Figure 50), suggesting there is a more varied 
response in how BGCs are being utilized at 30°C. PCA at both 37°C and 30°C showed 
that variation between A. oerlinghausenensis CBS 139183T and A. fischeri strains was 
largely captured along the second principal component; in contrast, the differences 
between A. oerlinghausenensis CBS 139183T and A. fumigatus strains are captured 
along the first principal component (Figure 50D-E). Taken together, these results 
suggest that the three A. fischeri strains and A. oerlinghausenensis were the most 




Figure 41. A. oerlinghausenensis and A. fischeri Have More Similar Secondary 
Metabolite Profiles Than A. fumigatus. (A) UPLC-MS chromatograms of secondary 
metabolite profiles of A. fumigatus and its closest relatives, A. oerlinghausenensis and A. 
fischeri at 37°C and 30°C (left and right, respectively). (B) Hierarchical clustering of 
chromatograms (1,920 total features) reveals A. oerlinghausenensis clusters with A. 
fischeri and not its closest relative, A. fumigatus at 37°C and 30°C (left and right, 
respectively).   
 
In summary, even though A. oerlinghausenensis is phylogenetically more closely 
related to A. fumigatus than to A. fischeri (Figure 39A), our chemical analyses suggest 
that the secondary metabolite profile of A. oerlinghausenensis is more similar to the 
profile of A. fischeri  than it is to the profile of A. fumigatus (Figures 41B and 50B-E). The 
similarity of secondary metabolite profiles of A. oerlinghausenensis and A. fischeri is 
consistent with our finding that the genome of A. oerlinghausenensis shares higher 
numbers of BGCs and gene families with A. fischeri than with A. fumigatus (Figure 40). 
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The broad clustering patterns in secondary metabolite-based plots (Figure 50B-E) are 
less robust than, but consistent with, those of BGC-based plots (Figure 50A), suggesting 
that the observed similarities in the secondary metabolism-associated genotypes of A. 
oerlinghausenensis and A. fischeri are likely reflected in their chemotypes.  
Conservation and Divergence Among Biosynthetic Gene Clusters 
Implicated in A. fumigatus Pathogenicity. Secondary metabolites are known to play a 
role in A. fumigatus virulence.27 We therefore conducted a focused examination of 
specific A. fumigatus BGCs and secondary metabolites that have been previously 
implicated in the organism’s ability to cause human disease (Table 4.1). We found 
varying degrees of conservation and divergence that were associated with the absence 
or presence of a secondary metabolite. Among conserved BGCs that were also 
associated with conserved secondary metabolite production, we highlight the mycotoxins 
gliotoxin and fumitremorgin. Interestingly, we note that only A. fischeri strains 
synthesized verruculogen, a secondary metabolite that is implicated in human disease 
and is encoded by the fumitremorgin BGC.220, 239 Among BGCs that exhibited varying 
degrees of sequence divergence and divergence in their production of the corresponding 
secondary metabolites, we highlight those associated with the production of the 
trypacidin and fumagillin/pseurotin secondary metabolites. We found that nonpathogenic 
close relatives of A. fumigatus produced some but not all mycotoxins, which provides 





Table 4.1. Select A. fumigatus Secondary Metabolites Implicated in Modulating Host 
Biology 
 
A list of select secondary metabolites implicated in human disease and their functional 
role are described here. All secondary metabolites listed or analogs thereof were 
identified during secondary metabolite profiling. Plus (+) and minus (-) signs indicate the 
presence or absence of the BGC and secondary metabolite, respectively. For example, 
+/+ indicates both BGC presence and evidence of secondary metabolite production, 
whereas +/- indicates BGC presence but no evidence of secondary metabolite 
production. ‘+/+’ cells are colored orange; ‘-/-’ cells are colored blue; ‘+/-’ and ‘-/+’ cells 
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Gliotoxin. Gliotoxin is a highly toxic compound and known virulence factor in A. 
fumigatus.34 Nearly identical BGCs encoding gliotoxin are present in all pathogenic (A. 
fumigatus) and nonpathogenic (A. oerlinghausenensis and A. fischeri) strains examined 
(Figure 42). Additionally, we found that all examined strains synthesized 
bisdethiobis(methylthio)gliotoxin a derivative from dithiogliotoxin, involved in the down-
regulation of gliotoxin biosynthesis,240 one of the main mechanisms of gliotoxin 
resistance in A. fumigatus.239 
 
 
Figure 42. Conservation in the Gliotoxin BGC Correlates with Conserved Production of 
Gliotoxin Analogs in A. fumigatus and Nonpathogenic Close Relatives. Microsynteny 
analysis reveals a high degree of conservation in the BGC encoding gliotoxin across all 
isolates. The known gliotoxin gene cluster boundary is indicated above the A. fumigatus 
Af293 BGC. Black and white squares correspond to evidence or absence of evidence of 
secondary metabolite production, respectively. Genes are drawn as arrows with 
orientation indicated by the direction of the arrow. Gene function is indicated by gene 
color. Grey boxes between gene clusters indicate BLAST-based similarity of nucleotide 
sequences defined as being at least 100 bp in length, share at least 30% sequence 
similarity, and have an expectation value threshold of 0.01. Genus and species names 
are written using the following abbreviations: Afum: A. fumigatus; Aoer: A. 
oerlinghausenensis; Afis: A. fischeri. Below each genus and species abbreviation is the 
cluster family each BGC belongs to and their cluster number. 
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Fumitremorgin and Verruculogen. Similarly, there is a high degree of 
conservation in the BGC that encodes fumitremorgin across all strains (Figure 43). 
Fumitremorgins have known antifungal activity, are lethal to brine shrimp, and are 
implicated in inhibiting mammalian proteins responsible for resistance to anticancer 
drugs in mammalian cells.27 We found that conservation in the fumitremorgin BGC is 
associated with the production of fumitremorgins in all isolates examined. The 
fumitremorgin BGC is also responsible for the production of verruculogen, which is 
implicated to aid in A. fumigatus pathogenicity by changing the electrophysical properties 
of human nasal epithelial cells.220 Interestingly, we found that only A. fischeri strains 
produced verruculogen under the conditions we analyzed. 
 
 
Figure 43. Conservation and Divergence in the Locus Encoding the Fumitremorgin and 
Intertwined Fumagillin/Pseurotin BGCs. Microsynteny analysis reveals conservation in 
the fumitremorgin BGC across all isolates. Interestingly, only A. fischeri strains 
synthesize verruculogen, a secondary metabolite also biosynthesized by the 
fumitremorgin BGC. In contrast, the intertwined fumagillin/pseurotin BGCs are 
conserved between A. fumigatus and A. oerlinghausenensis but divergent in A. fischeri. 
BGC conservation and divergence is associated with the presence and absence of a 
secondary metabolite, respectively. The hysame convention used in Figure 42 is used to 
depict evidence of a secondary metabolite, represent genes and broad gene function, 
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BGC sequence similarity, genus and species abbreviations, and BGC cluster families 
and cluster numbers 
 
Trypacidin. Examination of the trypacidin BGC, which encodes a spore-borne 
and cytotoxic secondary metabolite, revealed a conserved cluster found in four 
pathogenic and nonpathogenic strains: A. fumigatus Af293, A. fumigatus CEA10, A. 
oerlinghausenensis CBS 139183T, and A. fischeri NRRL 181 (Figure 51). Furthermore, 
we found that three of these four isolates (except A. fischeri NRRL 181) biosynthesized 
a trypacidin analog, monomethylsulochrin. Examination of the microsynteny of the 
trypacidin BGC revealed that it was conserved across all four genomes with the 
exception A. fischeri NRRL l81, which lacked a RING (Really Interesting New Gene) 
finger gene. Interestingly, RING finger proteins can mediate gene transcription.241 We 
confirmed the absence of the RING finger protein by performing a sequence similarity 
search with the A. fumigatus Af293 RING finger protein (AFUA_4G14620; EAL89333.1) 
against the A. fischeri NRRL 181 genome. In the homologous locus in A. fischeri, we 
found no significant BLAST hit for the first 23 nucleotides of the RING finger gene 
suggestive of pseudogenization. Taken together, we hypothesize that presence/absence 
polymorphisms or a small degree of sequence divergence between otherwise 
homologous BGCs may be responsible for the presence or absence of a toxic secondary 
metabolite in A. fischeri NRRL 181. Furthermore, inter- and intra-species patterns of 
trypacidin presence and absence highlight the importance of strain heterogeneity when 
examining BGCs. 
Fumagillin/pseurotin. Examination of the intertwined fumagillin/pseurotin BGCs 
revealed that fumagillin has undergone substantial sequence divergence and that 
pseurotin is absent from strains of A. fischeri. The fumagillin/pseurotin BGCs are under 
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the same regulatory control152 and biosynthesize secondary metabolites that cause 
cellular damage during host infection (fumagillin)38 and inhibit immunoglobulin E 
production (pseurotin)41. Microsynteny of the fumagillin BGC reveals high sequence 
conservation between A. fumigatus and A. oerlinghausenensis; however, sequence 
divergence was observed between A. oerlinghausenensis and A. fischeri (Figure 43). 
Accordingly, fumagillin production was only observed in A. fumigatus and A. 
oerlinghausenensis and not in A. fischeri. Similarly, the pseurotin BGC is conserved 
between A. fumigatus and A. oerlinghausenensis. Rather than sequence divergence, no 
sequence similarity was observed in the region of the pseurotin cluster in A. fischeri, 
which may be due to an indel event. Accordingly, no pseurotin production was observed 
among A. fischeri strains. Despite sequence conservation between A. fumigatus and A. 
oerlinghausenensis, no evidence of pseurotin biosynthesis was observed in A. 
oerlinghausenensis, which suggests regulatory decoupling of the intertwined 
fumagillin/pseurotin BGC. Alternatively, the genes downstream of the A. fumigatus 
pseurotin BGC, which are absent from the A. oerlinghausenensis locus, may contribute 
to BGC production and could explain the lack of pseurotin production in A. 
oerlinghausenensis.  Altogether, these results show a striking correlation between 
sequence divergence and the production (or absence) of secondary metabolites 
implicated in human disease among A. fumigatus and nonpathogenic closest relatives.  
Discussion 
Aspergillus fumigatus is a major fungal pathogen nested within a clade (known 
as section Fumigati) of at least 60 other species, the vast majority of which are 
nonpathogenic.216, 217 Currently, it is thought that the ability to cause human disease 
evolved multiple times among species in section Fumigati.217 Secondary metabolites 
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contribute to the success of the major human pathogen A. fumigatus in the host 
environment27 and can therefore be thought of as “cards” of virulence.26, 226 However, 
whether the closest relatives of A. fumigatus, A. oerlinghausenensis and A. fischeri, both 
of which are nonpathogenic, biosynthesize secondary metabolites implicated in the 
ability of A. fumigatus to cause human disease remained largely unknown. By examining 
genomic and chemical variation between and within A. fumigatus and its closest 
nonpathogenic relatives, we identified both conservation and divergence (including 
within species heterogeneity) in BGCs and secondary metabolite profiles (Figures 39-43, 
47, and 49-51; Tables 4.1, 4.3, and 4.4). Examples of conserved BGCs and secondary 
metabolites include the major virulence factor, gliotoxin (Figure 42), as well as several 
others (Figures 43 and 51; Tables 4.1, 4.3, and 4.4); examples of BGC and secondary 
metabolite heterogeneity or divergence include pseurotin, fumagillin, and several others 
(Figure 43; Tables 4.1, 4.3, and 4.4). Lastly, we found that the fumitremorgin BGC, 
which biosynthesizes fumitremorgin in all three species, is also associated with 
verruculogen biosynthesis in A. fischeri strains (Figure 43). 
One of the surprising findings of our study was that although A. 
oerlinghausenensis and A. fumigatus are evolutionarily more closely related to each 
other than to A. fischeri (Figure 39), A. oerlinghausenensis and A. fischeri appear to be 
more similar to each other than to A. fumigatus in BGC composition, gene family 
content, and secondary metabolite profiles. The power of pathogen-nonpathogen 
comparative genomics is best utilized when examining closely related species.16, 123, 217, 
242, 243 Genomes from additional strains from the closest known nonpathogenic relatives 
of A. fumigatus, including from the closest species relative A. oerlinghausenensis, A. 
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fischeri, and other nonpathogenic species in section Fumigati will be key for 
understanding the evolution of A. fumigatus pathogenicity.  
Our finding that A. oerlinghausenensis and A. fischeri shares more gene families 
and BGCs with each other than they do with A. fumigatus (Figures 39C, 40, 47, and 48) 
suggests that the evolutionary trajectory of the A. fumigatus ancestor was marked by 
gene loss. We hypothesize that there were two rounds of gene family and BGC loss in 
the A. fumigatus stem lineage: (1) gene families and BGCs were lost in the common 
ancestor of A. fumigatus and A. oerlinghausenensis and (2) additional losses occurred in 
the A. fumigatus ancestor. In addition to losses, we note that 548 gene families and 16 
BGCs are unique to A. fumigatus, which may have resulted from genetic innovation 
(e.g., de novo gene formation) or unique gene family and BGC retention (Figure 40). In 
line with the larger number of shared BGCs between A. oerlinghausenensis and A. 
fischeri, we found their secondary metabolite profiles were also more similar (Figures 41, 
50). Notably, the evolutionary rate of the internal branch leading to the A. fumigatus 
common ancestor is much higher than those in the rest of the branches in our genome-
scale phylogeny (Figure 46B), suggesting that the observed gene loss and gene gain / 
retention events specific to A. fumigatus may be part of a wider set of evolutionary 
changes in the A. fumigatus genome. Analyses with a greater number of strains and 
species will help further test the validity of this hypothesis. More broadly, these results 
suggest that comparisons of the pathogen A. fumigatus against either the non-pathogen 
A. oerlinghausenensis (this manuscript) or the non-pathogen A. fischeri16, 226 (and this 
manuscript) will both be instructive in understanding the evolution of A. fumigatus 
pathogenicity.  
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When studying Aspergillus pathogenicity, it is important to consider any genetic 
and phenotypic heterogeneity between strains of a single species.32, 33, 137, 227-233 Our 
finding of strain heterogeneity among gene families, BGCs, and secondary metabolites 
in A. fumigatus and A. fischeri (Figures 39-41, 47, 48, and 50) suggests considerable 
strain-level diversity in each species. For example, we found secondary metabolite 
profile strain heterogeneity was greater in A. fumigatus than A. fischeri (Figure 50B-E). 
These results suggest that strain-specific secondary metabolite profiles may play a role 
in variation of pathogenicity among A. fumigatus strains. In support of this hypothesis, 
differential secondary metabolite production has been associated with differences in 
virulence among isolates of A. fumigatus.33 More broadly, our finding supports the 
hypothesis that strain-level diversity is an important parameter when studying 
pathogenicity.33, 137, 227-233 
 
 
Figure 44. Secondary Metabolism-Associated “Cards” of Virulence Among A. fumigatus 
and Close Relatives. Secondary metabolites contribute to the “hand of cards”’ that 
enable A. fumigatus to cause disease. Here, we show that the nonpathogenic closest 
relatives of A. fumigatus possess a subset of the A. fumigatus secondary metabolism-
associated cards of virulence. We hypothesize that the unique combination of cards of 
A. fumigatus contributes to its pathogenicity and that the cards in A. oerlinghausenensis 
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and A. fischeri (perhaps in combination with other non-secondary-metabolism-
associated cards, such as thermotolerance) are insufficient to cause disease. 
Pathogenic and nonpathogenic species are shown in red and black, respectively. 
Cartoons of Aspergillus species were obtained from WikiMedia Commons (source: M. 
Piepenbring) and modified in accordance with the Creative Commons Attribution-Share 
Alike 3.0 Unported license (https://creativecommons.org/licenses/by-sa/3.0/deed.en).  
 
Secondary metabolites contribute to A. fumigatus virulence through diverse 
processes including suppressing the human immune system and damaging tissues 
(Table 4.1). Interestingly, we found that the nonpathogens A. oerlinghausenensis and A. 
fischeri produced several secondary metabolites implicated in the ability of A. fumigatus 
human disease, such gliotoxin, trypacidin, verruculogen, and others (Figures 42, 43, and 
51; Tables 4.1 and 4.5). Importantly, our work positively identified secondary metabolites 
for many structural classes implicated in a previous taxonomic study (Samson et al. 
2007). These results suggest that several of the secondary metabolism-associated cards 
of virulence present in A. fumigatus are conserved in closely related nonpathogens 
(summarized in Figure 44) as well as in closely related pathogenic species, such as A. 
novofumigatus.143 Interestingly, disrupting the ability of A. fumigatus to biosynthesize 
gliotoxin attenuates but does not abolish virulence,34, 174, 228 whereas disruption of the 
ability of A. fischeri NRRL 181 to biosynthesize secondary metabolites, including 
gliotoxin, does not appear to influence virulence.226 Our findings, together with previous 
studies, support the hypothesis that individual secondary metabolites are “cards” of 
virulence in a larger “hand” that A. fumigatus possesses.  
Materials and Methods 
Strain Acquisition, DNA Extraction, and Sequencing. Two strains of 
Aspergillus fischeri (NRRL 4161 and NRRL 4585) were acquired from the Northern 
Regional Research Laboratory (NRRL) at the National Center for Agricultural Utilization 
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Research in Peoria, Illinois, while one strain of Aspergillus oerlinghausenensis (CBS 
139183T) was acquired from the Westerdijk Fungal Biodiversity Institute, Utrecht, The 
Netherlands. These strains were grown in 50 ml of liquid yeast extract soy peptone 
dextrose (YESD) medium. After approximately seven days of growth on an orbital 
shaker (100 rpm) at room temperature, the mycelium was harvested by filtering the liquid 
media through a Corning®, 150 ml bottle top, 0.22µm sterile filter and washed with 
autoclaved distilled water. All subsequent steps of DNA extraction from the mycelium 
were performed following protocols outlined previously.14 The genomic DNA from these 
three strains was sequenced using a NovaSeq S4 at the Vanderbilt Technologies for 
Advanced Genomes facility (Nashville, Tennessee, US) using paired-end sequencing 
(150 bp) strategy with the Illumina TruSeq library kit. 
Genome Assembly, Quality Assessment, and Annotation. To assemble and 
annotate the three newly sequenced genomes, we first quality-trimmed raw sequence 
reads using Trimmomatic, v0.36244 using parameters described elsewhere 
(ILLUMINACLIP:TruSeq3-PE.fa:2:30:10, leading:10, trailing:10, slidingwindow:4:20, 
minlen:50).245 The resulting paired and unpaired quality-trimmed reads were used as 
input to the SPAdes, v3.11.1,246 genome assembly algorithm with the ‘careful’ parameter 
and the ‘cov-cutoff’ set to ‘auto’.  
We evaluated the quality of our newly assembled genomes, using metrics based 
on continuity of assembly and gene-content completeness. To evaluate genome 
assemblies by scaffold size, we calculated the N50 of each assembly (or the shortest 
contig among the longest contigs that account for 50% of the genome assembly’s 
length).247 To determine gene-content completeness, we implemented the BUSCO, 
v2.0.1,248 pipeline using the ‘genome’ mode. In this mode, the BUSCO pipeline 
107 
examines assembly contigs for the presence of near-universally single copy orthologous 
genes (hereafter referred to as BUSCO genes) using a predetermined database of 
orthologous genes from the OrthoDB, v9.249 We used the OrthoDB database for 
Pezizomycotina (3,156 BUSCO genes). Each BUSCO gene is determined to be present 
in a single copy, as duplicate sequences, fragmented, or missing. Our analyses indicate 
the newly sequenced and assembled genomes have high gene-content completeness 
and assembly continuity (average percent presence of BUSCO genes: 98.80 ± 0.10%; 
average N50: 451,294.67 ± 9,696.11; Figure 45). These metrics suggest these genomes 
are suitable for comparative genomic analyses.  
To predict gene boundaries in the three newly sequenced genomes, we used the 
MAKER, v2.31.10, pipeline250 which, creates consensus predictions from the collective 
evidence of multiple ab initio gene prediction software. Specifically, we created 
consensus predictions from SNAP, v2006-07-28 (Korf 2004), and AUGUSTUS, 
v3.3.2,251 after training each algorithm individually on each genome. To do so, we first 
ran MAKER using protein evidence clues from five different publicly available 
annotations of Aspergillus fungi from section Fumigati. Specifically, we used protein 
homology clues from A. fischeri NRRL 181 (GenBank accession: GCA_000149645.2), 
A. fumigatus Af293 (GenBank accession: GCA_000002655.1), Aspergillus lentulus IFM 
54703 (GenBank accession: GCA_001445615.1), Aspergillus novofumigatus IBT 16806 
(GenBank accession: GCA_002847465.1), and Aspergillus udagawae IFM 46973 
(GenBank accession: GCA_001078395.1). The resulting gene predictions were used to 
train SNAP. MAKER was then rerun using the resulting training results. Using the SNAP 
trained gene predictions, we trained AUGUSTUS. A final set of gene boundary 
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predictions were obtained by rerunning MAKER with the training results from both SNAP 
and AUGUSTUS. 
 
Table 4.2. Species and Strains Used in the Present Study.  











CBS 139183T Environmental + + This study 
Aspergillus fischeri NRRL 4585 Environmental + + This study 
Aspergillus fischeri NRRL 4161 Unknown + + This study 
Aspergillus fischeri NRRL 181 Environmental + + 
(Fedorova 
et al. 2008) 
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Aspergillus fischeri IBT 3007 Environmental + - 
(Zhao et al. 
2019)252 
Aspergillus fischeri IBT 3003 Environmental + - 











Clinical + + 
(Fedorova 










Z5 Environmental + - 
(Miao et al. 
2015)253 
‘+’ and ‘-’ indicate if BGCs and secondary metabolite profiling was conducted on a 
particular strain. More specifically ‘+’ indicates the strain was analyzed whereas ‘-’ 
indicates that the strain was not analyzed. 
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To supplement our data set of newly sequenced genomes, we obtained publicly 
available ones. Specifically, we obtained genomes and annotations for A. fumigatus 
Af293 (GenBank accession: GCA_000002655.1), A. fumigatus CEA10 (strain synonym: 
CBS 144.89 / FGSC A1163; GenBank accession: GCA_000150145.1), A. fumigatus 
HMR AF 270 GenBank accession: GCA_002234955.1), A. fumigatus Z5 (GenBank 
accession: GCA_001029325.1),  A. fischeri NRRL 181 (GenBank accession: 
GCA_000149645.2). We also obtained assemblies of the recently published A. fischeri 
genomes for strains IBT 3003 and IBT 3007252 which, lacked annotations. We annotated 
the genome of each strain individually using MAKER with the SNAP and AUGUSTUS 
training results from a close relative of both strains, A. fischeri NRRL 4161. Altogether, 
our final data set contained a total of ten genome from three species: four A. fumigatus 
strains, one A. oerlinghausenensis strain, and five A. fischeri strains (Table 4.2).  
Maximum Likelihood Phylogenetics and Bayesian Estimation of Divergence 
Times. To reconstruct the evolutionary history among the ten Aspergillus genomes, we 
implemented a recently developed pipeline,216 which relies on the concatenation-
approach to phylogenomics254 and has been successfully used in reconstructing 
species-level relationships among Aspergillus and Penicillium fungi.216, 255 The first step 
in the pipeline is to identify single copy orthologous genes in the genomes of interest 
which, are ultimately concatenated into a larger phylogenomic data matrix. To identify 
single copy BUSCO genes across all ten Aspergillus genomes, we used the BUSCO 
pipeline with the Pezizomycotina database as described above. We identified 3,041 
BUSCO genes present at a single copy in all ten Aspergillus genomes and created multi-
FASTA files for each BUSCO gene that contained the protein sequences for all ten taxa. 
The protein sequences of each BUSCO gene were individually aligned using Mafft, 
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v7.4.02,256 with the same parameters as described elsewhere.216 Nucleotide sequences 
were then mapped onto the protein sequence alignments using a custom Python, v3.5.2 
(https://www.python.org/), script with BioPython, v1.7.257 The resulting codon-based 
alignments were trimmed using trimAl, v1.2.rev59,258 with the ‘gappyout’ parameter. The 
resulting trimmed nucleotide alignments were concatenated into a single matrix of 
5,602,272 sites and was used as input into IQ-TREE, v1.6.11.259 The best-fitting model 
of substitutions for the entire matrix was determined using Bayesian information criterion 
values.260 The best-fitting model was a general time-reversible model with empirical base 
frequencies that allowed for a proportion of invariable sites and a discrete Gamma model 
with four rate categories (GTR+I+F+G4).261-264 To evaluate bipartition support, we used 
5,000 ultrafast bootstrap approximations.265    
To estimate divergence times among the ten Aspergillus genomes, we used the 
concatenated data matrix and the resulting maximum likelihood phylogeny from the 
previous steps as input to Bayesian approach implemented in MCMCTree from the 
PAML package, v4.9d.266 First, we estimated the substitution rate across the data matrix 
using a “GTR+G” model of substitutions (model = 7), a strict clock model, and the 
maximum likelihood phylogeny rooted on the clade of A. fischeri strains. We imposed a 
root age of 3.69 million years ago according to results from recent divergence time 
estimates of the split between A. fischeri and A. fumigatus.216 We estimated the 
substitution rate to be 0.005 substitutions per one million years. Next, the likelihood of 
the alignment was approximated using a gradient and Hessian matrix. To do so, we 
used previously established time constraints for the split between A. fischeri and A. 
fumigatus (1.85 to 6.74 million years ago).216 Lastly, we used the resulting gradient and 
Hessian matrix, the rooted maximum likelihood phylogeny, and the concatenated data 
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matrix to estimate divergence times using a relaxed molecular clock (model = 2). We 
specified the substitution rate prior based on the estimated substitution rate 
(rgene_gamma = 1 186.63). The ‘sigma2_gamma’ and ‘finetune’ parameters were set to 
‘1 4.5’ and ‘1’, respectively. To collect a high-quality posterior probability distribution, we 
ran a total of 5.1 million iterations during MCMC analysis which, is 510 times greater 
than the minimum recommendations.267 Our sampling strategy across the 5.1 million 
iterations was to discard the first 100,000 results followed by collecting a sample every 
500th iteration until a total of 10,000 samples were collected.   
Identification of Gene Families and Analyses of Putative Biosynthetic Gene 
Clusters. To identify gene families across the ten Aspergillus genomes, we used a 
Markov clustering approach. Specifically, we used OrthoFinder, v2.3.8.268 OrthoFinder 
first conducts a blast all-vs-all using the protein sequences of all ten Aspergillus 
genomes and NCBI’s Blast+, v2.3.0,269 software. After normalizing blast bit scores, 
genes are clustered into discrete orthogroups using a Markov clustering approach. We 
clustered genes using an inflation parameter of 1.5. The resulting orthogroups were 
used proxies for gene families. 
To identify putative biosynthetic gene clusters (BGCs), we used the gene 
boundaries predictions from the MAKER software as input into antiSMASH, v4.1.0 
(Weber et al. 2015). To identify homologous BGCs across the ten Aspergillus genomes, 
we used the software BiG-SCAPE, v20181005.270 Based on the Jaccard Index of 
domain types, sequence similarity among domains, and domain adjacency, BiG-SCAPE 
calculates a similarity metric between pairwise combinations of clusters where smaller 
values indicate greater BGC similarity. BiG-SCAPE’s similarity metric can then be used 
as an edge-length in network analyses of cluster similarity. We evaluated networks using 
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an edge-length cutoff from 0.1-0.9 with a step of 0.1 (Figure 47). We found networks with 
an edge-length cutoff of 0.4-0.6 to be similar and based further analyses on a cutoff of 
0.5. Because BiG-SCAPE inexplicably split the gliotoxin BGC of the A. fumigatus Af293 
strain into two cluster families even though the BGC was highly similar to the gliotoxin 
BGCs of all other strains, we supplemented BiG-SCAPE’s approach to identifying 
homologous BGCs with visualize inspection of microsyteny and blast-based analyses 
using NCBI’s BLAST+, v2.3.0269 for BGCs of interest. Similar sequences in microsynteny 
analyses were defined as at least 100 bp in length, at least 30 percent similarity, and an 
expectation value threshold of 0.01. Lastly, to determine if any BGCs have been 
previously linked to secondary metabolites, we cross referenced BGCs and BGC 
families with those found in the MIBiG database239 as well as previously published A. 
fumigatus BGCs. BGCs not associated with secondary metabolites were considered to 
likely encode for unknown compounds. 
Identification and characterization of secondary metabolite production 
General Experimental Procedures. The 1H NMR data were collected using a 
JOEL ECS-400 spectrometer, which was equipped with a JOEL normal geometry 
broadband Royal probe, and a 24-slot autosampler, and operated at 400 MHz. 
HRESIMS experiments utilized either a Thermo LTQ Orbitrap XL mass spectrometer or 
a Thermo Q Exactive Plus (Thermo Fisher Scientific); both were equipped with an 
electrospray ionization source. A Waters Acquity UPLC (Waters Corp.) was utilized for 
both mass spectrometers, using a BEH C18 column (1.7 m; 50 mm x 2.1 mm) set to a 
temperature of 40oC and a flow rate of 0.3 ml/min. The mobile phase consisted of a 
linear gradient of CH3CN-H2O (both acidified with 0.1% formic acid), starting at 15% 
CH3CN and increasing linearly to 100% CH3CN over 8 min, with a 1.5 min hold before 
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returning to the starting condition. The HPLC separations were performed with Atlantis 
T3 C18 semi-preparative (5 m; 10 x 250 mm) and preparative (5 m; 19 x 250 mm) 
columns, at a flow rate of 4.6 ml/min and 16.9 ml/min, respectively, with a Varian Prostar 
HPLC system equipped with a Prostar 210 pumps and a Prostar 335 photodiode array 
detector (PDA), with the collection and analysis of data using Galaxie Chromatography 
Workstation software. Flash chromatography was performed on a Teledyne ISCO 
Combiflash Rf 200 and monitored by both ELSD and PDA detectors.  
Chemical Characterization. To identify the secondary metabolites that were 
biosynthesized by A. fumigatus, A. oerlinghausenensis, and A. fischeri, these strains 
were grown as large-scale fermentations to isolate and characterize the secondary 
metabolites. To inoculate oatmeal cereal media (Old fashioned breakfast Quaker oats), 
agar plugs from fungal stains grown on potato dextrose agar; difco (PDA) were excised 
from the edge of the Petri dish culture and transferred to separate liquid seed media that 
contained 10 ml YESD broth (2% soy peptone, 2% dextrose, and 1% yeast extract; 5 g 
of yeast extract, 10 g of soy peptone, and 10 g of D-glucose in 500 ml of deionized H2O) 
and allowed to grow at 23˚C with agitation at 100 rpm for three days. The YESD seed 
cultures of the fungi were subsequently used to inoculate solid-state oatmeal 
fermentation cultures, which were either grown at room temperature (approximately 
23˚C under 12h light/dark cycles for 14 days), 30˚C, or 37˚C; all growths at the latter two 
temperatures were carried out in an incubator (VWR International) in the dark over four 
days. The oatmeal cultures were prepared in 250 ml Erlenmeyer flasks that contained 10 
g of autoclaved oatmeal (10 g of oatmeal with 17 ml of deionized H2O and sterilized for 
15–20 minutes at 121°C). For all fungal strains three flasks of oatmeal cultures were 
grown at all three temperatures, except for A. oerlinghausenensis (CBS 139183T) at 
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room temperature and A. fumigatus (Af293) at 37˚C. For CBS 139183T, the fungal 
cultures were grown in four flasks, while for Af293 eight flasks were grown in total. The 
growths of these two strains were performed differently from the rest because larger 
amounts of extract were required in order to perform detailed chemical characterization.  
The cultures were extracted by adding 60 ml of (1:1) MeOH-CHCl3 to each 250 
ml flask, chopping thoroughly with a spatula, and shaking overnight (~ 16 h) at ~ 100 
rpm at room temperature. The culture was filtered in vacuo, and 90 ml CHCl3 and 150 ml 
H2O were added to the filtrate. The mixture was stirred for 30 min and then transferred to 
a separatory funnel. The organic layer (CHCl3) was drawn off and evaporated to dryness 
in vacuo. The dried organic layer was reconstituted in 100 ml of (1:1) MeOH–CH3CN and 
100 ml of hexanes, transferred to a separatory funnel, and shaken vigorously. The 
defatted organic layer (MeOH–CH3CN) was evaporated to dryness in vacuo. 
To isolate compounds, the defatted extract was dissolved in CHCl3, absorbed 
onto Celite 545 (Acros Organics), and fractioned by normal phase flash chromatography 
using a gradient of hexane-CHCl3-MeOH. Aspergillus fischeri strain NRRL 181 was 
chemically characterized previously.16, 271 A. fumigatus strain Af293, grown at 37°C, was 
subjected to a 12g column at a flow rate of 30 ml/min and 61.0 column volumes, which 
yielded four fractions. Fraction 2 was further purified via preparative HPLC using a 
gradient system of 30:70 to 100:0 of CH3CN-H2O with 0.1% formic acid over 40 min at a 
flow rate of 16.9 ml/min to yield six subfractions. Subfractions 1, 2 and 5, yielded 
cyclo(L-Pro-L-Leu)272 (0.89 mg), cyclo(L-Pro-L-Phe)273 (0.71 mg), and 
monomethylsulochrin274 (2.04 mg), which eluted at approximately 5.7, 6.3, and 10.7 min, 
respectively. Fraction 3 was further purified via preparative HPLC using a gradient 
system of 40:60 to 65:35 of CH3CN-H2O with 0.1% formic acid over 30 min at a flow rate 
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of 16.9 ml/min to yield four subfractions. Subfractions 1 and 2 yielded pseurotin A275 
(12.50 mg) and bisdethiobis(methylthio)gliotoxin169 (13.99 mg), which eluted at 
approximately 7.5 and 8.0 min, respectively.  
A. fumigatus strain CEA10, grown at 37°C, was subjected to a 4g column at a 
flow rate of 18 ml/min and 90.0 column volumes, which yielded five fractions. Fraction 1 
was purified via preparative HPLC using a gradient system of 50:50 to 100:0 of CH3CN-
H2O with 0.1% formic acid over 45 min at a flow rate of 16.9 ml/min to yield eight 
subfractions. Subfraction 1, yielded fumagillin276 (1.69 mg), which eluted at 
approximately 18.5 min. Fraction 2 was purified via semi-preparative HPLC using a 
gradient system of 35:65 to 80:20 of CH3CN-H2O with 0.1% formic acid over 30 min at a 
flow rate of 4.6 ml/min to yield 10 subfractions. Subfraction 5 yielded fumitremorgin C277 
(0.25 mg), which eluted at approximately 15.5 min. Fraction 3 was purified via 
preparative HPLC using a gradient system of 40:60 to 100:0 of CH3CN-H2O with 0.1% 
formic acid over 30 min at a flow rate of 16.9 ml/min to yield nine subfractions. 
Subfraction 2 yielded pseurotin A (1.64 mg), which eluted at approximately 7.3 min. 
Aspergillus oerlinghausenensis strain CBS 139183T, grown at RT, was subjected 
to a 4g column at a flow rate of 18 ml/min and 90 column volumes, which yielded 4 
fractions. Fraction 3 was further purified via preparative HPLC using a gradient system 
of 35:65 to 70:30 of CH3CN-H2O with 0.1% formic acid over 40 min at a flow rate of 16.9 
ml/min to yield 11 subfractions. Subfractions 3 and 10 yielded spiro [5H,10H-
dipyrrolo[1,2-a:1′,2′-d]pyrazine-2-(3H),2′-[2H]indole]-3′,5,10(1′H)-trione278 (0.64 mg) and 
helvolic acid279 (1.03 mg), which eluted at approximately 11.5 and 39.3 min, respectively. 
(NMR data Figures 53-59). 
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Metabolite Profiling by Mass Spectrometry. The metabolite profiling by mass 
spectrometry, also known as dereplication, was performed as stated previously.188 
Briefly, ultraperformance liquid chromatography-photodiode array-electrospray ionization 
high resolution tandem mass spectrometry (UPLC-PDA-HRMS-MS/MS) was utilized to 
monitor for secondary metabolites across all strains (Af293, CEA10, CEA17, CBS 
139183T, NRRL 181, NRRL 4161, and NRRL 4585). Utilizing positive-ionization mode, 
ACD MS Manager with add-in software IntelliXtract (Advanced Chemistry Development, 
Inc.; Toronto, Canada) was used for the primary analysis of the UPLC-MS 
chromatograms. The data from 19 secondary metabolites are provided in Table 4.5, 
which for each secondary metabolite lists: molecular formula, retention time, UV-
absorption maxima, high-resolution full-scan mass spectra, and MS-MS data (top 10 
most intense peaks). 
Metabolomics Analyses. Principal component analysis (PCA) analysis was 
performed on the UPLC-MS data. Untargeted UPLC-MS datasets for each sample were 
individually aligned, filtered, and analyzed using MZmine 2.20 software 
(https://sourceforge.net/projects/mzmine/).280 Peak detection was achieved using the 
following parameters, A. fumigatus at (Af293, CEA10, and CEA17): noise level (absolute 
value), 1×106; minimum peak duration, 0.05 min; m/z variation tolerance, 0.05; and m/z 
intensity variation, 20%; A. fischeri (NRRL 181, NRRL 4161, and NRRL 4585): noise 
level (absolute value), 1×106; minimum peak duration, 0.05 min; m/z variation tolerance, 
0.05; and m/z intensity variation, 20%; and all strains (Af293, CEA10, CEA17, CBS 
139183T, NRRL 181, NRRL 4161, and NRRL 4585): noise level (absolute value), 7×105; 
minimum peak duration, 0.05 min; m/z variation tolerance, 0.05; and m/z intensity 
variation, 20%. Peak list filtering and retention time alignment algorithms were used to 
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refine peak detection. The join algorithm integrated all sample profiles into a data matrix 
using the following parameters: m/z and retention time balance set at 10.0 each, m/z 
tolerance set at 0.001, and RT tolerance set at 0.5 mins. The resulting data matrix was 
exported to Excel (Microsoft) for analysis as a set of m/z – retention time pairs with 
individual peak areas detected in triplicate analyses. Samples that did not possess 
detectable quantities of a given marker ion were assigned a peak area of zero to 
maintain the same number of variables for all sample sets. Ions that did not elute 
between 2 and 8 minutes and/or had an m/z ratio less than 200 or greater than 800 Da 
were removed from analysis. Relative standard deviation was used to understand the 
quantity of variance between the technical replicate injections, which may differ slightly 
based on instrument variance. A cutoff of 1.0 was used at any given m/z – retention time 
pair across the technical replicate injections of one biological replicate, and if the 
variance was greater than the cutoff, it was assigned a peak area of zero. Final 
chemometric analysis, data filtering281 and PCA was conducted using Sirius, v10.0 
(Pattern Recognition Systems AS),282 and dendrograms were created with Python. The 
PCA scores plots were generated using data from either the three individual biological 
replicates or the averaged biological replicates of the fermentations. Each biological 
replicate was plotted using averaged peak areas obtained across four replicate 
injections (technical replicates). 
Data Availability. Sequence reads and associated genome assemblies 
generated in this project are available in NCBI’s GenBank database under the BioProject 
PRJNA577646. Additional descriptions of the genomes including predicted gene 
boundaries are available through figshare 
https://doi.org/10.6084/m9.figshare.12055503). The figshare repository is also populated 
118 
with other data generated from genomic analysis. Among genomic analyses, we provide 
information about predicted BGCs, results associated with network-based clustering of 
BGCs into cluster families, phylogenomic data matrices, and trees.  
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Table 4.3. A Table of Secondary Metabolites Produced by Each Species and Strain. ‘+’ 
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Table 4.5. Chemical Structures, Chemical Formulas, Retention Times, UV Absorption 
Maxima, (+)-ESI HRMS, and (+)-ESI CID MS/MS Data of Fumigati Fungal Secondary 
Metabolites. 
 

































































































































































































































































































aMass spectrometry data are reported as m/z values with the difference in ppm between 




Figure 45. Metrics of Genomes Assembly Quality and Number of Predicted Gene. 
Genome size, N50, number of genes, number of scaffolds and percent single copy 
BUSCO genes (scBUSCO) are depicted here. Examination of metrics reveal genomes 
are of sufficient quality for comparative genomics purposes. Of concern, we noted A. 
oerlinghausenensis CBS 139183T was assembled into 5,300 contigs; however, we 
evaluated the assembly’s N50 value and gene content completeness (461,327 base 
pairs and 98.90% BUSCO genes present in single copy, respectively) and found the A. 
oerlinghausenensis genome is suitable for comparative genomic analyses. Strains in 




Figure 46. A Reconstructed Evolutionary History and Timetree of A. fumigatus and its 
Closest Relatives. (top) Divergence times were estimated using a concatenated matrix 
of 3,041 genes (5,602,272 sites). Blue bars at each node correspond to the 95% 
divergence time confidence interval. Divergence times and confidence intervals for each 
internode are shown on the right side of the figure. (bottom) A phylogeny where branch 
lengths represent substitutions per site rather than geologic time. A cladogram is drawn 
to the right of the phylogeny to clarify divergences where branch lengths are short (e.g., 




Figure 47. Species and Strain Heterogeneity Among BGC Cluster Presence and 
Absence. (A) Networks using edge cut-offs ranging from 0.1-0.9 with a step of 0.1 were 
evaluated. Networks from 0.4 to 0.6 were qualitatively similar. Thus, we used cluster 
families inferred from the network using an edge cut-off of 0.5. (B) Examination of the 
number of strains in each cluster family reveal a wide variation. For example, all 10 
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genomes are represented in 17 cluster families; in contrast, 18 cluster families have only 
one BGC. (C) Species occupancy among cluster families reveal A. fischeri has the 
largest number of unique BGCs followed by A. fumigatus and A. oerlinghausenensis. 
 
 
Figure 48. Gene Family Presence and Absence Follows a Similar Pattern to BGCs. 
Orthogroups were used as proxies for gene families. A strain-level UpSet plot for gene 





Figure 49. Structures of Isolated Fungal Metabolites. Secondary metabolites produced 
in sufficient quantity were isolated for structural determination. The structures of 
compounds are correlated to each strain from where they were isolated. Structural 
moieties biosynthesized by terpene synthases, polyketide synthases, and non-ribosomal 





Figure 50. Principal Component Analysis of BGC Presence and Absence and 
Secondary Metabolite Profiles Mirror One Another. (A) Principal component analysis of 
BGC presence and absence reveal that each species is distinct from the other. 
Furthermore, A. oerlinghausenensis is between A. fischeri and A. fumigatus. (B, C) 
Broadly, similar patterns of species relationships in principal component space are 
observed among all metabolites produced at 37°C and 30°C. (D, E) Similar results were 
observed for isolatable metabolites. 
 
 
Figure 51. Small Sequence Divergences in the Trypacidin BGC are Associated with the 
Production of Trypacidin or the Lack Thereof. The trypacidin BGC is found in A. 
fumigatus strains Af293 and CEA10, A. oerlinghausenensis CBS 139183T, and A. 
fischeri NRRL 181. Evidence of trypacidin biosynthesis is found in all isolates with the 
exception of A. fischeri NRRL 181. The absence of trypacidin biosynthesis is associated 
with the absence of a RING finger gene in A. fischeri NRRL 181. Black and white 
squares correspond to evidence or no evidence of secondary metabolite production, 
respectively. Grey boxes connecting BGCs represent BLAST-based similarity of 
nucleotide sequences defined as being at least 100 bp in length, share at least 30% 
sequence similarity, and have an expectation value threshold of 0.01. Genus and 
species names are written using the following abbreviations: Afum: A. fumigatus; Aoer: 




Figure 52. Panels A-C demonstrate an example of the dereplication process used to 
identify bisdethiobis(methylthio)gliotoxin (5) in the extract of CBS 139183T. Panel A 
shows the base peak chromatogram of an extract of CBS 139183T (top), the extracted 
ion chromatogram of the same extract using the m/z value for compound 5 (middle) and 
the retention time for a standard of compound 5 (bottom). This demonstrates a retention 
time match between the standard and the peak in the extracted ion chromatogram. 
Panel B demonstrates a match between the isotopic ratios and the accurate mass for 
the peak highlighted in Panel A for the extracted ion chromatogram (middle) and 
compound 5 (bottom). Panel C demonstrates a match between the fragmentation 
patterns of the peak in the base peak chromatogram (top) and a standard of 5 (bottom). 
In summation, these data confirm the presence of 5 in CBS139183T grown on oatmeal at 
37°C. A similar process was used for all of the compounds that were identified via 
dereplication in this manuscript (i.e. Tables 4.5-4.7). 
 
 




Figure 54. 1H NMR spectrum of monomethylsulochrin (3) (400 MHz; CDCl3).  
 
 
Figure 55. 1H NMR spectrum of pseurotin A (4) (400 MHz; CDCl3). 
 
 




Figure 57. 1H NMR spectrum of fumagillin (6) (400 MHz; CDCl3). 
 
 
Figure 58. 1H NMR spectrum of spiro-[5H,10H-dipyrrolo[1,2-a:1ʹ,2ʹ-d]pyrazine-2-(3H),2ʹ-
[2H]indole]-3ʹ,5,10(1ʹH)-trione (8) (400 MHz; CDCl3). 
 
 




MAPPING THE FUNGAL BATTLEFIELD: USING IN SITU CHEMISTRY AND 
DELETION MUTANTS TO MONITOR INTERSPECIFIC CHEMICAL INTERACTIONS 
BETWEEN FUNGI 
 
Sonja L. Knowles, Huzefa A. Raja, Allison J. Wright, Ann Marie L. Lee, Lindsay K. 
Caesar, Nadja B. Cech, Matthew E. Mead, Jacob L. Steenwyk, Laure N. A. Ries, 




Fungi grow in competitive environments, and to cope, they have evolved 
strategies, such as the ability to produce a wide range of secondary metabolites. This 
begs two related questions. First, how do secondary metabolites influence fungal 
ecology and interspecific interactions? Second, can these interspecific interactions 
provide a way to “see” how fungi respond, chemically, within a competitive environment? 
To evaluate these, and to gain insight into the secondary metabolic arsenal fungi 
possess, we co-cultured Aspergillus fischeri, a genetically tractable fungus that produces 
a suite of mycotoxins, with Xylaria cubensis, a fungus that produces the fungistatic 
compound and FDA-approved drug, griseofulvin. To monitor and characterize fungal 
chemistry in situ, we used the droplet-liquid microjunction-surface sampling probe 
(droplet probe). The droplet probe makes a microextraction at defined locations on the 
surface of the co-culture, followed by analysis of the secondary metabolite profile via 
liquid chromatography-mass spectrometry. Using this, we mapped and compared the
 spatial profiles of secondary metabolites from both fungi in monoculture versus co-
culture. X. cubensis predominantly biosynthesized griseofulvin and dechlorogriseofulvin 
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in monoculture. In contrast, under co-culture conditions a deadlock was formed between 
the two fungi, and X. cubensis biosynthesized the same two secondary metabolites, 
along with dechloro-5`-hydroxygriseofulvin and 5`-hydroxygriseofulvin, all of which have 
fungistatic properties, as well as mycotoxins like cytochalasin D and cytochalasin C. In 
contrast, in co-culture, A. fischeri increased the production of the mycotoxins 
fumitremorgin B and verruculogen, but otherwise remained unchanged relative to its 
monoculture. To evaluate that secondary metabolites play an important role in defense 
and territory establishment, we co-cultured A. fischeri lacking the master regulator of 
secondary metabolism laeA with X. cubensis. We found that the reduced secondary 
metabolite biosynthesis of the ΔlaeA strain of A. fischeri eliminated the organism’s ability 
to compete in co-culture and led to its displacement by X. cubensis. These results 
demonstrate the potential of in situ chemical analysis and deletion mutant approaches 
for shedding light on the ecological roles of secondary metabolites and how they 
influence fungal ecological strategies; co-culturing may also stimulate the biosynthesis of 
secondary metabolites that are not produced in monoculture in the laboratory. 
Fungi naturally grow in competitive environments, such as soil, plants, and 
animal tissues.3 They have evolved a diversity of ecological strategies to combat their 
competitors, which include rapid growth, stress recovery, and the use and negation of 
inhibitors.29 Interaction-driven secondary metabolite discovery (i.e. co-culturing) can 
exploit the ability of fungi to produce secondary metabolites that have evolved to combat 
various competitors. Co-culturing experiments often activate the biosynthesis of defense
 secondary metabolites, allowing one to “see” how fungi respond, chemically, within a 
competitive environment.57, 58 They also provide a window to understanding fungal 
ecology and the ecological relevance of secondary metabolites. 
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Previous studies have shown that fungal genomes have a rich diversity of 
biosynthetic gene clusters,9, 11, 283, 284 and that fungi have the potential to produce 
numerous chemically diverse secondary metabolites; however, a large proportion of 
biosynthetic gene clusters are silent under traditional laboratory culture conditions.18, 43, 
47-49, 284 One possibility is that only a fraction of the potential secondary metabolites are 
produced, likely due to fungal domestication as a result of repeated culturing at optimal 
media conditions. Another possibility is that the stressors that elicit the expression of 
certain secondary metabolites are not present.17, 284 
Co-culturing is a promising approach for activating regulatory mechanisms that 
result in the biosynthesis of otherwise silenced secondary metabolites for targeted 
interaction discovery.60 For example, when Trichophyton rubrum and Bionectria 
ochroleuca were co-cultured, there was an activation of silent biosynthetic gene clusters, 
as evidenced by a new secondary metabolite that was only present in the zone 
separating the two fungi.285 It has also been shown that co-culturing two fungi can 
increase the quantity of certain secondary metabolites that were previously being 
biosynthesized.17, 62, 286 A potential reason for these activations is interspecific 
interactions. These interactions can cause chemical cues to be exuded to the 
environment between two or more species competing for nutrition and space that could 
result in the activation of biosynthetic gene clusters.56, 287, 288 
Over the last decade numerous mass spectrometry tools have been utilized to 
study microbial interactions in situ to obtain a holistic understanding of the chemical 
interactions between two competing microbes.289-291 Most studies have explored 
bacterial-bacterial interactions and fungal-bacterial interactions in situ in a Petri plate,290-
293 but there are a few studies that have explored the mapping and characterization of 
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fungal-fungal interactions in situ.289, 294-296 One of the main issues that precludes in situ 
studies on fungi is the uneven morphology (heterogeneous topography) of fungal 
mycelia, which is not easily amenable to in situ ionization techniques without modifying 
the culture.3, 289, 297, 298 The problem of uneven topology can be overcome by using the 
droplet–liquid microjunction–surface sampling probe (droplet probe).299, 300 Importantly, 
mapping the chemical entities of fungi as they compete in situ can address chemical 
ecology questions, such as where (spatially) and when (temporally) the compounds are 
biosynthesized, and such data are typically lost in previous studies on co-culturing fungi 
through the use of a traditional chemical extraction processes.288, 301, 302  
A connection has been established in the literature between the production of 
secondary metabolites produced by fungi and their role in ecological chemical 
interactions.303, 304 It is well known that laeA (loss of aflR expression, with aflR being the 
regulatory gene for aflatoxin biosynthesis) is a global regulator and controls both fungal 
growth and development and is responsible for over 50% of secondary metabolites 
produced in Aspergillus as well as other genera.305, 306 It has been reported that deletion 
mutants laeA are less pathogenic.305 However, what is not known is what would happen 
if a laeA mutant of Aspergillus fischeri were grown in co-culture with a competing fungus.  
In other words, by monitoring the chemical interaction between fungi in situ, could a wild 
type and laeA mutant of Aspergillus fischeri co-cultured with another fungus help answer 
the role of secondary metabolites for defense? We hypothesized, based on the large 
body of previous literature, that since laeA is integral to both growth and development as 
well as production of secondary metabolites,305 a ΔlaeA mutant would be unable to battle 
with other fungi. Thus, as the chemical arsenal of the ΔlaeA mutant is affected, this in 
turn would affect its ability to occupy space and survive. Such experimental studies 
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would help shed light on the biological roles of secondary metabolites in fungi and 
provide experimental evidence for the ecological role of secondary metabolites in fungi 
in situ.  
In this study, we evaluated the co-culturing of two fungi, Aspergillus fischeri and 
Xylaria cubensis, in situ and observed distinct chemical profile changes resulting from 
the interspecific interactions between them. X. cubensis commonly occurs as an 
endophyte (endosymbiotic) and decomposer (saprobic)9 and biosynthesizes the 
fungistatic secondary metabolite griseofulvin, an FDA-approved drug.289, 307 Fungistatic 
denotes that it inhibits fungal growth, rather than kills competing fungi, and we 
hypothesized, therefore, that the resulting stress in a co-culture environment would allow 
us to examine how secondary metabolite production changes when the two species 
interact. 
Aspergillus fischeri was chosen due to its genetic tractability and its evolutionary 
relatedness with A. fumigatus, the human pathogen.16, 308, 309 It also has its own 
metabolite weaponry in the form of mycotoxins.16 The secondary metabolites of 
Aspergilli, including A. fischeri, are largely controlled by the master regulator protein 
laeA.16, 205, 306, 310, 311. A deletion strain of A. fischeri where laeA was knocked out (ΔlaeA) 
was co-cultured with X. cubensis. Concomitant with reduction of the biosynthesis of 
secondary metabolites, A. fischeri lost its competitive advantage, and X. cubensis was 








Figure 60. The Diversity of Secondary Metabolites Isolated from the Co-Culture of Wild 
Type Aspergillus fischeri (NRRL 181) and Xylaria cubensis (G536). The color of the 
structure indicates the different biosynthetic class of the secondary metabolites; blue = 




Co-culture Analysis of the Junction Between A. fischeri and X. cubensis via 
Droplet Probe Reveals Varied Chemical Diversity Not Present in Either 
Monoculture. To obtain baseline data, the monoculture of X. cubensis was sampled by 
droplet probe, and the LC-MS base peak chromatogram only showed two peaks, which 
corresponded to griseofulvin (8) and dechlorogriseofulvin (9) as determined by 
comparison of accurate mass and retention time of a standard.188, 307 Griseofulvin (8) and 
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dechlorogriseofulvin (9) were present in multiple spots across the mycelium, with both 
more concentrated at the mycelial edge. The monoculture of wild type A. fischeri was 
analyzed in an identical manner, and based on the same data analyses, sartorypyrone A 
(1), aszonalenin (2), acetylaszonalenin (3), fumitremorgin A (4), fumitremorgin B (5), 




Figure 61. The Chromatograms from the Droplet Probe Analysis of the Monocultures, as 
Taken at the Mycelial Edge. Wild type A. fischeri (top; black) indicates the presence of 
sartorypyrone A (1), aszonalenin (2), acetylaszonalenin (3), fumitremorgin A (4), 
fumitremorgin B (5), and verruculogen (6). X. cubensis (bottom; green) shows 
dechlorogriseofulvin (9) and griseofulvin (8), which are analogues that have fungistatic 




In Situ Co-Culture Analysis of A. fischeri and X. cubensis Via Droplet Probe 
Reveals Varied Chemical Diversity at the Junction Between the Two Fungi Not 
Present in the Monoculture Experiments. A deadlock was formed in the A. fischeri 
and X. cubensis co-culture (Figure 62). The two fungi grew toward the middle of the 
plate, and at the junction where both fungal mycelia overlap, neither of the two was able 
to grow further. The LC-MS profile showed distinct peaks (i.e. the presence of multiple 
ions) in co-culture (Figure 63), some of which were absent from the monocultures. 
 
 
Figure 62. Wild Type A. fischeri can Form a Deadlock while ΔlaeA A. fischeri Gets 
Displaced by X. cubensis During the Co-Culture. The left image shows the growths of 
wild type A. fischeri and the right image shows the growths of ΔlaeA A. fischeri with X.; 
cubensis over a three-week timeline. 
 
Griseofulvin (8) and dechlorogriseofulvin (9) were not detected in the region of the co-
culture where only X. cubensis mycelia were growing, however, both of these 
compounds were detected at the junction. Alternately, the monoculture had more 
accumulation of griseofulvin (8) and dechlorogriseofulvin (9) at the colony edge, but 
these compounds were present throughout the mycelia. The co-culture of wild type A. 
fischeri had the same secondary metabolites present as the monoculture. However, 
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secondary metabolite production was altered during co-culturing (Figure 63). For 
example, verruculogen (6) and fumitremorgin B (5) showed an average increase in 
production of about 2 and 2.5 orders of magnitude, respectively, relative to their 
production in monoculture across three biological replicates in situ. 
 
 
Figure 63. Co-Culture Produces Greater Diversity of Secondary Metabolites Over That 
of the Monocultures. The chromatograms from the droplet probe analysis of the co-
cultures shows only three out of the eight spots examined are shown here, with the 
corresponding colored dot indicating the location at which the mycelium was sampled. 
Wild type A. fischeri (Top) showed the presence of the secondary metabolites as seen in 
monoculture (Figure 61); however, there were differences in the relative abundance of 
the mycotoxins such as verruculogen and fumitremorgin B during their growth in co-
culture. The junction (middle) where both fungal mycelia interact revealed the presence 
of griseofulvin and dechlorogriseofulvin, which were not present anywhere else in the co-
culture. It also indicated the presence of secondary metabolites that were not present in 
the monoculture growths of either of the two fungi (asterisks). X. cubensis (bottom) did 
not show the presence of the two previously present secondary metabolites (griseofulvin 
and dechlorogriseofulvin), nor did it show the presence of any secondary metabolites. 
 
Large-Scale Fermentation of Co-Culture Indicated the Activation of 
Previously Silent Secondary Metabolites. To isolate and elucidate the structures of 
newly found secondary metabolite peaks in the junction between the two fungal species 
in the co-culture experiment, a large-scale fermentation of X. cubensis and wild type A. 
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fischeri as a mixed co-culture on solid media was executed. The fungal growth was 
extracted and purified to isolate compounds that were characterized. In the co-culture 
griseofulvin (8) and dechlorogriseofulvin (9),307 which were present in the monoculture, 
were isolated, as were the two analogues 5`-hydroxygriseofulvin (10) and dechloro-5`-
hydroxygriseofulvin (11),307 which were not observed in monoculture (Figures 79-82). 
The mycotoxins cytochalasin D (12),312 cytochalasin Q (13),188 cytochalasin C (14), 
zygosporin E (15),313, 314 and 7-O-acetylcytochalasin B (16),315 (Figure 64) were 
observed in monoculture, albeit at extremely low concentrations that did not afford 
structural characterization. However, under co-culture conditions, they increased in 
abundance to an extent that afforded isolation and full structural characterization 
(Figures 83-86). Finally, hirsutatin A (17),316 which was not detected in the monoculture, 




Figure 64. Increase in Chemical Diversity in the Co-Culture Caused the Characterization 
of Secondary Metabolite Not Seen in Monoculture. The chromatogram produced from 
the large-scale extraction of mixed co-culture. Black arrows indicate the secondary 
metabolites from the monoculture of wild type A. fischeri; green arrows indicate the 
secondary metabolites from the monoculture of X. cubensis; and red arrows indicate the 




Metabolomics Analyses Shows Different Chemical Entities in the 
Monoculture Versus Co-Culture. Comparison of metabolite profiles is often achieved 
using multivariate statistical modeling protocols such as principal component analysis 
(PCA) 317. To determine the degree of difference between the metabolite profiles 
observed during the large-scale mono or co-culture, PCA scores and loadings plots were 
generated (Figures 65a and 65b). Untargeted metabolomics analyses of fungal samples 
using LC-MS yielded 2111 features (unique m/z-retention time pairs) for 60 samples 
(five biological replicates of X. cubensis, A. fischeri, and the co-culture of the two fungal 
organisms, all analyzed in quadruplicate). Examination of these plots illustrated that 
clusters of X. cubensis, A. fischeri, and the co-culture of the two organisms were 
clustered distinctly in the PCA plot, which accounted for 89.9% of the variability among 




Figure 65a. Principal component analysis (PCA) scores plot of fungal samples shows 
distinct differences between the co-culture and monocultures. Five biological replicates 
of each sample type are plotted using peak area data for each sample that was an 
average of four injections (four technical replicates). Distinct clusters were observed 
between X. cubensis, A. fischeri, and co-cultured organisms. Figure 65b. Loadings plot 
from untargeted mass spectrometry based PCA of fungal samples shows the presence 
of unique and upregulated secondary metabolites in the co-culture. Metabolites with 
positive values along the horizontal axis were more heavily represented in co-cultures 
than monocultures or were unique to the co-culture entirely. Yellow squares = 
compounds that were detected at a lower abundance in the co-culture than in the 
monoculture of Aspergillus fischeri. Purple triangles = compounds that showed 
increased production in the co-culture and were produced by one or both fungi (Table 
5.1). Orange diamonds = compounds that were only detected in co-culture samples. 
Gray circles = compounds that do not contribute to the difference between the cultures. 
Metabolites were identified following isolation using a combination of mass spectral and 
NMR data. In cases where compounds were of too low abundance to be isolated, 
comparisons were made against the literature using m/z values from high-resolution 
mass spectrometry data. Identifications based on mass alone, without purification, are 
tentative. 
 
To evaluate which compounds contributed to the separation between groups, the 
PCA loadings plot was inspected (Figure 65b) using averaged data from both biological 
and technical replicates. Inspection of principal component loadings enables 
identification of variables that are responsible for the observed groupings in the PCA 
scores plot; the more a given variable diverges from other variables in the loadings plot, 
the more it contributes to the separation between groups in the scores plot. The two 
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components utilized for this loadings plot explained 86.2% of the variability among 
samples (PC1=66.5%, PC2=19.8%). In this plot, compounds were identified as those 
that were 1) more abundant in the co-culture, 2) less abundant in the co-culture, and 3) 
unique to the co-culture (Table 5.1).  Metabolites with positive values along the x-axis, 
including griseofulvin analogues, cytochalasins, and a compound with a novel chemical 
scaffold (sample ID 01063-99-2) were detected in greater abundance in co-culture than 
in monocultures (purple triangles), or were completely unique to the co-culture (orange 
diamonds), and are responsible for the shift observed of the co-culture samples in the 
PCA scores plot.  
Genome Mining Implicates X. cubensis as the Species Producing 
Cytochalasin During the Co-Culture. To determine whether A. fischeri or X. cubensis 
produced the cytochalasin congeners isolated from the co-culture, a combination of 
genome mining and mass spectrometry was used. Cytochalasins are a wide structural 
class of mycotoxins and are very common in Xylariales species.318-321 To attempt to 
determine which organism was producing cytochalasin D during the co-culture 
experiment, we searched for genes orthologous to a previously described biosynthetic 
gene cluster responsible for cytochalasin E production in Aspergillus clavatus. 322 A 
putative cytochalasin cluster was not found in A. fischeri, and only 4 out of 8 individual 
cytochalasin genes were identified in the genome and they were unclustered (Table 5.2). 
Potential orthologs for the Non-ribosomal Peptide Synthase-Polyketide Synthase hybrid 
and enoyl reductase genes were found in a biosynthetic gene cluster in A. fischeri that 
likely produces the secondary metabolite aspyridone.16 Sequencing of the genome of X. 
cubensis has not been reported, and the closest evolutionary relative that has a 
sequenced genome is Rosellinia necatrix.289, 323 Upon analysis of the R. necatrix 
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genome, a complete cytochalasin gene cluster was found (Table 5.2) and led us to 
hypothesize that X. cubensis was responsible for biosynthesizing the cytochalasins 
isolated from the batch co-culture. Furthermore, un-isolatable amounts of the 
cytochalasins were detected by mass spectrometry in the mono-culture of X. cubensis, 
thus supporting our hypothesis that the cytochalasins were most likely biosynthesized by 
X. cubensis during co-culture. 
In situ Analysis of a Co-Culture Between ΔlaeA A. fischeri and X. cubensis 
Reveals the Ecological Importance of Secondary Metabolites in Interspecies 
Chemical Interactions. A less diverse secondary metabolite profile was observed in 
ΔlaeA A. fischeri compared to the wild type A. fischeri, while the growth rates between 
the strains was equivalent.16 Mycelial displacement was observed when ΔlaeA A. 
fischeri was grown with X. cubensis. Once the junction was formed (about two weeks), 
X. cubensis continued to grow and took up more territory from the ΔlaeA A. fischeri. 
After three weeks the mycelium of ΔlaeA A. fischeri had been covered by X. cubensis 
(Figure 62).  
Discussion 
In this study, we performed the chemical analysis of two fungi, Aspergillus fischeri and 
Xylaria cubensis, under both monoculture and co-culture conditions to characterize the 
secondary metabolites produced by these fungi using both in situ analysis with droplet 
probe as well as large-scale fermentation (Figure 66). Specifically, we found that the 
secondary metabolites identified by comparing the analytical profiles in monoculture 
were different than those observed from co-culture in situ (Figures 61 and 63). In co-
culture, the signals for secondary metabolites present at the junction, or the region of 
conflict zone 324, appeared to be unique and were formed as a result of the interspecies 
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cross talk between the two fungi (Figure 63). We also found that when wild type A. 
fischeri was co-cultured with Xylaria cubensis, a junction or conflict zone was formed. 
However, when ΔlaeA A. fischeri was co-cultured with X. cubensis, the conflict zone was 
disturbed and ΔlaeA A. fischeri was displaced by X. cubensis (Figure 62). When X. 
cubensis and wild type A. fischeri were co-cultured in large-scale, so as to isolate and 
characterize the compounds, we showed an increase in chemical diversity, including a 
putative novel scaffold, suggesting the co-culture stimulated cryptic biosynthesis in one 
or both fungi (Figure 64). 
 
 
Figure 66. Overview of How the Secondary Metabolites Biosynthesized During the 
Monoculture and Co-Culture Were Analyzed. Aspergillus fischeri (NRRL 181) and 
Xylaria cubensis (G536) were grown as monocultures in separate Petri plates before 
they were co-cultured. The co-culture and monocultures are then analyzed (left) via in 
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situ microextractions where spatial mapping was performed, which provides a map of 
how the secondary metabolites are distributed along the co-culture landscape in the 
Petri plate. Large-scale fermentation (mixed culture; right) where both fungi were 
transferred together onto solid fermentation media in 250 mL Erlenmeyer flasks and the 
co-culture was allowed to grow for 3-4 weeks. Subsequently the cultures were extracted 
with organic solvents using standard natural product extraction and characterization 
protocols 
  
In situ analysis of co-culture between wild type A. fischeri and X. cubensis 
reveals that chemistry not previously observed in monocultures was produced at the 
junction or conflict zone in interspecies chemical interactions. Most studies of fungi-fungi 
co-culture or fungi-bacteria co-culture demonstrate that when two microbes are co-
cultivated, new chemical compounds are biosynthesized by one or both microbes as a 
result of some interspecies interaction or interspecies cross talk.325 Using droplet probe, 
we observed new chemical profiles at the junction between the two-competing species 
(Figure 63). A similar result was found in a co-culture study between Aspergillus 
nidulans with Streptomyces hygroscopicus,326 which reported the physical interaction 
and close contact between S. hygroscopicus and A. nidulans stimulated the production 
of aromatic polyketides. Another recent study, which performed in situ mapping using 
MALDI-imaging-HRMS, demonstrated the increased production of prodigiosin produced 
by endophytic Serratia marcescens when grown in co-culture with endophytic fungi,290 
where higher amounts of prodigiosin were produced at the contact site between the 
fungal and bacterial cultures. Thus, by sampling fungi and their surrounding 
environment, in situ methods have the ability to map the location of fungal metabolites. 
The ability to map chemical diversity of secondary metabolites in situ provides an ability 
to probe biological questions directly, such as why the fungus produces such 
compounds and how they are spatially distributed. Determining whether a compound is 
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produced for defense, communication, attraction, or other purposes, can be explored via 
these mapping experiments.289, 298 
In situ visualization of griseofulvin production in monoculture versus co-culture 
was different, due to the differential accumulation of griseofulvin (8), suggesting how 
antagonistic or combative species use allelochemicals for attack on other microbes to 
break through the conflict zone. Griseofulvin is an antifungal compound that can be 
classified as an allelochemical (allomone), which is implicated in interspecies 
interactions that can benefit the producing organism, but not the receiving one.289, 307, 327 
The question of how fungi protect themselves from such armaments is often pondered. 
They seem to have at least three specific mechanisms to do so, including the up 
regulation of efflux transporters, detoxifying enzymes, and duplicate copies of the target 
protein.284, 328, 329 
Furthermore, our study provides a striking visualization of how fungi use 
secondary metabolites during interspecies interactions. We demonstrate that when X. 
cubensis is grown in monoculture and sampled via droplet probe, griseofulvin (8) and 
dechlorogriseofulvin (9) are present in the mycelium but mostly towards the outer edge 
of the growing colony (Figure 61). This was observed in three biological replicates in 
situ, indicating that X. cubensis may be marshaling these fungistatic allelochemicals to 
the front line of the “battlefield”. Similarly, previous literature also reports that when X. 
cubensis is grown in co-culture with Penicillium restrictum, that the majority of 
griseofulvin was exuded to the colony edge,289 thus suggesting it makes the antifungal 
compound but does not keep it inside its own mycelium, perhaps protecting itself via 
enhancement of efflux.284, 328 In the present study, we see that in fact there is no trace of 
antifungal compound in the mycelium of X. cubensis in co-culture (Figure 63). Rather, 
152 
we observe that several fungistatic antifungal compounds (griseofulvin (8), 
dechlorogriseofulvin (9), and two analogues 5`-hydroxygriseofulvin (10) and dechloro-5`-
hydroxygriseofulvin (11)) are sent out towards the junction where the two species have 
formed a deadlock or conflict zone (Figures 62 and 63). Thus, the in situ experiments 
demonstrate how X. cubensis is using its secondary metabolite arsenal to stop the 
growth of wild type A. fischeri.  
Overproduction of griseofulvin has also been reported in guttates from X. 
cubensis, when it was grown in media enriched with the antifungal compound 
amphotericin B.330 Our spatial study of griseofulvin and its analogues using droplet probe 
provides experimental evidence that in more complex environments, such as co-
cultures, the location and the amounts of key secondary metabolites (i.e. griseofulvin 
and analogues) are both up regulated as well as outwardly extruded towards the 
competing fungal species. In a previous study, we also found that when Coniolariella 
spp., which is known to produce the herbicidal compound mevalocidin,331 were 
examined by droplet probe, the secondary metabolites were concentrated in the guttates 
and in the surrounding media.332 These data confirm our observation in the present 
study that antagonistic compounds are extruded outwardly towards the receiving 
organism for maximum benefit to the producing organism. Together, our results suggest 
that both the amounts and spatial distributions of secondary metabolites can vary during 
interspecies interactions.  
When wild type A. fischeri and X. cubensis were grown together, a deadlock was 
formed (Figure 62), where neither fungus was able to capture territory from the other.333 
Even though X. cubensis was able to biosynthesize secondary metabolites that stunt the 
growth of the competing fungus, A. fischeri was most likely able to compete due to the 
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presence of its secondary metabolite arsenal, such as the fumitremorgin class of 
alkaloids (4-7). Droplet probe analysis of the co-culture of wild type A. fischeri and X. 
cubensis in situ suggested that no new secondary metabolites were biosynthesized by 
wild type A. fischeri (Figure 63). However, in the three spatial locations sampled in the 
co-culture where there was only A. fischeri mycelium, there was a relative change in the 
relative abundance of the mycotoxins produced. For example, the relative abundance of 
the mycotoxins verruculogen (6) (on average 99-fold) and fumitremorgin B (5) (on 
average 156-fold) increased in co-culture versus monoculture, as seen by the area 
under the curve. This was observed across three separate biological replicates in situ, 
suggesting that A. fischeri increased the abundance of its mycotoxin biosynthesis to 
better compete with X. cubensis.334, 335 
Manipulating global transcriptional regulators may shed light on the biosynthesis 
of secondary metabolites in fungi.336 The deletion mutant of laeA provides support to the 
notion that secondary metabolites are akin to a fungal arsenal;11 if they are no longer 
available to the fungus, it loses the space, and eventually the battle, during interspecies 
interactions. LaeA is an important regulator of secondary metabolism in Aspergillus spp.. 
205, 305 We confirmed this observation in A. fischeri, when we studied the chemical 
profiles of ΔlaeA A. fischeri.16 Our results found that the majority of the secondary 
metabolites produced by the wild type strain were produced at a lower abundance in the 
ΔlaeA A. fischeri.16 Based on those findings we hypothesized that because the ΔlaeA 
strain has a perturbed secondary metabolite arsenal, it would be unable to compete with 
griseofulvin producing X. cubensis. When the ΔlaeA strain was co-cultured with X. 
cubensis, the conflict zone was disturbed, and ΔlaeA A. fischeri was displaced by 
outward production of griseofulvin and its analogues by X. cubensis (Figure 62). Our 
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study thus provides visual evidence using in situ mapping that fungi utilize secondary 
metabolites in order to compete ecologically with other microbes for nutrition and space. 
We hypothesize here that if the chemical diversity of secondary metabolites is perturbed 
(ΔlaeA A. fischeri), it could lead to loss of small molecules, the loss of territory, and 
defeat in the fungal battlefield during interspecies interactions.337 Further studies using 
genetic knock outs are however, necessary to provide further support of our hypothesis.  
Previously silenced secondary metabolites are expressed in co-culture during 
stressful conditions, likely due to the activation of silent genes.17, 325, 326, 338, 339 Because 
Petri plates with nutrient agar produce a low yield, particularly when only a small portion 
of the plate has the chemistry of interest (i.e. the junction), a scale up study was 
conducted to enhance the amounts of secondary metabolites. The scale up allowed for 
characterization of the newly activated secondary metabolites (Figure 64), as well as the 
secondary metabolites previously present (Figure 61). It confirmed the presence of 
compounds 1 - 7 from A. fischeri, as well as compound 8 and 9 in X. cubensis. It also 
showed the activation of griseofulvin analogues (compounds 10 and 11), all of which 
have fungistatic properties. Similarly, the biosynthesis of cytochalasin mycotoxins were 
activated in co-culture conditions, and hirsutatin A (17) was also isolated from the mixed 
co-culture.316 This compound has only been reported from an insect pathogenic 
fungus Hirsutella nivea (Hypocreales, Ascomycota), but never from A. fischeri nor X. 
cubensis. There is no biosynthetic gene cluster linked to this metabolite, but with a trace 
amount being detectable in the monoculture of X. cubensis, we hypothesize that it may 
have biosynthesized this secondary metabolite. The activation of these defensive 
secondary metabolites during co-culturing was most likely due to the signaling and threat 
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assessment that occurred between the two fungi, suggesting that hirsutatin A (17) 
provides X. cubensis with some sort of competitive advantage.  
Among the new signals present in the chromatographic profile of the large-scale 
co-culture, we were pleased to find an unknown peak (01063-99-2; Figure 64), which 
upon chemical characterization revealed a novel chemical scaffold suggesting that co-
culturing of the two cultures in large-scale resulted in the stimulation of cryptic 
biosynthetic gene clusters in one or both fungi.  The complete chemical characterization 
and identification of the producer strain of the unknown peak is currently ongoing. 
Numerous previous studies have found new chemistry in large-scale co-culture 
fermentations.56, 286, 340, 341 
Materials and Methods 
General Experimental Procedures. The NMR data were collected using a 
JOEL ECS-400 spectrometer, which was equipped with a JOEL normal geometry 
broadband Royal probe, and a 24-slot autosampler, and operated at 400 MHz for 1H and 
100 MHz for 13C, a JOEL ECA-500 spectrometer operating at 500 MHz for 1H and 125 
MHz for 13C (Both from JOEL USA, Inc.), or an Agilent 700 MHz spectrometer (Agilent 
Technologies), equipped with a cryoprobe, operating at 700 MHz for 1H and 175 MHz for 
13C. HRMS experiments utilized either a Thermo LTQ Orbitrap XL mass spectrometer or 
a Thermo Q Exactive Plus (Thermo Fisher Scientific); both were equipped with an 
electrospray ionization source. A Waters Acquity UPLC (Waters Corp.) was utilized for 
both mass spectrometers, using a BEH C18 column (1.7 m; 50 mm x 2.1 mm) set to a 
temperature of 40oC and a flow rate of 0.3 ml/min. The mobile phase consisted of a 
linear gradient of CH3CN-H2O (both acidified with 0.1% formic acid), starting at 15% 
CH3CN and increasing linearly to 100% CH3CN over 8 min, with a 1.5 min hold before 
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returning to the starting condition. The HPLC separations were performed with Atlantis 
T3 C18 semi-preparative (5 m; 10 x 250 mm) and preparative (5 m; 19 x 250 mm) 
columns, at a flow rate of 4.6 ml/min and 16.9 ml/min, respectively, with a Varian Prostar 
HPLC system equipped with a Prostar 210 pumps and a Prostar 335 photodiode array 
detector (PDA), with the collection and analysis of data using Galaxie Chromatography 
Workstation software. Flash chromatography was performed on a Teledyne ISCO 
Combiflash Rf 200 and monitored by both ELSD and PDA detectors.  
Isolation and Identification of Aspergillus fischeri and Xylaria cubensis. 
Aspergillus fischeri strain NRRL 181 was obtained from ARS Culture Collection 
(NRRL).16 The A. fischeri laeA mutant was prepared using methods outlined 
previously.16 Xylaria cubensis strain G536 was isolated as an endophyte from surface 
sterilized twigs of Asimina triloba and identified using molecular methods as outlined 
previously.289 
Cultures of Aspergillus fischeri and Xylaria cubensis on Solid Nutrient 
Media in Petri Plates. Aspergillus fischeri and Xylaria cubensis were maintained on 
potato dextrose agar (PDA; Difco). To establish individual monocultures, an agar plug 
from the leading edge of the colony was cut out aseptically and transferred onto 50 mm 
Petri plates with oatmeal agar (OMA; Difco). Oatmeal was chosen since this condition 
yielded enhanced biosynthesis of secondary metabolites.16 The monocultures were 
grown for 18 days. For co-culture, an agar plug from each of the two strains was placed 
approximately 40 mm apart on the Petri plate with OMA media. The Petri plates were 
incubated at room temperature (~22˚C) for 18 days under 12-hr light/dark cycles. For 
both monoculture and co-culture growths, in situ analyses were conducted after 18 days 
(Figure 66). 
157 
In situ Chemical Analysis Using Droplet Probe. To characterize the 
secondary metabolic profiles of monocultures and co-cultures in situ, the droplet probe 
was used to chemically map the locations of the biosynthesized secondary metabolites. 
Sampling the surface of fungi in situ was performed using the droplet-liquid 
microjunction-surface sampling probe (droplet probe), using methodology detailed 
previously.289, 297, 299, 300, 342 Briefly, it uses a CTC/LEAP HTC PAL auto-sampler (LEAP 
Technologies Inc.) that has been converted to an automated droplet probe system. The 
microextractions (~5 μl) were performed using 1:1 MeOH:H2O. The droplet was 
dispensed at a rate of 2 μl/s from the needle, held on the fungal surface for 2 seconds, 
and then withdrawn at the same rate before injecting into an LC-MS system (Figure 67). 
The LC-MS used a solvent system of CH3CN and H2O, with both being acidified with 
0.1% formic acid. The chromatography method had a flow rate of 0.3 ml/min and a 
gradient of 15% to 100% CH3CN over 8 min, holding at 100% for 2 min, and returned to 
the starting conditions for 2 min. The surface of the fungal mycelia were sampled for 




Figure 67. General Procedure for How the Droplet Probe Works. A microextraction 
using 1:1 H2O:MeOH (H2O for droplet retention and MeOH for extraction) is performed in 
situ at the desired location on the surface of the living fungal cultures. That droplet is 
then injected into an LC-MS system, which allows for separating and analyzing the 
different peaks, which correspond to different secondary metabolites. 
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Xylaria cubensis and wild type Aspergillus fischeri were grown side by side on 
OMA for 14 days. This plate was sampled spatially perpendicular to the interface of the 
co-culture at eight locations.  Wild type A. fischeri was sampled in three locations. The 
first sampling point was the point of inoculation, and then two points were evenly spaced 
before the junction of the two fungal mycelia. Two spots were sampled within the 
junction where both fungal mycelia overlap. Two spots were sampled in the mycelium of 
X. cubensis with them being evenly distributed through the mycelium. The final location 
sampled was the stroma of Xylaria cubensis (Figure 70). This was performed on three 
separate Petri plates for biological replication, and the results were similar. 
Large-Scale Fermentation of Aspergillus fischeri and Xylaria cubensis Co-
Cultures. To identify the secondary metabolites that were biosynthesized during the co-
culture experiment, they were grown in large-scale fermentation to isolate and 
characterize the secondary metabolites. To inoculate oatmeal cultures, agar plugs from 
A. fischeri and X. cubensis growths on PDA were cut from the edge of the cultures and 
transferred to separate liquid seed media that contained 10 ml YESD broth (2% soy 
peptone, 2% dextrose, and 1% yeast extract; 5 g of yeast extract, 10 g of soy peptone, 
and 10 g of D-glucose in 500 ml of deionized H2O) and cultivated at 22˚C with agitation 
at 100 rpm for 3 (A. fischeri) and 5 days (X. cubensis). YESD seed cultures of both fungi 
grown individually were subsequently used to inoculate 16, 250 ml Erlenmeyer flasks 
that contained 10 g of autoclaved Quaker Breakfast Oatmeal each (10 g of oatmeal with 
17 ml of deionized H2O and sterilized for 15–20 mins at 121°C) and grown at room 
temperature for 4 weeks. 
Chemical Characterization of Aspergillus fischeri and Xylaria cubensis Co-
Cultures. To characterize the secondary metabolites produced from the co-culture, the 
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fungal cultures underwent extraction and purification to isolate secondary metabolites. 
The large-scale co-culture was extracted by adding 60 ml of (1:1) MeOH–CHCl3 to each 
250 ml flask, chopping thoroughly with a spatula, and shaking overnight (~ 16 h) at ~ 
100 rpm at 22oC. The culture was filtered in vacuo, and 90 ml CHCl3 and 150 ml H2O 
were added to the filtrate. The mixture was stirred for 30 min and then transferred to a 
separatory funnel. The organic layer (CHCl3) was drawn off and evaporated to dryness 
in vacuo. The dried organic layer was reconstituted in 100 ml of (1:1) MeOH–CH3CN and 
100 ml of hexanes, transferred to a separatory funnel, and shaken vigorously. The 
defatted organic layer (MeOH–CH3CN) was evaporated to dryness in vacuo. 
The defatted extract was dissolved in CHCl3, absorbed onto Celite 545 (Acros 
Organics), and fractionated by normal phase flash chromatography using a gradient of 
hexane-CHCl3-MeOH at a 30 ml/min flow rate and 61.0 column volumes, which yielded 
five fractions. Fraction 1 was purified further via preparative HPLC using a gradient 
system 90:10 to 100:0 of CH3CN-H2O with 0.1% formic acid over 30 min at a flow rate of 
16.9 ml/min to yield eight subfractions. Subfraction eight (32.74 mg), which eluted at 30 
min, yielded aszonalenin (2) and fumitremorgin A (4). Fraction 2 was purified further via 
preparative HPLC using a gradient system 20:80 to 100:0 of CH3CN-H2O with 0.1% 
formic acid over 30 min at a flow rate of 16.9 ml/min to yield twelve subfractions. 
Subfractions 2, 3, 4, 5, 9 and 10 yielded dechloro-5`-hydroxygriseofulvin (11) (0.20 mg), 
5`-hydroxygrisoefulvin (10) (0.48 mg), dechlorogriseofulvin (9) (0.80 mg), griseofulvin (8) 
(0.88 mg), verruculogen (6) (0.18 mg), and sartorypyrone A (1) (0.34mg), which eluted at 
approximately 13.4, 15.2, 15.7, 17.5, 26.1, and 30.3 min, respectively. Fraction 3 was 
purified further via preparative HPLC using a gradient system 40:60 to 75:25 of CH3CN-
H2O with 0.1% formic acid over 30 min at a flow rate of 16.9 ml/min to yield twelve 
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subfractions. Subfractions 3, 4, 5, 6, 7, 8, and 12 yielded compounds cytochalasin D (12) 
(16.64 mg), acetylaszonalenin (3) (5.94 mg), 7-O-acetylcytochalasin B (16) (0.47 mg), 
cytochalasin C (14) (1.08 mg), hirsutatin A (17) (0.76 mg), fumitremorgin B (5) (0.41 mg), 
zygosporin E (15), and the C-11 epimer of verruculogen TR-2 (7), which eluted at 
approximately 13.5, 15.6, 18.5, 20.0, 24.0, 27.5, and 30.0 min, respectively. Compounds 
15 and 7 co-eluted in a single fraction (18.37 mg) and were further purified via 
preparative HPLC using a gradient system 50:50 to 55:45 of CH3CN-H2O with 0.1% 
formic acid over 30 min at a flow rate of 16.9 ml/min to yield 0.65 and 1.73 mg, 
respectively.  
LC-MS Analysis. To detect metabolites, LC-MS analysis was conducted in the 
positive ion mode. The mass spectrometer scanned across a mass range of m/z 200 to 
2000 at a resolution of 70,000, and a spray voltage of 4,000. It was coupled to an 
Acquity UPLC system (Waters Corp.), which had a flow rate of 0.3 ml/min and utilized a 
BEH C18 column (2.1 mm x 50 mm, 1.7 μm) that was operated at 40oC. The mobile 
phase consisted of Fisher Optima LC-MS grade CH3CN–H2O (both acidified with 0.1% 
formic acid). The gradient began at 15% CH3CN and linearly increased to 100% CH3CN 
over 8 mins. It was held at 100% CH3CN for 1.5 mins before returning to starting 
conditions to re-equilibrate.  
Metabolomics Analyses. Principal component analysis (PCA) analysis was 
conducted on the LC-MS data obtained for the large-scale fermentations of the mono 
and co-cultures. Untargeted LC-MS datasets for each sample were individually aligned, 
filtered, and analyzed using MZmine 2.20 software (http://mzmine.sourceforge.net/).280 
Peak detection was achieved using the following parameters: noise level (absolute 
value), 1×106; minimum peak duration, 0.05 min; m/z variation tolerance, 0.05; and m/z 
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intensity variation, 20%. Peak list filtering and retention time alignment algorithms were 
used to refine peak detection. The join algorithm integrated all sample profiles into a 
data matrix using the following parameters: m/z and retention time (RT) balance set at 
10.0 each, m/z tolerance set at 0.001, and RT tolerance set at 0.5 mins. The resulting 
data matrix was exported to Excel (Microsoft) for analysis as a set of m/z – RT pairs with 
individual peak areas detected in quadruplicate analyses. Samples that did not possess 
detectable quantities of a given marker ion were assigned a peak area of zero to 
maintain the same number of variables for all sample sets. Ions that did not elute 
between 2 and 8 minutes and/or had an m/z ratio less than 200 or greater than 800 were 
removed from analysis. Final chemometric analysis, including hierarchical cluster 
analysis and data filtering281 and PCA was conducted using Sirius version 10.0 (Pattern 
Recognition Systems AS).282 The PCA scores and loadings plots were generated using 
data from five individual biological replicates of the large scale fermentations. Each 
biological replicate was plotted using averaged peak areas obtained across four 
replicate injections (technical replicates).  The same number of replicate analyses were 
used for each monoculture and the co-culture.  
Identifying Secondary Metabolite Genes in A. fischeri and X. cubensis. To 
identify which strains likely produced the secondary metabolites in co-culture we utilized 
the genome of A. fischeri and Rosellinia necatrix, a close evolutionary relative of X. 
cubensis.323 Individual proteins from the Aspergillus clavatus cytochalasin E cluster were 
used as web-based, blastp343 queries (accessed on 8-22-18) against the entire X. 
cubensis or A. fischeri proteomes found on the non-redundant protein sequences 
databases of NCBI. A Reciprocal Best BLAST approach141 was performed to infer 
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orthology between cytochalasin cluster proteins and blast hits found in A. fischeri and X. 
cubensis. 
Conclusions 
Fungal interactions are fascinating, but how these chemical ecology interactions 
occur in nature is poorly understood. This is mainly due to the frequent difficulty of 
measuring secondary metabolites in situ during fungal interactions, which hinders our 
understanding of what happens during chemical interaction when two fungi interact in 
situ. The droplet probe technique helped gain insight into the ecology of interspecies 
interactions and spatial distribution of the secondary metabolites in situ, information that 
is typically lost through a traditional extraction protocol. Our data revealed that while 
fungi are growing in a more complex environment (co-culture), they respond differently 
to interspecies interaction and alter the distribution and production of key secondary 
metabolites accordingly. Based on the results presented herein, we hypothesize that 
ΔlaeA A. fischeri co-culture experiments demonstrate that secondary metabolites may 
provide a competitive advantage to the producing fungi, and that such metabolites could 
play an important role in shaping interspecies chemical interactions. A total of 18 
secondary metabolites were biosynthesized in large-scale co-culture. Of those 
metabolites, two were characterized from the monoculture of X. cubensis and seven 
were characterized from the monoculture of A. fischeri. Thus, nine were characterized 
solely from the co-culture experiment, which included a putative novel scaffold that was 
biosynthesized only in co-culture. If we are to understand the full extent of fungal 
secondary metabolites in drug discovery, and the potential role of such metabolites in 
structuring fungal communities in nature, in situ information about species interactions 





Table 5.1. List of altered features in the co-culture of X. cubensis and A. fischeri 




formula, δ [ppm]) 
Adducts, fragments, and 













320.120 [M+H]+, 13C isotope 
(C27H19O6+, 3.124) 
 
341.099 [M+Na]+ ([C27H18O6 
+ Na]+, 2.932) 
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354.081 [M+H]+, 13C isotope 
(C17H18ClO6+, 4.236) 
 
355.075 [M+H]+, 37Cl 
























458.298 [M+H]+, 13C isotope 
(C28H41O5+, 1.724) 
 






A. fischeri  
01063-99-2 413.232 [M+H]+ 
/5.308 


































































































A. fischeri  
Hirsutatin A 677.374 [M+H]+ 
/5.514 (C34H53-
N4O10+, 0.0) 







List of altered features in the co-culture of X. cubensis and A. fischeri analyzed by LC-
MS.  
a RT in minutes 
b based on isotope patterns, adduct formation, and accurate mass, most likely a 
cytochalasin 
c cytochalasin Q from in house dereplication database, which analyzes molecular weight, 
retention time, UV absorbance, and MS2 data. 
 



















































































Table 5.3. Biological replicates Area Under the Curve for Average Increase in 
Mycotoxins During the Co-Culture. 
 
Sample Location Verruculogen AUC Fumitremorgin B AUC 
Monoculture ® plate 1 4802578 3500315 
Monoculture ® plate 2 1244114 364643 
   
Average monoculture 3023346 1932479 
   
Co-culture ® mycelium 
plate 1 and spot 1 
271914463 96673066 
Co-culture ® mycelium 
plate 1 and spot 2 
366115822 68873847 
Co-culture ® mycelium 
plate 1 and spot 3 
71382535 26574515 
Co-culture ® mycelium 
plate 2 and spot 1 
1524267537 1693328571 
Co-culture ® mycelium 
plate 2 and spot 2 
469851785 309567783 
Co-culture ® mycelium 
plate 2 and spot 3 
345340713 64012614 
Co-culture ® mycelium 
plate 3 and spot 1 
120837062 56565051 
Co-culture ® mycelium 
plate 3 and spot 2 
590479791 78819794 
   
Average Co-culture 470023714 299301905 
   






Figure 68. Wild type and ΔlaeA Aspergillus fischeri and Xylaria cubensis grown on Petri 
plates. A. Wild type Aspergillus fischeri (NRRL 181); B. ΔlaeA Aspergillus fischeri; C. 











Figure 70. Base peak of all eight spots across the co-culture. A total of eight locations 
were sampled across the co-culture (three spots on Aspergllus fischeri mycelium, two 
spots at the junction, two spots on Xylaria cubensis mycelium, and one spot on Xylaria 
cubensis stroma). Spatial difference of secondary metabolites across the co-culture 
(Plate 1) is shown using stacked chromatograms. 
 
 




Figure 72. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 
Bottom) both in CDCl3, of sartorypyrone A (1). 
 
 




Figure 74. 1H NMR spectrum (500 MHz, Top) and 13C NMR spectrum (125 MHz, 




Figure 75. 1H NMR spectrum (500 MHz, Top) and 13C NMR spectrum (125 MHz, 




Figure 76. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 




Figure 77. 1H NMR spectrum (500 MHz, Top) and 13C NMR spectrum (125 MHz, 




Figure 78. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 
Bottom) both in CDCl3, of C-11 epimer of verruculogen TR-2 (7). 
 
 




Figure 80. 1H NMR spectrum (400 MHz) in CDCl3, dechlorogriseofulvin (9). 
 
 
Figure 81. 1H NMR spectrum (400 MHz) in CDCl3, 5`-hydroxygriseofulvin (10). 
 
 




Figure 83. 1H NMR spectrum (400 MHz, Top) and 13C NMR spectrum (100 MHz, 
Bottom) both in CDCl3, of cytochalasin D (12). 
 
 




Figure 85. 1H NMR spectrum (400 MHz) in CDCl3, zygosporin E (15). 
 
 
Figure 86. 1H NMR spectrum (400 MHz) in CDCl3, 7-O-acetylcytochalasin B (16). 
 
 
Figure 87. 1H NMR spectrum (400 MHz) in CDCl3, hirsutatin A (17). 
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CHAPTER VI 
WHELDONE: CHARACTERIZATION OF A UNIQUE SCAFFOLD FROM THE CO-
CULTURE OF ASPERGILLUS FISCHERI AND XYLARIA FLABELLIFORMIS 
 
Sonja L. Knowles, Huzefa A. Raja, Israa H. Isawi, Laura Flores-Bocanegra, Patricia H. 
Reggio, Cedric J. Pearce, Joanna E. Burdette, Antonis Rokas, Nicholas H. Oberlies. 
Org. Lett. 2020, 22, 1878-1882. 
 
 
Wheldone (1) was isolated and elucidated from the co-culture of Aspergillus 
fischeri (NRRL 181) and Xylaria flabelliformis (G536), where secondary metabolite 
biosynthesis was stimulated by antagonism between these fungi. First observed via in 
situ analysis between these competing fungal cultures, the conditions were scaled to 
reproducibly generate 1, whose novel structure was elucidated by one- and two-
dimensional NMR and mass spectrometry. Compound 1 displayed cytotoxic activity 
against breast, ovarian, and melanoma cancer cell lines. 
Fungi have been explored for new compounds for nearly 100 years, and that has 
led to the discovery of unique chemical diversity possessing promising biological 
activities, ranging from antibiotic, to immunosuppressant, to cholesterol lowering.5, 344-347 
In nature, fungi grow in competition for resources, and as such, they have evolved the 
ability to adapt to changes in their environment. One of the ways they stave off rival 
organisms is through the activation of biosynthetic gene clusters, thereby stocking their 
arsenal for chemical warfare.6, 10, 12, 29, 59 Under standard lab conditions, fungi have been 
shown to produce only a fraction of their potential secondary metabolites.43, 348 As such,
 co-culturing fungi, forcing them to compete for limited resources, may present a 
pragmatic strategy to stimulate the biosynthesis of novel chemical diversity.17, 43, 62, 341, 349  
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To test this, fungi with antagonistic properties were chosen to participate in co-
culture experiments. The draft genome for Xylaria flabelliformis (strain G536; previously 
named Xylaria cubensis) was reported recently,14 and this strain biosynthesizes 
griseofulvin, which is an FDA-approved fungistatic compound that is known to interact 
with a broad range of fungi.289, 307, 330 Fungistatic denotes that it inhibits fungal growth, 
rather than killing competing fungi.350 We hypothesized that griseofulvin (and co-
biosynthesized analogues) would impart stress on the competing fungal culture, 
especially since we observed that X. flabelliformis exudes these compounds into its 
surroundings.15, 289  
Aspergillus fischeri (strain NRRL 181) was chosen as the challenger due to its 
genetic tractability16 and the biosynthesis of metabolite weaponry in the form of 
mycotoxins.15, 16, 334, 335 Indeed, bioinformatic analysis of the genomes of both organisms 
predicted the presence of as many as 48 biosynthetic gene clusters for ®16 and 86 
biosynthetic gene clusters for X. flabelliformis,14 yet only a relatively narrow range of 
secondary metabolites has been reported from either fungus. Our hypothesis was that 
the stress caused by the chemical warfare between these organisms would activate 





Figure 88. Wheldone (1) Was Isolated From the Co-Culture of Aspergillus fischeri and 
Xylaria flabelliformis. 
 
In a previous study, we reported the biosynthesis of several compounds that 
were found only in the co-culture, including one putative new structure.15 As reported 
herein, the isolation and characterization of a secondary metabolite (1) (Figure 88) with a 
novel chemical scaffold supported our postulate that co-culturing could generate new 
chemical diversity. This experiment was repeated several times in Petri dishes and in 
Erlenmeyer flasks (i.e. scaled up 5 times), demonstrating both a reproducible and 
scalable way to generate new fungal metabolites.  
Results 
To initiate this experiment, monocultures of X. flabelliformis and ® were 
examined first in situ (Petri plates) by the droplet probe351 to generate baseline profiles of 
the secondary metabolites. X. flabelliformis concentrates its fungistatic metabolites 
towards the colony edge (i.e. the youngest part of the fungal culture).289 Alternatively, ® 
had an even distribution of secondary metabolites across its mycelium (i.e. the colony 
edge and the colony center had similar metabolites and relative abundances).15 
Next, co-cultures of X. flabelliformis and ® were examined by droplet probe once a clear 
“junction” was formed (Figure 89 and larger version in Figure 99), which is the dividing 
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area that is essentially the “battlefield” between the two competing fungi. The profile of 
compounds in the X. flabelliformis side of the co-culture was interesting, as secondary 
metabolites were primarily observed in the junction. In contrast, ® was able to 
upregulate the biosynthesis of mycotoxins, suggesting that it was responding to the 
fungistatic properties imparted by the other fungus.15  
 
 
Figure 89. Panel A: Wheldone (1) was first noted as a minor component in the base 
peak chromatogram during in situ analysis15 of the junction that developed between ® 
and X. flabelliformis (shown in the box in the co-culture Petri dish at the right). Panel B: 
The base peak chromatogram of the scaled-up co-culture experiment (250 ml 
Erlenmeyer flasks), with the insert showing the mass spectrum of 1 and its adducts. 
Note that the chromatographic conditions were different between panels A (in situ 
analysis) and B (UPLC-MS), which is why the retention time of 1 varies. 
 
There were several known metabolites identified in the junction that were not 
observed in the monoculture, as reported recently.16, 60, 335 However, there was one 
minor peak that did not match with any metabolites in an in house database of over 525 
fungal metabolites,188 could not be characterized via mass defect filtering,189 and the 
molecular formula and spectroscopic data did not correlate to any organic compounds in 
the literature. Thus, this metabolite was targeted for isolation and characterization. 
Collectively, these data suggested that biosynthetic gene clusters, which were previously 
182 
silent, could be activated via co-culturing experiments to generate new chemical 
diversity. 
To isolate and characterize the compound observed in situ in the co-culture 
experiments, solid-phase co-cultures of ® and X. flabelliformis were grown on oatmeal 
(see the supporting information). The organic extract [CHCl3–MeOH (1:1)] of the 
fermentation product underwent purification using normal-phase flash chromatography 
to afford six fractions. Upon further purification via C18 preparative HPLC, fraction 2 
yielded compound 1 (5.48 mg) (Figure 88). The purity (99%) of 1 was assessed via 
UPLC-MS (Figure 92). This process was repeated five times to isolate larger quantities 
of 1 (>15 mg), showing the reproducibility and scalability of co-culturing experiments. 
 
Table 6.1. 1H (700 MHz), 13C (175 MHz), and HMBC NMR Data for 1 in CD3OD 
Pos δC, type δH (J, Hz) 
HMBC (H → 
C) 
1 172.2, C   
2 122.6, CH 5.71 (d, 15.97) 4, 1 
3 137.4, CH 7.40 (d, 16.00) 6, 2, 4, 5, 1 
4 137.1, C   
5 142.8, CH 6.46 (t, 1.96) 6, 7, 3, 4 
6 74.8, CH2 
4.75 (dd, 12.01, 1.30) 
4.81 (dd, 12.01, 1.03) 
4, 5 
7 95.2, C   
8 76.1, CH 3.54 (d, 10.41) 23, 9, 7, 19 
9 43.0, CH 3.84 (dd, 10.45, 2.12) 
15, 10, 8, 7, 
17, 19 
10 44.0, CH 1.96 (dt, 10.78, 3.49) 16 
11 31.6, CH 1.19 (m)  
12 36.4, CH2 
0.94 (dq, 12.82, 2.63) 
1.56 (m) 
 







Compound 1 was obtained as a white amorphous powder with a molecular 
formula of C25H34O6 as determined via HRESIMS along with 1H, 13C, and edited-HSQC 
NMR data (Table 6.1), demonstrating an index of hydrogen deficiency of 9. The 13C 
NMR data (Table 6.1) indicated the presence of 25 carbons, inclusive of two carbonyl, 
eight vinylic, four oxygenated, and eleven aliphatic carbons. The 1H and edited-HSQC 
NMR data (Table 6.1) indicated four methyls, five olefinic protons, four methines, and 
three methylenes. The HMBC correlations from H-3 to C-1 and C-2, and from H-2 to C-
1, as well as COSY cross correlations between H-3 and H-2, indicated a trans (JH-3/H-2 = 
15.97 Hz) α,β-unsaturated carboxylic acid. The COSY correlation between H-5 and H2-6, 
the HMBC correlations from H2-6 to C-5, H-5 to C-7 and C-4, and H3-23 to C-7 and C-5, 
along with the oxygenated carbons at C-6 (δC 74.8) and C-7 (δC 95.2) established the 
methylated 2,5-dihydrofuran ring. HMBC correlations between H-2 to C-4, and H-3 to C-
5 and C-4, formed the connection between furan ring and the α,β-unsaturated carboxylic 
acid. 
 




15 34.6, CH 2.88 (br s)  
16 142.9, CH 5.81 (br s) 25, 14, 10, 19 
17 133.6, C   
18 121.9, CH 6.57 (s) 
9, 8, 17, 19, 
20 
19 157.3, C   
20 208.7, C   
21 74.2, CH 4.41 (q, 7.04) 22, 20 
22 20.8, CH3 1.35 (d, 7.04) 21, 20 
23 19.3, CH3 1.42 (s) 8, 7, 5 
24 20.5, CH3 0.78 (d, 6.47) 11, 12, 10 
25 20.0, CH3 1.91 (d, 1.11) 17, 16, 19 
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Figure 90. Key COSY and HMBC correlations for 1. 
 
The COSY NMR spectrum of 1 displayed an eleven-proton spin system (H-8/H-
9/H-10/H-11/H3-24/H2-12/H213/H2-14/H-15/H-16/H3-25), which served to frame the 
bicyclic system (Figure 90). The seven membered-ring was discerned via HMBC 
correlations from H3-25 to C-19, H-9 to C-19 and C-17, and H-18 to C-9, C-17, and C-19. 
The α-hydroxy-1-propanone side chain was elucidated through the COSY correlations of 
H3-22 (δH/δC 1.35/20.8) and H-21 (δH/δC 4.41/74.2) and the HMBC correlations to C-20 
from both H3-22 and H-21; this side chain was connected to the seven-member ring via 
an HMBC correlation between H-18 and C-20. The bicyclic system was connected to the 
furan ring system via HMBC correlations from H-8 to C-7, and C-23, and H3-23 to C-8. 
The absolute configuration of 1 was assigned via the Mosher’s esters method95 and 
NOESY correlations (Figures 97 and 98), establishing the configuration as 




Figure 91. ΔδH values [Δδ (in ppm) = δS– δR] obtained for (S)- and ®-MTPA esters of 
wheldone (1) (1a and 1b, respectively) in pyridine-d5. 
 
 
Compound 1 was tested against a panel of tumor cell lines (Table 6.2), 
MDA−MB−231 (triple negative human breast cancer), OVCAR-3 (human ovarian 
cancer), and MDA-MB-435 (human melanoma cancer) using methods described 
previously.352 Although taxol was more potent, these data demonstrated that the cell 
lines responded to both compounds in the same rank (i.e. taxol and 1 display the highest 
and lowest activities in the same cell lines) with the highest response seen in MDA-MB-
435, followed by OVCAR3 and then MDA-MB-231.  
 
Table 6.2. Activity of 1 Against Three Tumor Cell Lines 
IC50 (μM)
a 
Compound MDA-MB-231 OVCAR-3 MDA-MS-435 
1 7.6 3.8 2.4 
taxol 0.17 0.0051 0.00043 
aIC50 values were determined as the concentration required to inhibit growth to 50% of 
control with a 72 h incubation. 
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Using the co-culturing of ® and X. flabelliformis, one novel compound (1) with 
cytotoxic activity was isolated and characterized. Our strategy employed the droplet 
probe351 to first pilot the co-culture conditions in a Petri dish, essentially scouting for 
changes in secondary metabolite profile at the intersection of the fungal cultures.15 Then, 
the co-cultures were scaled to reproducibly generate 1 on the mg scale, biosynthesizing 
enough material for further chemical and biological evaluation. Importantly, the scaled 
growths imparted a much higher concentration of 1 as compared to the Petri plates, 
likely because the antagonistic fungi were in close contact throughout the Erlenmeyer 
flask, as opposed to when they grow into each other in a Petri dish, which gives a visual 
indication of the battlefield (Figures 89 and 99), but is likely less efficient than constant 
interaction.  
During the peer review of this manuscript, we started co-culturing X. flabelliformis 
with another ascomycete fungus (strain MSX79272). Natural products studies on strain 
MSX79272 will be reported in more detail in the future; however, based on DNA 
barcoding,353 we know that it is not an Aspergillus sp. We were encouraged when we 
observed a peak in the extract from a co-culture experiment of these fungi that aligned 
with the retention time and HRMS data for 1 (Figure 100). The peak was isolated via 
HPLC, and a comparison between the 1H NMR data for 1 from both co-culture 
experiments were in concordance (Figure 100). Since 1 was generated when X. 
flabelliformis was used in co-culture experiments with two different fungal strains, we 
hypothesize biosynthesis by this organism. Of the limited fungal-fungal co-culture 
experiments in the literature (~40),52 this is the first example of using an alternate fungus 
to narrow down the biosynthetic source for the new chemical entity. Given that the 
genomes of both fungal strains used in this study have been sequenced, and putative 
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biosynthetic gene clusters have been predicted,14, 16 future studies will take advantage of 
the development of improved heterologous gene expression platforms for targeted 
production of fungal secondary metabolites354 and to identify the biosynthetic gene 
cluster responsible for the biosynthesis of wheldone. 
Materials and Methods 
General Experimental Procedures. Optical rotation data were obtained using a 
Rudolph Research Autopol III polarimeter, and UV spectra were measured with a Varian 
Cary 100 Bio UV−vis spectrophotometer. The NMR data were collected using an Agilent 
700 MHz spectrometer (Agilent Technologies), equipped with a cryoprobe, operating at 
700 MHz for 1H and 175 MHz for 13C. HRMS experiments utilized either a Thermo LTQ 
Orbitrap XL mass spectrometer or a Thermo Q Exactive Plus (Thermo Fisher Scientific); 
both were equipped with an electrospray ionization source. A Waters Acquity UPLC 
(Waters Corp.) was utilized for both mass spectrometers, using a BEH C18 column (1.7 
m; 50 mm x 2.1 mm) set to a temperature of 40oC and a flow rate of 0.3 mL/min. The 
mobile phase consisted of a linear gradient of CH3CN-H2O (both acidified with 0.1% 
formic acid), starting at 15% CH3CN and increasing linearly to 100% CH3CN over 8 min, 
with a 1.5 min hold before returning to the starting condition. The HPLC separations 
were performed with Atlantis T3 C18 preparative (5 m; 19 x 250 mm) column, with a 
Varian Prostar HPLC system equipped with a Prostar 210 pumps and a Prostar 335 
photodiode array detector (PDA), with the collection and analysis of data using Galaxie 
Chromatography Workstation software. Flash chromatography was performed on a 
Teledyne ISCO Combiflash Rf 200 and monitored by both ELSD and PDA detectors. 
Fungal Strain Isolation and Identification. Aspergillus fischeri strain NRRL 181 
was obtained from ARS Culture Collection (NRRL).16 Xylaria flabelliformis (formally 
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Xylaria cubensis) strain G536 was isolated as an endophyte from surface sterilized twigs 
of Asimina triloba and identified using molecular methods as outlined previously.289 The 
genome for X. flabelliformis was reported recently.14 
Fermentation, Extraction, and Isolation. Storage, fermentation, and extraction 
conditions were reported previously.15 Briefly, ® and X. flabelliformis were grown 
separately in 10 mL of YESD broth (2% soy peptone, 2% dextrose, and 1% yeast 
extract; 5 g of yeast extract, 10 g of soy peptone, and 10 g of D-glucose in 500 mL of 
deionized H2O) and cultivated at 22˚C with agitation at 100 rpm for 3 (®) and 5 days (X. 
flabelliformis). YESD seed cultures of both fungi grown individually were subsequently 
used to inoculate 16, 250 mL Erlenmeyer flasks that contained 10 g of autoclaved 
Quaker Breakfast Oatmeal each (10 g of oatmeal with 17 mL of deionized H2O and 
sterilized for 15–20 mins at 121°C). Following incubation at room temperature for 3 
weeks, each solid culture was extracted by adding 60 mL of 1:1 MeOH-CHCl3. 
Subsequently, each culture was chopped with a spatula and left to shake overnight (~16 
hrs) at ~100 rpm at room temperature. The cultures (16 flasks) were combined and 
filtered in vacuo, and 1500 mL CHCl3 and 2400 mL H2O were added to the filtrate. The 
mixture was stirred for 30 min and then transferred to a separatory funnel. The organic 
layer (CHCl3) was drawn off and evaporated to dryness in vacuo. The dried organic layer 
was reconstituted in 300 mL of (1:1) MeOH-CH3CN and 300 mL of hexanes, transferred 
to a separatory funnel, and shaken vigorously. The defatted organic layer (MeOH-
CH3CN) was evaporated to dryness in vacuo. The organic layer (1.28 g) was dissolved 
in CHCl3, absorbed onto Celite 545 (Acros Organics), and fractionated by normal phase 
flash chromatography using a gradient of hexane-CHCl3-MeOH at a 30 mL/min flow rate 
and 61.0 column volumes, which yielded six fractions. Fraction two (239.22 mg) was 
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further purified via preparative HPLC using a gradient system 50:50 to 90:10 of CH3CN-
H2O with 0.1% formic acid over 30 min at a flow rate of 16.9 mL/min to yield 14 
subfractions. Subfraction four (5.48 mg), which eluted at 14.0 min, yielded wheldone (1). 
This process has been repeated several times to isolate larger quantities of 1, showing 
the reproducibility of co-culturing ® and X. flabelliformis. 
Preparation of the ®- and (S)-MTPA Ester Derivatives of wheldone. To 0.25 
mg of compound 1 were added 450 μL of pyridine-d5, and the solution was transferred 
into an NMR tube. To initiate the reaction, 20 μL of ®-(‒)- α-methoxy-α-
(trifluoromethyl)phenylacetyl (MTPA) chloride were added with careful shaking and then 
monitored immediately by 1H NMR at the following time points: 0, 5, 10, and 15 min. The 
reaction was found to be complete in 5 min, yielding the mono (S)-MTPA ester derivative 
(1a). 1H NMR data of 1a (500 MHz, pyridine-d5): δH 1.55 (3H, H3-22), 1.88 (3H, H3-25). 
In an analogous manner, 0.25 mg of compound 1 dissolved in 400μL pyridine-d5 was 
reacted in a second NMR tube with 20 μL of S-(+)-α-methoxy-α-
(trifluoromethyl)phenylacetyl (MTPA) chloride for the same time points, to afford the 
mono ®-MTPA ester derivative (1b). 1H NMR data of 1b (500 MHz, pyridine-d5): δH 1.61 
(3H, H3-22), 1.76 (3H, H3-25). 
Wheldone (1).White, amorphous powder; [α]D20 = +182 (c 0.10, MeOH); UV (MeOH) λmax 
(log ε) 262 (3.74), 217 (3.70) nm; 1H NMR (CD3OD, 700 MHz) and 13C (CD3OD, 175 
MHz) (See Table 1); HRESIMS m/z 431.2423 [M+H]+ (calcd. For C25H35O6, 431.2433). 
Cytotoxicity Assay. Human melanoma cancer cells MDA-MB-435, human 
breast cancer cells MDA-MB-231 and human ovarian cancer cells OVCAR3 were 
purchased from the American Type Culture Collection (Manassas, VA). The cell line was 
propagated at 37°C in 5% CO2 in RPMI 1640 medium, supplemented with fetal bovine 
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serum (10%), penicillin (100 units/mL), and streptomycin (100 µg/mL). Cells in log phase 
growth were harvested by trypsinization followed by two washing to remove all traces of 
enzyme. A total of 5,000 cells were seeded per well of a 96-well clear, flat-bottom plate 
(Microtest 96®, Falcon) and incubated overnight (37°C in 5% CO2). Samples dissolved in 
DMSO were then diluted and added to the appropriate wells.  The cells were incubated 
in the presence of test substance for 72 h at 37°C and evaluated for viability with a 
commercial absorbance assay (CellTiter-Blue Cell Viability Assay, Promega Corp, 
Madison, WI) that measured viable cells. IC50 values are expressed in µM relative to the 


























Figure 97. NOESY NMR spectrum of compound 1 (400 MHz, CD3OD). 
 
Figure 98. Key NOESY correlations for compound 1. The structure is presented twice, 




Figure 99. A larger version of Figure 89 Panel A. 
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Figure 100. Data confirming the biosynthesis of 1 from a co-culture of X. flabelliformis 
vs. fungal strain MSX76272. Confirming the biosynthesis of 1 from a co-culture of X. 
flabelliformis vs. fungal strain MSX76272. A) UPLC-MS chromatogram (base peak of 
extract; top and 1; bottom) for the co-culture of X. flabelliformis vs strain MSX76272. B) 
Mass spectrum data of 1 isolated from X. flabelliformis vs. MSX76272. C) 1H NMR data 
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Most often, the structures of secondary metabolites are solved using a suite of 
NMR techniques. However, there are times when it can be challenging to position 
double bonds, particularly those that are fully substituted or when there are multiple 
double bonds in similar chemical environments. Ozone-Induced Dissociation Mass 
Spectrometry (OzID-MS) serves as an orthogonal structure elucidation tool, using 
predictable fragmentation patterns that are generated after ozonolysis across a carbon-
carbon double bond. This technique is finding growing use in the lipidomics community, 
suggestive of its potential value for secondary metabolites. This methodology was 
validated by confirming the double bond positions in five fungal secondary metabolites, 
specifically: ent-sartorypyrone E (1), sartorypyrone A (2), sorbicillin (3), trichodermic acid 
A (4), and AA03390 (5). This demonstrated its potential with a variety of chemotypes, 
ranging from polyketides to terpenoids, and including those in both conjugated and non-
conjugated polyenes. In addition, the potential of using this methodology in the context 
of a mixture was piloted by studying Aspergillus fischeri, first examining a traditional 
extract and then sampling a live fungal culture in situ. While the intensity of signals 
varied from pure compound to extract to in situ, the utility of the technique was 
preserved.  
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The structures of many organic compounds, particularly natural products, are 
typically elucidated by interpretation of a suite of NMR experiments.63-68 However, there 
are times when derivatization is required to finalize a structure. In the lore of drug 
discovery, camptothecin and taxol (paclitaxel) are two prominent examples,355-357 
although there are certainly scores of others. While NMR instrumentation and pulse 
sequences continue to evolve,358-360 some derivatizations are used fairly often in 
structure elucidation, such as reductions/oxidations,361-363 reactions to assign absolute 
configuration, either via installing heavy atoms for X-ray crystallography or the use of 
Mosher’s esters,92, 93, 95, 96, 156 and peptide hydrolysis/Marfey’s analysis.364-366 In short, the 
reactions of organic chemistry remain beneficial for structural analysis.  
Challenges can arise when striving to position double bonds in structurally 
complex natural products via NMR, particularly for fully substituted double bonds and 
compounds with multiple double bonds in similar chemical environments.72-74 During the 
initial steps of structure elucidation of secondary metabolites, many factors can lead to 
the assignment of an incorrect structure,69-71 and common examples include endocyclic 
vs. exocyclic double bonds75, 76 and a change in functional groups.77, 78 As new 
techniques are developed, this often leads to structural re-assignments.363, 367-369 Again, 
even with the latest advancements in NMR, there is room for orthogonal techniques that 
serve to either assign, or at least verify, the de novo structure elucidation of natural 
products. In addition, with the growing popularity of metabolomics, where structures may 
be inferred solely from hyphenated mass spectrometry data, a tool that could position 
carbon-carbon double bonds could be valuable, particularly for discerning the structures 
of isobars.80 
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In a molecule containing carbon-carbon double bonds, low energy collision-
induced dissociation (CID) cannot be used readily for their positioning in a polyene motif 
due to their high stability. To overcome this challenge, alternative approaches were 
introduced to derivatize such bonds, with the aim of inducing diagnostic fragment ions 
under CID. There are many selective reactions, and some of them were coupled with 
mass spectrometry to pinpoint the double bond location in a molecule, such as: dimethyl 
disulfate reaction,370 Paternò-Büchi reaction,371, 372 ozonolysis, and meta 
chloroperoxybenzoic acid (m-CPBA)373 epoxidation reaction. The common requirement 
between these methods (with the exception of ozonolysis) is that the reaction was 
performed in solution phase prior to the ionization, which leads to the loss of information 
about the accurate mass of the intact molecule and the need to use CID to induce 
subsequent diagnostic product ions. Hence, when using collision energy to fragment the 
desired bond, additional fragments would be generated from neighboring bonds, leading 
to a complicated spectrum, and as a result, such data were time consuming to 
interpret.374 
Ozonolysis, which uses ozone to cleave alkene double bonds, is a well-known 
reaction that is covered in nearly all introductory organic chemistry classes.375 In the 
past, ozone (O3) gas was employed to study the carbon-carbon double bonds of lipids in 
solution and at the ionization source of the mass spectrometer (a technique termed 
OzESI). Every unsaturated molecule would interact with ozone at the ionization source, 
to produce the molozonide, and this would subsequently cleave to the Criegee and 
carbonyl product ions (discussed further below). However, the detected ions would be 
the combination of the ozonolysis products and ESI products (i.e. electrospray 
ionization). Hence, a full scan mass spectrum of a complex sample under such 
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conditions would be convoluted with information of precursor ions and product ions in 
the same scan. Moreover, one cannot assign the product ion to the original parent ions. 
As a result, OzESI experiments were not recommended for complex samples, and as 
expected, the resulting data from an OzESI experiment were both complicated and 
lacked intact structural characterization information.376, 377 
To circumvent the aforementioned challenges, ozone-induced dissociation mass 
spectrometry (OzID-MS) was introduced in 2008,79 which implements the ozonolysis 
reaction in the gas phase inside the mass spectrometer. This approach provided the 
mass selection option for intact structure elucidation of double bond positional isomers of 
lipids before the targeted ion reacted with ozone in the trap chamber.80-85 The 
mechanism of OzID-MS is based on the fundamentals of ozonolysis, which selectively 
cleaves carbon-carbon double bonds, particularly those on the acyl chains of lipids. This 
results in unique product ions, aldehyde or ketone, depending on the double bond 
substitution before the cleavage, and a Criegee ion, which is a carbonyl oxide zwitterion 
(Figure 102).86 This mechanism has the advantages of being both reliable and 
predictable, thereby facilitating downstream data analysis. Recently, OzID-MS has 
become a prominent technique for pinpointing the location of double bonds in the fatty 
acyl chains of lipids exactly because of the predictable cleavage patterns and unique 
fragments.79, 80, 82, 85 
Given the promise of OzID-MS for facilitating double bond placement in lipids, it 
is somewhat surprising that this technique has rarely been used in natural products, with 
most examples being of compounds similar to fatty acids but with various head 
groups.378-380 For example, it aided in the elucidation of double bond locations in several 
bisresorcinol and hexadecenoylanthranilic acid isomers.379, 380 While it is not possible to 
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replace the tools and value of NMR characterization, OzID-MS can serve as an 
orthogonal structure elucidation tool. Essentially, initiation of ozonolysis across a carbon-
carbon double bond in a mass spectrometer provides valuable data that complement 
those derived from NMR experiments. Since OzID-MS is effectively a tandem mass 
spectrometry technique, it has the further advantage of not requiring pure compounds, 
which means the technique can be applied to a complex sample matrix. With the goal of 
expanding the utility of this technique, we piloted its use with a range of fungal 
metabolites as pure compounds, in the context of an extract, and in situ. 
 
 





Figure 102. In ozonolysis carbon-carbon double bonds react with ozone via a 1,3-
dipolar cycloaddition. Two products are formed via the subsequent retro 1,3-diplolar 
cycloaddition, resulting in a ketone/aldehyde and a Criegee intermediate. The red arrows 
(top) and blue arrows (bottom) represent the two routes in which the molozonide can 
undergo the retro 1,3-diplolar cycloaddition 
 
Results 
Structure Elucidation by Traditional NMR and Mass Spectrometry 
Techniques. In ongoing studies of the genetic and secondary metabolite profiles of 
Aspergillus fischeri, which is of interest due to its close evolutionary relationship with the 
human pathogen Aspergillus fumigatus, we have characterized a series of fungal 
metabolites, including seven known compounds, one new natural product, and two new 
compounds.16 The structure of one of the latter, which was assigned the trivial name ent-
sartorypyrone E (1), was elucidated by traditional spectroscopic and spectrometric 
techniques, and all of those data are discussed in the Supporting Information. Mosher’s 
esters analysis95 was attempted to assign the absolute configuration of position 20, but 
unfortunately, those data were inconclusive. This was supported by the literature, which 
showed that this methodology does not work well for vicinal diols.381 Instead, the 
Snatzke method would need to be implemented, but due to the paucity of sample, this 
was not conducted.382-384 During the final drafting of this manuscript, the structure of 
sartorypyrone E was published by Bang et al.,385 and our NMR data were in agreement. 
However, those authors reported performing Mosher’s ester analysis, establishing the 
hydroxy in the S configuration. Since the measured [α]D20 value for 1 was opposite in 
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sign, although of greater magnitude, to the value reported for sartorypyrone E,385 we 
hypothesized position 20 as R, as suggested by the trivial name ent-sartorypyrone E (1). 
When the structure of 1 was solved via NMR data, the double bond locations 
were assigned through HMBC and COSY correlations (Figure 103). The double bond 
between positions 8 and 9 was identified by the COSY correlation of H-26 to H-8 and the 
HMBC correlations of H-10 to C-8, C-9, and C-26 and H-8 to C-3, C-10, and C-26. The 
double bond between positions 12 and 13 was identified by the COSY correlations of H-
25 to H-12 and the HMBC correlations of H-14 to C-12, C-13, and C-25 and H-12 to C-
10, C-14, and C-15. The double bond between positions 16 and 17 was identified by the 
COSY correlation of H-24 to H-16 and the HMBC correlations of H-18 to C-16, C-17, and 
C-24 and H-16 to C-14, C-18, and C-24. Thus, 2D NMR data were instrumental for 
positioning the double bonds.  
Structure Elucidation by Traditional NMR and Mass Spectrometry 
Techniques. For Compound 1. Ent-sartorypyrone E (1) was obtained as a white solid 
with a molecular formula of C26H40O5 as determined via HRESIMS along with 1H, 13C, 
and edited-HSQC NMR data (Table 7.2), demonstrating an index of hydrogen deficiency 
of 7. Inspection of the MS and NMR data suggested 1 as an analogue of sartorypyrone 
A (2).162 For example, 1 showed a trisubstituted unsaturated δ-lactone moiety, as noted 
by two conjugated double bonds (δC 100.6, 165.5, 100.5, and 160.3 for C-3, C-4, C-5, 
and C-6 respectfully) containing one olefinic proton (δH 5.75 for H-5), both of which were 
conjugated with an ester (δC 165.6 for C-2). Additional similarities included NMR signals 
characteristic of two sequential isoprene units, which were connected to the α-position 
(δC 100.6 for C-3) of the δ-lactone moiety. Key differences between compound 2162 and 1 
were in the terminal part of the terpenoid side chain. Specifically, compound 1 lacked the 
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terminal cyclohexane moiety along with the acetyl group seen in 2, which were replaced 
by a dihydroxy unsaturated isoprene unit, as indicated by NMR data characteristic of two 
methyls (δH/δC 1.2/26.4; 1.2/23.2 for CH3-22 and CH3-23, respectively), two methylenes 
(δH/δC 2.22/2.06/26.8; 1.40/1.59/29.5 for CH2-18 and CH2-19, respectively), one 
oxymethine (δH/δC 3.36/78.3, for CH-20), and a quaternary oxygenated carbon (δC 73.1 
for C-21) (Figures 110 and 111). These data, along with further analysis of the 2D-NMR 
data, including COSY and HMBC experiments (Figure 103), yielded the structure of 




Figure 103. Key COSY and HMBC correlations for compound 1 
 
Analysis of Double Bond Positions in Pure Compounds by OzID-MS. The 
OzID-MS technique was tested on the fungal metabolites ent-sartorypyrone E (1), 
sartorypyrone A (2), sorbicillin (3),386, 387 trichodermic acid A (4),388 and AA03390 (5),389 
where the observed accurate masses corresponding to the carbonyl/Criegee product 
ions confirmed the placement of double bonds in these molecules. Infusion of sodium 
acetate into the mass spectrometry system (see Experimental) was used to increase the 
abundance of sodiated adducts, which are needed to effect fragmentation in the OzID-
MS experiment.80, 81, 390  
When performing OzID-MS on compound 1, the sodium ion can associate with 
the hydroxy moieties at the end of the isoprene chain (left side of molecule) or the 
= HMBC correlations   = COSY correlations 
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oxygens in the lactone ring (right side of molecule), which is why all the theoretically 
possible carbonyl and Criegee ions were observed from both ends of the molecule. 
Regardless of where sodium associated with 1 (i.e. [M + Na]+), the targeted parent ion 
was observed at m/z 455.2772. When sodium associated with the hydroxys at the ends 
of the isoprene chain, the double bonds were cleaved into ketones (previously di-
substituted) and Criegee ions (Figure 104A). The ketones were observed at positions C-
9 (m/z 319.2248), C-13 (m/z 251.1634), and C-17 (m/z 183.0992), and the Criegee ions 
were observed at positions C-9 (m/z 335.2202), C-13 (m/z 267.1579), and C-17 (m/z 
199.0954) (Table 7.3). When sodium associated with the lactone ring, the double bonds 
were cleaved into aldehydes (previously mono-substituted) and Criegee ions (Figure 
104). The aldehydes were observed at positions C-8 (m/z 191.0332), C-12 (m/z 
259.0954), and C-16 (m/z 327.1578), and the Criegee ions were observed at positions 
C-8 (m/z 207.0287), C-12 (m/z 275.0902) and C-16 (m/z 343.1526) (Table 7.3). To verify 
the unique product ions of OzID-MS, 1 was re-analyzed under the identical parameter 
settings, but with argon in replacement of ozone (Figure 104B); as expected, the OzID 





Figure 104. A: The OzID-MS spectrum of ent-sartorypyrone E (1) after targeted OzID 
fragmentation. The structure of 1 is shown on the top left. The purple, green, and orange 
boxes around the diterpene double bonds indicate positions where ozonolysis occurred. 
The informative OzID fragments are labeled with the colors corresponding to the 
structure. The capital letters represent the ketone fragments, and the lower-case letters 
represent the Criegee ion fragments. The A/a corresponds to the sodium ion associating 
with the lactone ring (right side of the molecule), whereas the B/b corresponds to the 
sodium ion associating with hydroxys at the end of the isoprene chain (left side of the 
molecule). The OzID-MS products (shown under spectrum) are color and letter coded to 
represent the cleaved double bond, and these data are tabulated in Supporting 
Information Table 7.3. B: Compound 1 being analyzed in argon, to demonstrate that the 
fragments in A are unique to OzID-MS 
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A known metabolite, sartorypyrone A (2), was also isolated from I, and it was 
subjected to OzID-MS to validate the technique, illustrating its use as an orthogonal tool 
for pinpointing the location of double bonds within a chain. Given their structural 
similarities, sodium associated with compound 2 in a manner largely analogous to what 
was observed with 1. For instance, regardless of where sodium associated with the 
molecule (i.e. [M + Na]+), the targeted parent ion was observed at m/z 479.2784. When 
the sodium associated with lactone ring, there were two pairs of OzID product ions, 
corresponding to double bonds at C-12 (m/z 259.0984 and 275.0936) and C-8 (m/z 
191.0335 and 207.0283), recognized as aldehyde (previously mono-substituted) and 
Criegee ions, respectively, in each pair. However, when sodium associated with the 
ester, only a pair of ozonolysis product ions were observed, representing those induced 
at C-8 and recorded at m/z 343.1948 and 359.2246, corresponding to the ketone and 
Criegee ions, respectively (Figure 105 and Table 7.6). While this was slightly different 
than what was observed with 1, since C-12 was not cleaved, we were not surprised by 
these results. OzID-MS is known to be a charged-induced reaction, and as such, the 
distance and interaction between where the sodium adduct was formed, relative to the 
double bond, can hinder the efficiency of ozonolysis.390 An example of this phenomenon 
is sphingomyelin, where OzID-MS was able to characterize the double bonds in the fatty 
acyl chains, but not the double bond on the long chain base.391 This is an important 
distinction for OzID-MS, as the distance of the double bond(s) from where the sodium 
associates to form the adduct is important. Even though it was not possible to obtain 
product ions from ozonolysis at the C-12 position when sodium associated with the left 
side of molecule, the data from the OzID products from when sodium associated with the 
lactone ring confirmed the position of this carbon-carbon double bond.  
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Figure 105. The OzID-MS spectrum of 2 after targeted OzID fragmentation. The 
structure of 2 is shown on the top left. The green and orange boxes around the double 
bonds indicate positions where the ozonolysis occurred. The informative OzID fragments 
are labeled with the colors corresponding to the structure, analogous to those in Figure 
104. The OzID-MS products (shown under spectrum) are color and letter coded to 
represent the double bond that was cleaved, and these data are tabulated in Table 7.6 
 
 
Next, a selection of other fungal metabolites from our compound library were 
examined, such as the polyketide 3, which has conjugated double bonds and was first 
described from Penicillium notatum.386, 387 In a conjugated system, in addition to the 
aldehyde/ketone and Criegee ion fragments, a diagnostic epoxide is observed.80 In this 
example, sodium can associate with the hydroxys or ketone to form a singly charged [M 
+ Na]+ species observed at m/z 255.1053. The double bonds at positions C-2′ (m/z 
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217.0475) and C-4′ (m/z 243.0625) were cleaved into aldehydes, confirming their 
positions (Figure 106 and Table 7.7). A highlight of this structure was the unique 
formation of the epoxide ring [M+Na+16]+ caused by the loss of dioxygen and a 
hydrocarbon radical from a conjugated double bond.392 This observation indicated 
conjugated double bonds, which was confirmed by the product ion of an epoxide ring 
between positions C-4′ and C-5′ (m/z 271.0966), which has been observed previously 
with the use of this technique to discern conjugated double bonds in fatty acids.80  
 
 
Figure 106. The OzID-MS spectrum of 3 after targeted OzID fragmentation. The 
structure of 3 is shown on the top left. The green and orange boxes around the double 
bonds indicate positions where ozonolysis occurred. The informative OzID fragments are 
labeled with the colors corresponding to the structure, analogous to those in Figure 104. 
The OzID-MS products (shown under spectrum) are color and letter coded to represent 
the double bond that was cleaved, and these data are tabulated in Table 7.7 
 
Compound 4 is a terpenoid with conjugated double bonds that was described 
originally from the endophytic fungus Trichoderma spirale.388 The sodiated adduct of this 
compound was found to favor the hydroxy moieties on the ring based on the recorded 
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OzID-MS product ions. Besides the expected ozonolysis product ions observed at m/z 
261.1485, 287.1632, and 303.1581, a product ion of [M+Na+16]+ was also obtained at 
m/z 359.1840, analogous to 3 and as expected for a conjugated system (Figure 107 and 
Table 7.8).  
 
 
Figure 107. The OzID-MS spectrum of 4 after targeted OzID fragmentation. The 
structure of 4 is shown on the top left. The green and orange boxes around the double 
bonds indicate positions where ozonolysis occurred. The informative OzID fragments are 
labeled with the colors corresponding to the structure, analogous to those in Figure 104. 
The OzID-MS products (shown under spectrum) are color and letter coded to represent 
the double bond that was cleaved, and these data are tabulated in Table 7.8. 
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With compound 5 (a meroterpenoid originally described from the deep-sea 
fungus Phomopsis lithocarpus),389 the diagnostic ion [M+Na+16]+ was observed at m/z 
469.2548 due to conjugation. In addition, the expected OzID-MS products, specifically 
the aldehyde (m/z 371.1844 and 397.1985) and Criegee ions (m/z 387.1808 and 
413.2004) were observed (Figure 108 and Table 7.9). 
 
 
Figure 108. The OzID-MS spectrum of 5 after targeted OzID fragmentation. The 
structure of 5 is shown on the top left. The green and orange boxes around the double 
bonds indicate positions where the ozonolysis occurred. The informative OzID fragments 
are labeled with the colors corresponding to the structure, analogous to those in Figure 
104. The OzID-MS products (shown under spectrum) are color and letter coded to 
represent the double bond that was cleaved, and these data are tabulated in Table 7.9 
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As could be seen from data generated by analyzing compounds 1-5, OzID-MS 
can be used to verify the position of carbon-carbon double bonds in secondary 
metabolites. Since ozonolysis is sensitive and results in predictable fragmentation 
patterns, the expected product ions can be calculated and matched with the acquired 
data. This represents an efficient and orthogonal approach to confirm the assignment of 
double bond positions. In addition, the signal of [M+Na+16]+ can be used as a diagnostic 
ion to confirm the presence of conjugated double bonds. In total, OzID-MS confirmed the 
locations of the double bonds in a series of structurally diverse fungal secondary 
metabolites, serving as orthogonal confirmation of double bond positioning based on 
NMR experiments.   
Structural Confirmation from Extract and in situ by Direct Infusion OzID-
MS. To test whether this technique could work in the context of a multi-component 
mixture, the organic extract of a fermentation of Aspergillus fischeri was subjected to 
OzID-MS. The precursor ion was targeted, and then OzID-MS was performed. The 
fragment ions from this experiment were identical to those observed with the pure 
compound (1) (Figures 104 and 109). While the intensity of the signals was not as 
robust, we could confidently assign the positions of the double bonds. This was of 
particular relevance, since 1 was only a minor component of the extract (Figure 115).  
In addition, there is growing interest in studying the chemistry of nature in situ via 
a variety of techniques.393, 394 As such we tested if double bond placement could be 
elucidated by coupling OzID-MS with the droplet probe.297, 351 We envisaged this could 
be powerful for co-culture studies, where interspecific interactions may stimulate the 
biosynthesis of unique metabolites.15, 17, 341 A Petri dish of I was analyzed via this 
technique, and the sodiated precursor ion of compound 1 was observed in the full scan 
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spectrum. Subsequently, OzID-MS was performed through the targeted analysis of the 
precursor ion. The product ions that were present in the complex and in situ extracts 
mirrored those of the pure compound (Figures 104 and 109). These data confirmed that 
OzID-MS can also aid as an orthogonal structure elucidation tool for a compound within 
the context of an extract and/or in situ, albeit at a lower concentration (Figure 109, 
Tables 7.4 and 7.5). In addition, these results demonstrated the sensitivity of approach, 
regardless of the low abundance of the targeted compound in the extract or in situ.  
 
 
Figure 109. The OzID-MS studies of Aspergillus fischeri showing the analysis of 
compound 1 in the context of an extract (panel A) and from in situ sampling of a Petri 
dish of a life culture (panel B). The fragmentation patterns in both cases are analogous 
to those in Figure 104, and these data are tabulated in Tables 7.4 and 7.5 
 
In summary, OzID-MS shows promise as a methodology that can be used to 
support the positioning of double bonds in secondary metabolites. The most straight 
forward approach may be to first use NMR experiments to elucidate a structure, and 
then employ OzID-MS fragment ions to confirm and/or pinpoint the location of carbon-
carbon double bonds. While only a limited set of fungal metabolites were analyzed, we 
do not expect unforeseen challenges with other natural products, particularly since its 
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application in the lipidomics community continues to grow. The predictable nature of the 
fragmentation patterns expected in an OzID-MS experiment may lead to emerging tools, 
such as artificial intelligence,395, 396 and again, the omics community may take the lead in 
this regard, but the results should benefit natural products research too. In addition, it is 
very tantalizing to add this technique to the growing spectrum of tools that are being 
used to study natural products in situ, particularly since the sensitivity of mass 
spectrometry can be capitalized upon to select for ions of interest for OzID-MS analysis, 
even those in low abundance. Key considerations for implementing this technique have 
been summarized (Table 7.1), and it is worth noting that this system was assembled 
using commercially available components that has been detailed previously.80, 81 
 
Table 7.1. Key considerations for performing OzID-MS analysis. 
Observation Diagnostics 
Why infuse salt adducts such as Na+? 
The counter ion aids in OzID 
fragmentation. Essentially, the increased 
intensity of the ozonide ions leads to an 
increase in the ozonolysis efficiency.390 
Other salts could be used, such as those 
that produce Li+ ions.  
What differentiates the observation of 
aldehyde vs. ketone peaks? 
This is based on the double bond 
substitution before OzID fragmentation 
occurs. If the carbon was di-substituted, 
then it becomes a ketone. Alternatively, if it 
was mono-substituted it becomes an 
aldehyde. 
What is the Criegee ion? 




Why is OzID-MS observed to occur 
from both sides of a molecule?   
The counter ion (i.e. Na+) typically 
associates with oxygenation, and if two 
spots are available on either side of the 
metabolite, then both the theoretical 
carbonyl/Criegee ions pairs are observed. 
Why are not all of the “potential” 
fragments produced for every double 
bond? 
The distance between where the adduct 
associates and the double bond affects 
reactivity.80, 391 
Why is [M+Na+16]+ a diagnostic 
observation? 
This ion confirms that the metabolite has 
conjugated double bonds due to the 
formation of an epoxide.80, 392 
 
 
Materials and Methods 
General Experimental Procedures. Optical rotation data were obtained using a 
Rudolph Research Autopol III polarimeter, and UV spectra were measured with a Varian 
Cary 100 Bio UV−vis spectrophotometer. The NMR data were collected using a JOEL 
ECS-400 spectrometer, which was equipped with a JOEL normal geometry broadband 
Royal probe, and a 24-slot autosampler, and operated at 400 MHz for 1H, a JOEL ECA-
500 spectrometer operating at 500 MHz for 1H, or an Agilent 700 MHz spectrometer, 
equipped with a cryoprobe, operating at 700 MHz for 1H and 175 MHz for 13C. HRMS 
experiments utilized either a Thermo LTQ Orbitrap XL mass spectrometer or a Thermo 
Q Exactive Plus; both were equipped with an electrospray ionization source. A Waters 
Acquity UPLC was utilized for both mass spectrometers, using a BEH C18 column (1.7 
m; 50 mm x 2.1 mm) set to a column temperature of 40oC and a flow rate of 0.3 
mL/min. The mobile phase consisted of a linear gradient of CH3CN-H2O (acidified with 
0.1% formic acid), starting at 15% CH3CN and increasing linearly to 100% CH3CN over 8 
min, with a 1.5 min hold before returning to the starting conditions. OzID-MS data were 
collected using a Waters Synapt G2 HDMS. The HPLC separations were performed with 
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an Atlantis T3 C18 semi-preparative (5 m; 10 x 250 mm) and preparative (5 m; 19 x 
250 mm) columns, at a flow rate of 4.6 mL/min and 16.9 mL/min, respectively, with a 
Varian Prostar HPLC system equipped with a Prostar 210 pumps and a Prostar 335 
photodiode array detector (PDA), with the collection and analysis of data using Galaxie 
Chromatography Workstation software. Flash chromatography was performed on a 
Teledyne ISCO Combiflash Rf 200 and monitored by both ELSD and PDA detectors.  
Fungal Material. Aspergillus fischeri strain NRRL 181 was obtained from ARS 
Culture Collection (NRRL), and as described previously,15, 16 the large-scale fermentation 
was grown on solid breakfast oatmeal (Old-fashioned breakfast Quaker oats). This was 
prepared by adding 10 g oatmeal to a 250 mL Erlenmeyer flask with 16 mL of DI-H2O, 
which was autoclaved at 121oC for 30 min. After inoculation, the culture was grown for 
14 days at room temperature. 
Extraction and Isolation. To each of the solid fermentation cultures (10 flasks) 
of I, 60 mL of CHCl3-MeOH (1:1, v/v) were added, and the cultures were chopped using 
a spatula followed by shaking overnight (~ 16 hrs.). The resulting slurries were vacuum 
filtered, and 90 mL of CHCl3 and 150 mL of DI H2O were added to the filtrate. This 4:1:5 
CHCl3:MeOH:H2O mixture was partitioned in a separatory funnel, and the organic layer 
was drawn off and evaporated to dryness in vacuo. This sample was then reconstituted 
and partitioned with 100 mL CH3CN:MeOH (1:1, v/v) and 100 mL of hexanes. The 
organic layer was then evaporated to dryness to generate 440mg of the organic extract. 
The sample was then dissolved in CHCl3, absorbed onto celite 545 (Acros Organics, 
celite 545), and fractioned by normal phase flash chromatography using a gradient of 
hexane-CHCl3-CH3OH at an 18 mL/min flow rate and 90.0 column volumes over 24.0 
min to produce five fractions. Fraction 1 was purified further via preparative HPLC using 
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a gradient system 20:80 to 100:0 of CH3CN-H2O (with 0.1% formic acid) over 30 min at a 
flow rate of 16.9 mL/min to yield seven subfractions. Subfraction 4 yielded 2 (2.88 mg), 
which eluted at approximately 17.0 min. Fraction 3 was purified further via preparative 
HPLC using the same gradient system to yield ten subfractions. Subfraction 4 yielded 1 
(1.17 mg), which eluted at approximately 17.2 min.  
ent-sartorypyrone E (1): white solid; [α]D20 = +10 (c 0.02, MeOH); UV (MeOH) λmax (log ε) 
286 (2.85), 239 (2.83) nm; 1H and 13C NMR data, Table 7.2; HRESIMS [M + H]+ 
433.2941 (calculated for C26H41O5, 433.2948). 
General Procedure for OzID-MS. The OzID-MS experiment was performed on 
the modified Waters Synapt G2 HDMS as reported previously in detail.80, 81 A 
commercially available O3 generator [O3 MEGA (MKS Inc.)] was used to convert O2 to 
O3 (6%), and it was plumbed to the trap and transfer cell in the TRIWAVE region through 
a t-valve, essentially replacing the commonly used collision gas (argon) (Figure 119). 
Previously, we developed a method, coined ”ion dam,” to enhance the ozonolysis 
efficiency of unsaturated molecules with ozone inside the high-resolution Traveling wave 
MS.81 This works by having ions indirectly prolonged in the trap cell to extend their 
reaction time with ozone. O3 was introduced to the system at 4 mL/min, creating a 
pressure of 1.32x10-2 mbar in the trap cell, which is the reaction chamber for the 
ozonolysis gas phase reaction. The excess or unused O3 is delivered to the converting 
chamber, creating O2, which is sent to the exhaust system. A commonly voiced concern 
is that O3 can be highly corrosive due to its oxidative properties; however, in over five 
years of operation, such damage has not been observed on this system, likely because 
only a small amount of O3 is needed to induce ozonolysis. Similar experiments have 
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been reported in the literature using several different mass spectrometry platforms 
and/or vendors.79, 392, 397, 398  
Pure Compound and Extract Analysis via Direct Infusion of OzID-MS. The 
Synapt G2 HDMS was directly infused with 10 mmol sodium acetate at 8 L/min using 
an automated syringe pump at the beginning of every injection series to increase the 
relative abundance of sodium ions. Pure compounds were prepared at a concentration 
of 0.05 mg/mL and the organic extract at 2.0 mg/mL, both in MeOH, and kept at -20C 
until analyzed. Pure compounds and an organic extract were directly infused at 8 L/min 
using an automated syringe pump in the positive mode; due to the system being flushed 
with sodium acetate the predominant ions were sodiated adducts.  
The ESI source conditions were finalized as: spray voltage, 3.0 kV; sampling 
cone, 45 V; extraction cone, 6 V; source temperature, 100 °C; desolvation temperature, 
200 °C; cone gas flow, 50 L/h; desolvation gas flow, 500 L/h. Isolation of precursor ions 
was carried out in the quadrupole at ~1Th isolation width (LM=16, HM =15). All spectra 
were acquired for 30s at 0.5s/scan. For pure compound OzID-MS, the traveling wave in 
the trap was optimized and operated accordingly to the “ion dam” setting,81 i.e. trap 
entrance, 5.0V; bias, 2.0V; trap dc, 0.1V; exit, 0V; trap wave velocity, 8m/s; wave height, 
0.2V; for extract, same parameters were applied except trap entrance was set to 3V and 
dc to -0.5V to increase signal intensity. Default instrument settings for all the remaining 
parameters were applied. The instrument was calibrated daily in Resolution mode using 
sodium iodide following manufacturer’s instructions obtaining less than 5 ppm RMS 
residual mass. Both the full scan and MS/MS levels were mass-corrected traceable to 
the reference lock mass using MassLynx v4.1 instrument control software (Waters 
Corp.). 
220 
In situ OzID-MS. Sampling of the surface of the fungus in situ was performed by 
a CTC/LEAP HTC PAL auto-sampler (LEAP Technologies Inc.) that was converted to an 
automated droplet probe system, as detailed previously.297, 351 Briefly, the 
microextractions (5 μL) were performed by using MeOH:H2O (1:1, v/v), with water being 
for droplet retention and MeOH for the microextraction, on the surface of the fungus. The 
droplet was dispensed at a rate of 2 μL/s from the needle, held on the surface for 2 s, 
then withdrawn at the same rate with each droplet extraction performed thrice to 
concentrate the sample. Traditionally, the droplet probe is connected to a UPLC-MS 
system, which is how the droplet is then analyzed.156, 342, 399, 400 However, currently 
software is not available to monitor the CTC/LEAP HTC PAL autosampler with the 
Synapt G2 HDMS. Thus, after conducting the microextraction via droplet probe, the 
solution was loaded into an offline 20 μL sample loop. A solvent system MeOH:H2O (1:1, 
v/v) controlled by the Synapt G2 HDMS was connected to the sample loop to carry the 
sample to the ESI source at 5 μL/min. The OzID-MS analysis instrument settings were 
























































Position δH δC Mult (J in Hz) 
2  165.6  
3  100.6  
4  165.5  
5 5.75 100.5 d (1.1) 
6  160.3  
7 3.23 23.0 d (7.4) 
8 5.31 120.6 m 
9  140.9  
10 2.10 39.5 m 
11 2.12 25.8 m 
12 5.04 123.6 m 
13  135.6  
14 1.99 39.4 m 
15 2.08 26.1 m 
16 5.15 125.1 m 









dddd (14.0, 10.6, 8.4, 5.7) 
1.59 m 
20 3.36 78.3 dd (10.6, 1.9) 
21  73.1  
22 1.15 23.2 s 
23 1.20 26.4 s 
24 1.60 15.8 s 
25 1.58 16.0 s 
26 1.77 16.3 s 
27 2.18 19.7 s 
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 327.1583 327.1573 3.1 
* The measured value was close to the noise level which caused the ppm shift to be out 








Table 7.6. Table of accurate masses for the OzID products of compound 2 
 
 


































































Parent Mass C28H40O5Na+ 479.2784 479.2773 2.3 
B C20H32O3Na+ 343.1948 343.2249 87.7 
a C8H8O5Na+ 207.0283 207.0269 6.8 
b C20H32O4Na+ 359.2246 359.2198 13.3 
A C8H8O4Na+ 191.0335 191.0320 7.9 
a C13H16O5Na+ 275.0936 275.0895 14.9 
A C13H16O4Na+ 259.0984 259.0949 13.5 
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 303.1581 303.1567 4.6 
 
 
































































 469.2548 469.2566 3.8 
 
 
Figure 110. UPLC-PDA detector chromatogram of ent-sartorypyrone E (1) 
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Figure 111. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 













Figure 114. 1H COSY spectrum of ent-sartorypyrone E (1), CDCl3, 700 MHz 
 
 
Figure 115. UPLC-PDA detector chromatogram of an extract of A. fischeri grown on 




Figure 116. 1H NMR spectrum (400 MHz) in CDCl3, of sorbicillin (3) 
 
 
Figure 117. 1H NMR spectrum (500 MHz) in MeOD, of trichodermic acid A (4) 
 
 




Figure 119. Schematic of the Waters Synapt G2 HDMS modified to allow ozone in the 





OPPORTUNITIES AND LIMITATIONS FOR ASSIGNING RELATIVE 
CONFIGURATIONS OF ANTIBACTERIAL BISLACTONES USING GIAO NMR SHIFT 
CALCULATIONS 
 
Sonja L. Knowles, Christopher D. Roberts, Mario Augustinović, Laura Flores-Bocanegra, 
Huzefa A. Raja, Kimberly N. Heath-Borrero, Joanna E. Burdette, Joseph O. Falkinham 




Four new bislactones, dihydroacremonol (1), clonostachyone (2), acremodiol B 
(3), and acremodiol C (4), along with one known compound, hymeglusin (5), were 
isolated from cultures of two fungal strains (MSX59876 and MSX59260). Both strains 
were identified based on phylogenetic analysis of molecular data as Clonostachys spp., 
yet they biosynthesized a suite of related, but different, secondary metabolites. Given 
the challenges associated with elucidating the structures and configurations of 
bislactones, gauge-independent atomic orbital (GIAO) NMR calculations were tested as 
a complement to traditional NMR and HRESIMS experiments. Fortuitously, the 
enantiomer of the new natural product (4) was known as a synthetic compound, and the 
predicted configuration from GIAO NMR calculations (i.e., for the relative configuration) 
and optical rotation calculations (i.e., for the absolute configuration) matched those of 
the synthesis product. These results engendered confidence in using similar procedures, 
particularly the mixture of GIAO NMR shift calculations coupled with an orthogonal 
technique, to predict the configuration of 1-3; however, there were important limitations, 
which are discussed for each of these. The metabolites displayed antimicrobial activities,
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 with compounds 1 and 4 being the most potent against Staphylococcus aureus with 
MICs of 1 µg/mL and 4 µg/mL, respectively. 
Macrolides are well known antibiotics that have been used since the early 1950s, 
when the first, and most well studied macrolide antibiotic, erythromycin, was 
marketed.401, 402 Bislactones are a subgroup of macrolides and some of them have been 
investigated for their antibacterial properties.88-90, 403 However, assigning either the 
relative or absolute configuration of this class of compounds can be challenging. For 
instance, the bislactone, acremodiol, first described in 2002,404 was assigned a relative 
configuration as 5R,6R,11R,14R based on NOESY correlations. Nevertheless, the 
5R,6R,11R,14R and 5R,6R,11S,14R acremodiol analogues were both synthesized, but 
the spectroscopic data from neither of these matched those in the original paper,90 and 
as such, both the relative and absolute configuration of acremodiol remains uncertain. 
Another example of challenges with bislactones is 4-keto-clonostachydiol, which was 
first determined as 5R,10R,13R405 and was later reassigned based on synthesis and 
specific rotation as 5S,10S,13S.88, 89 In summary, determining the absolute, and 
sometimes even the relative, configurations of the bislactones remains problematic.  
There are several ways to probe either/both the relative and/or absolute 
configuration of natural products. In addition to total synthesis, the gold standard for 
absolute configuration is X-ray crystallography,91 often including the incorporation of a 
heavy atom,92, 93 and this is essentially a snapshot of the molecule in three dimensional 
space.94 Countless studies have also used Mosher’s ester method or Marfey’s 
reagent.95-98 While the former is used largely for molecules with secondary alcohols and 
the latter for molecules that incorporate amino acid building blocks, what they have in 
common is the requirement of semi-synthetic modification or degradation of the parent 
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natural product.95, 97, 98  Another method, electronic circular dichroism (ECD), is finding 
growing use, especially with the ability to compare calculated vs measured spectra, 
although this works best with metabolites that have a UV chromophore in the vicinity of 
the stereogenic element.99, 100 While NMR is very popular for structure elucidation, 
NOESY/ROESY 2D NMR experiments allow one to only assign the relative configuration 
of a molecule, unless those experiments are coupled with orthogonal data.64  
The use of GIAO NMR calculations for structure elucidation was reported by 
Bifulco and colleagues in 2002101, 102 and has been gaining popularity.103-107 This 
technique has been used more frequently in the ensuing years (Figure 122) and has 
aided in assigning the relative configuration or reassignment of several natural 
products.102, 105, 108-110 As noted previously, the configuration of bislactones has been 
challenging, resulting in several reassignments. Thus, GIAO NMR calculations were 
evaluated on this subgroup of macrolides, confirming and/or assigning the relative 
configuration of four metabolites isolated from two Clonostachys spp. (strains 




















Figure 120. Structures of compounds 1-5. 
 
Results 
In pursuit of structurally diverse metabolites with biological activity from fungi,406-
408 two fungal strains from the Mycosynthetix library were flagged for further study, as 
they biosynthesized metabolites that did not match an inhouse database of over 625 
fungal metabolites.188, 189 Based on phylogenetic analysis of molecular data,353 the 
strains were identified as Clonostachys spp.; however, each biosynthesized a similar, 
albeit, non-identical suite of polyketides (Figure 123; strain MSX59876 produced 1 and 
3-5 and strain MSX59260 produced 2). Of these, the data for 5 matched the literature for 
hymeglusin, which is also termed antibiotic 1233A.409, 410  
Compound 4 was obtained as a white, amorphous powder with a molecular 
formula of C14H22O6 as determined by HRESIMS data along with 1H, 13C, and edited-
HSQC NMR data (Table 8.1). The 1H NMR data matched the literature values for 
5R,6R,11R,14R acremodiol, which was generated via total synthesis (Figure 144);90 
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however the specific rotation of 4 ([α]D20 +25) was opposite to that of synthesized 
5R,6R,11R,14R acremodiol ([α]D20 -35.3);90 both of these values were obtained in CHCl3, 
and 4 was also analyzed in MeOH so as to compare with those measured for 1-3 (Table 
8.16). These data suggested that compound 4 was the enantiomer of 5R,6R,11R,14R 
acremodiol, and thus, had an absolute configuration of 5S,6S,11S,14S. This observation 
was used as a test case for the GIAO NMR calculations (Tables 8.12-8.14), to explore 
its accuracy for this subgroup of macrolides. In brief, all the minimized conformers of the 
possible structures were obtained (Figure 147). The NMR shielding constants were 
calculated from these conformers, converted into chemical shifts (ppm), and then the 
final chemical shift values were calculated (Tables 8.12-8.13).106, 107 The calculated 1H 
and 13C NMR shifts were scaled empirically (i.e., corrected mean absolute error) to 
remove system errors (Tables 8.12 and 8.13), which has proven to be common practice 
when working with these calculations.104, 105, 109 Then, two different NMR calculation 
methods were used to assess the relative configuration. First, the individual correlation 
coefficients for each isomer was calculated, followed by the geometric mean of the 1H 
and 13C NMR correlation coefficients (Table 8.14).104, 105 This gives a correlation 
coefficient for every possible isomer, and the isomer with a value closest to 1 is 
considered the most likely relative configuration,104 which in this case was either 
5S,6S,11S,14S or 5R,6R,11R,14R. Secondly, DP4+ (combined 1H and 13C) calculations 
for each isomer was calculated (Table 8.17), which gives the probability for every 
possible isomer, and the isomer with the highest probability is most likely the relative 
configuration.411 In this case it was either 5S,6S,11S,14S or 5R,6R,11R,14R. Thus, both 
methods were in agreement with each other. Again, given the specific rotation value of 4 
being opposite to the literature data for 5R,6R,11R,14R acremodiol,90 we hypothesize 
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the absolute configuration of 4 as 5S,6S,11S,14S. In addition, the optical rotation of 4 
was calculated (i.e., 4a in Table 8.16), further confirming the configuration as 
5S,6S,11S,14S, and ascribed the trivial name acremodiol C. 
Compound 1 was obtained as a white/yellow, amorphous powder with a 
molecular formula of C14H20O6 as determined by HRESIMS data along with 1H, 13C, and 
edited-HSQC NMR data (Table 8.1), demonstrating an index of hydrogen deficiency of 
5. The 13C NMR data (Table 8.1) indicated 14 carbons, including three carbonyl, two 
vinylic, three oxygenated, and six aliphatic carbons. The 1H and edited-HSQC NMR data 
(Table 8.1) indicated two methyls, two olefinic protons, three methines, and four 
methylenes. The HMBC correlations from H-10 to C-9 and C-8 and from H-9 to C-10 and 
C-8, as well as the COSY correlations between H-10 and H-9, indicated a trans (JH3/H2 = 
15.8 Hz) α,β-unsaturated ester (Figure 121). This half of the bislactone was formed 
through a seven-proton spin system (H-9/H-10/H-11/H2-12/H2-13/H-14/H3-16), as noted 
via COSY correlations. The other half of the bislactone was formed through HMBC and 
COSY correlations, focusing on correlations across two spin systems (i.e., H2-3/H2-4 and 
H-6/H3-15). HMBC correlations from H-6 and H3-15 to the keto group at C-5 (δC 208.0), 
and H2-3 and H2-4 to both C-5 and the ester carbonyl at C-2 (δC 171.5), formed the other 
side of the bislactone. These halves were connected to form the macrolide through the 
HMBC correlations of H-14 to C-2 and H-6 to C-8 coupled with the obvious oxygenation 
of H-14 (δH/δC 4.93/71.1) and H-6 (δH/δC 5.41/75.1). To probe the configuration of the 
stereogenic centers in 1, we first attempted Mosher’s ester analysis, but unfortunetely, 
no reaction was observed (data not shown). This line of inquiry was abandoned and 
instead, NMR calculations were performed. Utilizing the correlation coefficient method, 
the configuration of 1 was assigned as either 6S,11R,14R or 6R,11S,14S (Table 8.5). 
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Then, calculation of the optical rotations for these two possibilities were used to 
distinguish between enantiomers. The specific of 1 agreed in sign with the calculated 
value for 6R,11S,14S (i.e., [α]D20 +166 vs [α]D20 +51 (c 0.10, MeOH); Table 8.16). 
Interestingly, the DP4+ method indicates that the configuration of 1 was either 
6R,11R,14R or 6S,11S,14S (Table 8.17), and again, using the specific rotation data, the 
configuration was assigned as 6S,11S,14S (Table 8.16). The benefit of testing both 
approaches is the confluence of data for the 11S and 14S assignments. However, there 
was discordance for the 6 position, so this position remains unassigned. As a tentative 
assignment based on biosynthesis, position 6 could be the S configuration, since it is 
derived from the same biosynthetic pathway as compounds 3 and 4. The methods used 
to obtain this configuration were as described for 4 (Tables 8.3-8.5), and this compound 
was termed dihydroacremonol. 
 
   
1 2 3 
 
 
Figure 121. Key HMBC and COSY Correlations of Compounds 1-3. 
 
Compound 2 was obtained as a white, amorphous powder with a molecular 
formula of C14H20O6 as determined by HRESIMS data along with 1H, 13C, and edited-
HSQC NMR data (Table 8.1), demonstrating an index of hydrogen deficiency of 5. The 
NMR data indicated that 2 was a constitutional isomer of 1. The HMBC correlations from 
H-12 to C-11 and C-10 and from H-11 to C-12 and C-10, coupled with the COSY 
240 
correlations between H-12 and H-10, indicated a trans (JH3/H2 = 15.8 Hz) α,β-unsaturated 
ester (Figure 121). This portion of the bislactone was formed through a five-proton spin 
system (H-11/H-12/H-13/H-14/H3-16) as noted via COSY correlations (Figure 121). 
Similar to 1, the other portion of the bislactone was formed through HMBC and COSY 
correlations via two spin systems (H2-3/H2-4) and (H2-6/H2-7/H-8/H3-15). HMBC 
correlations from H2-7 and H2-6 to C-5 and H2-4 and H2-3 to C-5 and C-2 formed the 
other portion of the bislactone. These sections were connected through the HMBC 
correlations of H-14 to C-2 and H-8 to C-10, along with the oxygenation of H-8 (δH/δC 
4.90/71.2) and H-14 (δH/δC 4.77/75.1). The configuration of 2, which was assigned the 
trivial name clonostachyone, was assigned through GIAO NMR calculations and optical 
rotation calculations. The correlation coefficient method assigned the configuration of 2 
to be either 8S,13S,14R or 8R,13R,14S (Table 8.8), with optical rotation calculations 
indicating it was 8R,13R,14S (Table 8.16). The DP4+ method predicted the configuration 
to be either 8R,13S,14R or 8S,13R,14S (Table 8.17), with specific rotation data 
suggesting 8S,13R,14S (Table 8.16). Based on the discrepancies between the two 
methods at position 8, and similar to the discussion for compound 1 at position 6, the 
configuration of 2 was established 13R,14S, with the configuration of position 8 being 
ambiguous and assigned as 8S*. The methods used to cary out these calculations were 
as described for 4 (Tables 8.6-8.8). 
Compound 3 was obtained as a white, amorphous powder with a molecular 
formula of C14H22O6 as determined by HRESIMS data along with 1H, 13C, and edited-
HSQC NMR data (Table 8.1). As determined by spectroscopic data, compound 3 had 
the same planar structure as acremodiol and 4.90, 404 For example, the spin systems via 
COSY and HMBC were highly similar between compounds 3 and 4. However, because 
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the 1H NMR data displayed shift differences with 4 (Figures 144 and 145), GIAO NMR 
and optical rotation calculations were performed to ascertain the differences between 
these compounds. The correlation coefficient method suggested the configuration of 3 to 
be either 5R,6S,11R,14S or 5S,6R,11S,14R (Table 8.11), with optical rotation 
calculations indicating it was 5R,6S,11R,14S (Table 8.16). The DP4+ method predicated 
the configuration to be either 5S,6R,11R,14R or 5R,6S,11S,14S (Table 8.17), with the 
addition of optical rotation calculations suggesting the 5R,6S,11S,14S enantiomer. 
Based on the discrepancies between the two methods at position 11, the configuration of 
3 was established as, 5R,6S,14S, with the configuration of position 11 being ambiguous. 
As a tentative assignment based on biosynthesis, position 11 could be the S 
configuration, since it is derived from the same biosynthetic pathway as compounds 1 
and 4. Compound 3 was ascribed the trivial name acremodiol B, and the methods used 













Table 8.1. 1H and 13C NMR Data of Compound 1-4 
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Antimicrobial activities of compounds 1, 4, and 5 were measured against 
Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Methicillin-resistant 
S. aureus, and Bacillus anthracis. Compounds 1 and 4 had significant activity against S. 
aureus, with MICs of 1 µg/mL and 4 µg/mL, respectively (Table 8.2). Compound 1 was 
evaluated for cytotoxicity, as bislactones with a keto group have been active in leukemia 
cell lines;405 1 was inactive against MDA−MB−231 (triple negative human breast cancer), 
OVCAR-3 (human ovarian cancer), and MDA-MB-435 (human melanoma cancer) cell 
lines at >25 μM. Compound 1 warrants further investigation due to the promising 
antimicrobial activity coupled with the lack of cytotoxicity to mammalian cells.  
In summary, four new bislactones (1-4) and one known secondary metabolite (5) were 
isolated from two Clonostachys spp. Notably, compounds 1 and 4 showed significant 
activity against S. aureus. Owing to the fact that there have been many challenges in 
assigning the configuration of bislactones in the literature,88-90, 404, 405, 412 GIAO NMR 
calculations were used to assign the relative configurations of these metabolites and 
optical rotation calculations were used to assign the absolute configuration. The 
assignment of the absolute configuration of 4 is a noteworthy example, as few, if any, 
literature examples exist where the configuration of an isolated secondary metabolite 
was assigned using GIAO NMR calculations coupled with specific rotation data from a 
5-
OH 






 1.98, m       
13-
OH 
   
2.50, d 
(6.9) 
    
a CDCl3 (1H NMR 400 MHz, 13C NMR 100 MHz). ᵇ CDCl3 (1H NMR 700 MHz, 13C NMR 175 
MHz). 
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synthesized enantiomer.90, 404 This suggests that GIAO NMR calculations could be a 
credible tool for assigning the relative configuration of this subgroup of macrolides.  
 
Table 8.2. Antimicrobial Activity of Compounds 1, 4, and 5 Against a Panel of Bacteria 
Compounds P. aeruginosa E. coli S. aureus MRSA B. anthracis 
 Minimal Inhibitory Concentrations in µg/mL 
1 125 125 1 125 62.5 
4 125 125 4 125 125 
5 125 > 250 125 125 > 250 
penicillina > 250 16 0.25 0.50 0.25 
streptomycina 1 0.25 0.25 0.25 0.25 
erythromycina 62.5 16 0.50 0.25 0.25 
rifampina 62.5 4 0.25 0.25 0.25 
clarithromycina 125 16 0.25 > 250 0.25 
aPositive controls 
 
Materials and Methods 
General Experimental Procedures. Optical rotation data were obtained using a 
Rudolph Research Autopol III polarimeter, and UV spectra were measured with a Varian 
Cary 100 Bio UV−vis spectrophotometer. The NMR data were collected using either a 
JEOL ECS-400 spectrometer, which was equipped with a JEOL normal geometry 
broadband Royal probe, and a 24-slot autosampler, and operated at 400 MHz for 1H and 
100 MHz for 13C, or a JEOL ECS-500 spectrometer operating at 500 MHz for 1H and 125 
MHz for 13C or an Agilent 700 MHz spectrometer, equipped with a cryoprobe, operating 
at 700 MHz for 1H and 175 MHz for 13C. The NMR shifts were referenced to either CDCl3 
(1H 7.26ppm and 13C 77.2ppm) or DMSO-d6 (1H 2.50ppm). HRESIMS experiments 
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utilized either a Thermo LTQ Orbitrap XL mass spectrometer or a Thermo Q Exactive 
Plus; both were equipped with an electrospray ionization source. A Waters Acquity 
UPLC was utilized for both mass spectrometers, using a BEH C18 column (1.7 m; 50 
mm x 2.1 mm) set to a temperature of 40 oC and a flow rate of 0.3 mL/min. The mobile 
phase consisted of a linear gradient of CH3CN-H2O (both acidified with 0.1% formic 
acid), starting at 15% CH3CN and increasing linearly to 100% CH3CN over 8 min, with a 
1.5 min hold before returning to the starting condition. The HPLC separations were 
performed on a Varian Prostar HPLC system equipped with a Prostar 210 pumps and a 
Prostar 335 photodiode array detector (PDA), with the collection and analysis of data 
using Galaxie Chromatography Workstation software. The columns used for separations 
were either an Gemini C18 preparative (5 m; 21.2 x 250 mm) column at a flow rate of 
21.2 mL/min, or an Atlantis T3 C18 preparative (5 m; 19 x 250 mm) column at a flow 
rate of 16.9 mL/min. Flash chromatography was performed on a Teledyne ISCO 
Combiflash Rf 200 and monitored by both ELSD and PDA detectors.   
Fungal Identification. The fungal ITS region (ITS1–5.8S-ITS2) of the nuclear 
ribosomal operon was sequenced using primer combination ITS1F and ITS4.413 414 This 
region has been designated as the fungal barcoding marker. 415 Detailed methods for 
DNA extraction, PCR amplification, and Sanger sequencing of these strains followed 
procedures outlined by Raja et al.353 A BLAST search with strains MSX59260 and 
MSX59876 revealed that both showed highest affinities with members of Clonostachys 
(Ascomycota, Hypocreales, Bionectriaceae). Subsequently, all authentic Clonostachys 
spp. sequence data with taxon sampling were downloaded from a recent study by 
Lechat et al.416 followed by phylogenetic analysis using Maximum likelihood analysis 
using RAxML417, 418 on the CIPRES server419. Briefly, an alignment was constructed in 
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MAFFT256 using Geneious 9.1.8 (https://www.geneious.com) and analyzed using RAxML 
with the General time reversible model and 1000 fast bootstrap searches using The 
CIPRES Science Gateway V. 3.3. This revealed that strains MSX59260 and MSX59876 
displayed phylogenetic affinities with Clonostachys rogersoniana 420 strain CBS 582.89 
(≥90% RAxML bootstrap support). Previous studies by our team on C. rogersoniana 
resulted in the identification of verticillin analogues.399 Since strains MSX59260 and 
MSX59876 biosynthesized a different suite of metabolites, we suggest a more 
conservative approach to their identification, noting them both as Clonostachys sp., and 
their sequence data were deposited in GenBank (accession numbers: MSX59876: 
MW275356, MW275357; and MSX59260: MW275358, MW275359, respectively).  
Fermentation, Extraction, and Isolation. Strains MSX59876 and MSX59260 
were grown in two separate 2.8 L Fernback flasks containing 150 g of autoclaved rice 
prepared by adding twice the amount of distilled H2O. A seed culture grown in YESD 
(2% soy peptone, 2% dextrose, and 1% yeast extract; 5 g of yeast extract, 10 g of soy 
peptone, and 10 g of D-glucose in 500 mL of deionized H2O) medium was used as the 
inoculum. The rice-based culture was incubated at room temperature (~23 °C). 
Strain MSX59876 was extracted by adding 500 mL of 1:1 MeOH-CHCl3. Subsequently, 
the culture was chopped with a spatula and left to shake overnight (~16 hrs) at ~100 rpm 
at room temperature. The culture was combined and filtered in vacuo, and 450 mL 
CHCl3 and 750 mL H2O were added to the filtrate. The mixture was then transferred to a 
separatory funnel. The organic layer was drawn off and evaporated to dryness in vacuo, 
reconstituted in 300 mL of 1:1 MeOH-CH3CN and 300 mL of hexanes, transferred to a 
separatory funnel, and shaken vigorously. This defatted organic layer was evaporated to 
dryness in vacuo. The organic layer (636 mg) was then dissolved in CHCl3, absorbed 
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onto Celite 545 (Acros Organics) and was separated by normal phase flash 
chromatography using a gradient of hexane to CHCl3 to MeOH at a 30 mL/min flow rate 
and 61.0 column volumes, which yielded four fractions. Fraction two (50.2 mg) was 
further purified using preparative-HPLC using a gradient of 20:80 to 100:0 of CH3CN: 
H2O acidified with 0.1% formic acid over 30 min yielding four subfractions. Subfraction 
one, which eluted at 11.0 min, yielded dihydroacremonol (1; 10.9 mg). Fraction three 
(110.5 mg) was further purified by preparative-HPLC using a gradient of 20:80 to 60:40 
for 30 minutes then 60:40 to 80:20 for 15 min with CH3CN:H2O acidified with 0.1% formic 
acid yielding eight subfractions. Subfractions four and six yielded acremodiol C (4; 2.4 
mg) and hymeglusin (5; 7.9 mg), at 9.3 min and 28.5 min, respectively. Subfraction two 
underwent a further preparative-HPLC step with a gradient of 20:80 to 100:0 of CH3CN: 
H2O acidified with 0.1% formic acid over 30 min, yielding six subfractions. Subfraction 
one, which eluted at 10.3 min, yielded acremodiol B (3; 0.8 mg).  
In an analogous manner, strain MSX59260 was extracted, and the de-fatted 
organic extract (1004 mg) was absorbed onto Celite 545 and was separated by normal 
phase flash chromatography using a gradient of hexane to CHCl3 to MeOH at a 35 
mL/min flow rate and 61.0 column volumes, which yielded four fractions. Fraction two 
(110.5 mg) was purified using preparative- HPLC using a gradient of 20:80 to 60:40 of 
CH3CN: H2O acidified with 0.1% formic acid over 30 min yielding six subfractions. 
Subfraction two (7.8 mg) was further purified using preparative-HPLC using a gradient of 
20:80 to 100:0 of CH3CN: H2O acidified with 0.1% formic acid over 30 minutes yielding 
five subfractions. Subfraction two yielded clonostachyone (2; 0.8 mg), which eluted at 
10.0 min.  
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Dihydroacremonol (1): White/yellow, amorphous powder; [α]D20 = +51 (c 0.10, 
MeOH); UV (MeOH) λmax (log ε) 283 (1.83), 226 (2.87) nm; IR vmax 3408, 1715, 1688, 
1646 cm-1; 1H NMR (CDCl3, 400 MHz) and 13C (CDCl3, 100 MHz) (See Table 8.1); 
HRESIMS m/z 285.1329 [M+H]+ (calcd. For C14H20O6, 285.1338). 
Clonostachyone (2): White, amorphous powder; [α]D20 = +36 (c 0.10, MeOH); UV 
(MeOH) λmax (log ε) 274 (1.76), 223 (2.83) nm; 1H NMR (CDCl3, 400 MHz) and 13C 
(CDCl3, 100 MHz) (See Table 8.1); HRESIMS m/z 285.1326 [M+H]+ (calcd. For 
C14H20O6, 285.1338). 
Acremodiol B (3): White, amorphous powder; [α]D2s0 = +75 (c 0.10, MeOH); UV 
(MeOH) λmax (log ε) 225 (2.84) nm; 1H NMR (CDCl3, 700 MHz) and 13C (CDCl3, 175 
MHz) (See Table 8.1); HRESIMS m/z 287.1484 [M+H]+ (calcd. For C14H22O6, 287.1494). 
Acremodiol C (4): White, amorphous powder; [α]D20 = +22 (c 0.10, MeOH), [α]D20 
= +25 (c 0.04, CHCl3); UV (MeOH) λmax (log ε) 213 (3.47) nm; 1H NMR (CDCl3, 700 MHz) 
and 13C (CDCl3, 175 MHz) (See Table 8.1); HRESIMS m/z 287.1487 [M+H]+ (calcd. For 
C14H22O6, 287.1494). 
Cytotoxicity Assays. Human melanoma cancer cells MDA-MB-435, human 
breast cancer cells MDA-MB-231 and human ovarian cancer cells OVCAR3 were 
purchased from the American Type Culture Collection (Manassas, VA). The cell line was 
propagated at 37 °C in 5% CO2 in RPMI 1640 medium, supplemented with fetal bovine 
serum (10%), penicillin (100 units/mL), and streptomycin (100 µg/mL). Cells in log phase 
growth were harvested by trypsinization followed by two washing to remove all traces of 
enzyme. A total of 5,000 cells were seeded per well of a 96-well clear, flat-bottom plate 
(Microtest 96®, Falcon) and incubated overnight (37 °C in 5% CO2). Samples dissolved 
in DMSO were then diluted and added to the appropriate wells.  The cells were 
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incubated in the presence of test substance for 72 h at 37 °C and evaluated for viability 
with a commercial absorbance assay (CellTiter-Blue Cell Viability Assay, Promega Corp, 
Madison, WI) that measured viable cells. IC50 values are expressed in µM relative to the 
solvent (DMSO) control. Compound 1 was analyzed with four technical replicates and 
three biological replicates and was >90% pure by UPLC. 
Antimicrobial Measurement. Minimal inhibitory concentrations of the 
compounds were measured by broth microdilution against the following bacteria, namely 
Escherichia coli, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), 
Pseudomonas aeruginosa, Bacillus anthracis, MICs were measured by broth 
microdilution of fresh overnight cultures according to the Clinical and Laboratory 
Standards Institute (CCLI) guidelines with cation-adjusted Mueller–Hinton broth and an 
inoculum of 105 colony-forming units (CFU)/mL. Stocks of the compounds were 
dissolved in Mueller–Hinton broth Becton-Dickenson, Sparks, MD). The MIC (expressed 
as μg/mL) was defined as the lowest concentration of compound completely inhibiting 
the appearance of turbidity by eye and confirmed by absorbance 540 nm. All results 
represent the average of three independent measurements. Prior to testing, 1 and 4 
were confirmed >90% pure by UPLC. 
Computational Details. All molecular mechanics calculations were performed 
using Macromodel (Version 12.6) interface Maestro (Version 12.2) program. All 
conformational searches used the MMFF force field and torsional sampling Monte Carlo 
Multiple Minimum (MCMM) method with extended torsional sampling.106 The resulting 
conformers were filtered checked for duplicity and minimized using a DFT forcefield at 
the M062X/6-31+G (d,p) level of theory. NMR shielding constants were calculated at the 
GIAO method at B3LYP/6-311+G (2d,p) level of theory with the IEFPCM model in 
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chloroform solvent. The obtained shielding constants were converted into chemical shifts 
(ppm) by refereeing TMS to 0 ppm. The final 13C and 1H NMR shifts were calculated for 
each conformer based on the total Boltzmann distribution and relative energies. The 
NMR shifts for each particular species was calculated based on the Nature Protocol by 
Willoughby et al.106, 107 To calculate the corrected correlation coefficient (r) for the 




), then the individual correlation coefficients were 
calculated in excel (=correl(calculated, experimental)) and lastly, the geometric mean 
(𝑟𝑎𝑙𝑙 = 1 − √(1 − 𝑟𝐶)(1 − 𝑟𝐻)) of the correlation coefficients for 
13C and 1H was taken.104, 
105 The DP4+ calculations were carried out by using the spreadsheet provided by the 
Sarotti Group.411 To calculate the optical rotation values, the conformers generated for 
the NMR calculations were used. The optical rotations were calculated at the GIAO 
method at B3LYP/6-31G (d,p) level of theory in MeOH for 1-4 and in CHCl3 for 4,111, 421 























This graph was obtained by searching 2003 - April 2020 in SciFinder the terms: NMR 
calculation(s), GIAO, 13C calculations, and 1H calculations, with the duplicates being 
removed. 
 
Figure 122. Publications in the Journal of Natural Products on NMR calculations 
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Figure 124. LC-MS chromatogram and (+)-HRESIMS spectrum of compound 1 
 
 
Figure 125. 1H NMR spectrum (400 MHz, Top) and 13C NMR spectrum (100 MHz, 
Bottom) both in CDCl3, of dihydroacremonol (1) 
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Figure 128. 1H COSY spectrum of dihydroacremonol (1), CDCl3, 400 MHz 
 
 
Figure 129. LC-MS chromatogram and (+)-HRESIMS spectrum of compound 2 
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Figure 130. 1H NMR spectrum (400 MHz, Top) and 13C NMR spectrum (100 MHz, 












Figure 133. 1H COSY spectrum of clonostachyone (2), CDCl3, 400 MHz 
 
 
Figure 134. LC-MS chromatogram and (+)-HRESIMS spectrum of compound 3 
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Figure 135. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 












Figure 138. 1H COSY spectrum of acremodiol B (3), CDCl3, 700 MHz 
 
 
Figure 139. LC-MS chromatogram and (+)-HRESIMS spectrum of compound 4 
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Figure 140. 1H NMR spectrum (700 MHz, Top) and 13C NMR spectrum (175 MHz, 
















Figure 144. 1H NMR spectrum comparison of acremodiol B (3; Top) and acremodiol C 




Figure 145. 1H NMR spectrum comparison of acremodiol B (3; Top) and acremodiol C 




Figure 146. Phylogeny of MSX59260 and MSX59876. Maximum Likelihood analysis 
using RAxML showing the most likely tree (-lnL = 1618.89) from 44 taxa based on the 
ITS data (493 bp). Numbers refer to RAxML bootstrap support values ≥ 70% based on 
1000 replicates. Strains MSX59260 and MSX 59876 are in bold and identified as 
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Clonostachys sp., with phylogenetic affiliations to C. rogersoniana (Bionectriaceae, 
Hypocreales, Ascomycota). Bar indicates nucleotide substitutions per site. 
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Figure 147. The structure used in GIAO NMR calculations. GIAO NMR calculations 
cannot distinguish between enantiomers, therefore, only half of all possible 
stereoisomers are shown for each compound 
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Table 8.3. Calculated and experimental 13C shifts (in ppm) for 1a-1d 
Pos 13C Corrected Calculated 13C 
Experimental 
 1a 1b 1c 1d 1 
2 172.0426998 172.5395571 172.4469731 174.0128442 171.5 
3 30.28966952 32.62059702 31.53233881 30.66707685 34.9 
4 34.78250104 38.13332120 35.47345115 34.44929298 29.9 
5 212.8423169 212.7458301 212.4595536 213.6713997 208.0 
6 74.19171425 75.33996941 75.48626505 76.26699019 75.1 
8 162.9532295 163.8774110 163.7402996 166.3803791 164.4 
9 117.4768187 116.7519894 121.2598081 117.9834873 119.4 
10 155.4151128 157.9855808 154.3842260 159.0400148 151.7 
11 69.18461071 71.10933162 73.22123954 71.36944311 69.7 
12 27.73822869 31.12906912 31.26017738 29.55367677 29.0 
13 26.99576885 26.61778761 30.01647865 26.10948588 27.5 
14 68.55873166 72.19325383 69.00214826 70.87892078 71.1 
16 16.11940656 17.28191467 17.35213999 15.83207293 19.2 
19 13.21334508 15.01896584 14.47863357 14.18479602 16.7 
 
Table 8.4. Calculated and experimental 1H shifts (in ppm) for 1a-1d 
Pos 1H Corrected Calculated 1H 
Experimental 
 1a 1b 1c 1d 1 
3a 2.548170 2.268844 2.468521 2.468823 2.73 
3b 2.686907 2.762037 2.648671 2.442497 2.73 
4a 3.053595 2.805082 2.819389 2.191744 2.55 
4b 2.426290 2.459911 2.449257 3.105777 2.55 
6 5.387993 5.358350 5.138418 4.876544 5.41 
9 5.925194 6.015246 5.601510 5.853246 6.09 
10 7.063152 7.383758 6.566392 7.132419 7.02 
11 4.638037 4.535839 3.926989 4.440309 4.61 
12a 1.906984 1.929031 1.685036 1.733795 1.86 
12b 1.865961 1.519861 1.781658 1.895441 1.86 
13a 1.444922 1.566922 1.621858 2.046122 1.54 
13b 2.003478 1.628094 1.647885 1.433900 1.81 
14 4.746854 4.557121 4.443867 4.689824 4.93 
15 1.102736 1.421968 1.170226 1.402605 1.40 





Table 8.5. Average values of the correlation coefficients for 1a-1d. The “all” refers to 13C 
and 1H results combined using the geometric mean. 
 






Table 8.6. Calculated and experimental 13C shifts (in ppm) for 2a-2d 
Pos 13C Corrected Calculated 13C Experimental 
 2a 2b 2c 2d 2 
2 173.6536931 174.9212751 175.1868321 148.9784305 173.1 
3 28.27677235 28.13301049 28.48098282 26.07624936 28.5 
4 36.32197009 36.28245959 37.67707866 32.90117102 38.2 
5 212.6204795 212.6053341 213.1623715 183.0020226 206.9 
6 37.98529357 36.18022537 39.91819758 33.59369538 38.4 
7 25.68937607 24.91084298 27.98841333 22.95278146 27.6 
8 69.23499463 67.47162091 71.24559867 60.26041878 71.2 
10 165.3043168 164.7991334 165.3184673 141.4998486 165.3 
11 119.5935266 122.3200905 119.6141590 102.9446629 121.5 
12 153.0681503 149.4998930 153.9418041 133.7167530 146.5 
13 73.18790739 75.66826035 74.24326563 62.66656657 73.9 
14 71.37972690 72.98130337 73.81426738 62.99382748 75.1 
15 15.82685101 14.67257436 16.98380860 14.05646077 20.0 












Table 8.7. Calculated and experimental 1H shifts (in ppm) for 2a-2d 
Pos 1H Corrected Calculated 1H Experimental 
 2a 2b 2c 2d 2 
3a 2.145049737 2.607784357 2.102999442 1.913060077 2.34 
3b 2.657007474 2.184510764 2.807149994 1.708256947 2.80 
4a 2.354019025 2.985719376 2.338051912 2.277671693 2.60 
4b 2.981974657 2.306057217 2.992063798 2.070804477 2.87 
6a 2.435584627 2.408635673 2.492513397 2.024482054 2.42 
6b 2.761459083 2.735114306 2.589287434 1.945080287 2.60 
7a 1.790071171 2.303529255 1.406881543 1.286688469 1.95 
7b 1.871017620 1.474341989 2.205919631 1.776996414 2.08 
8 4.641675466 4.802595023 4.493749011 3.954076885 4.90 
11 5.738518574 5.688075962 5.809576441 5.151974698 5.97 
12 6.899531722 6.716776755 7.029872627 6.157425266 6.72 
13 4.085508982 3.858429505 4.080723027 3.626756632 4.17 
14 4.936516926 4.686109929 4.549915847 4.171303763 4.77 
15 1.143288857 1.101358610 1.131328667 0.822446716 1.29 
16 1.269765795 1.271671428 1.333513562 1.006794775 1.43 
 
Table 8.8. Average values of the correlation coefficients for 2a-2d. The “all” refers to 13C 
and 1H results combined using the geometric mean.. 
 






Table 8.9. Calculated and experimental 13C shifts (in ppm) for 3a-3h 
 
Pos 13C Corrected Calculated 13C Experimental 
 3a 3b 3c 3d 3e 3f 3g 3h 3 
2 171.5197 174.6740 172.0947 173.4645 172.4039 173.7352 173.0528 175.9863 175.0 
3 27.4380 32.7886 28.6026 28.3172 32.6808 28.2382 33.5399 32.6506 32.2 
4 26.8323 30.3368 27.4003 26.1792 29.9742 25.4791 30.6500 28.6878 26.4 
5 67.0823 70.8166 66.9625 70.9423 73.8761 71.7436 74.5763 71.0949 72.8 
6 71.5408 71.2465 72.2338 73.4615 73.6996 72.2281 74.8854 72.8943 73.7 
8 161.6200 163.2216 162.2793 164.5950 161.8752 164.6896 162.6564 164.7606 165.0 
9 116.1348 116.7969 120.7827 118.3148 117.1511 116.7506 121.5257 119.4166 120.9 
10 153.1101 153.3963 151.4339 155.8366 152.4968 156.2340 151.4299 156.6515 149.2 
11 68.1747 70.3955 72.3100 70.4554 69.2621 71.0433 73.5297 71.2701 69.4 
12 28.2042 31.1328 31.7023 31.0716 29.7094 34.6000 33.2739 31.4680 28.3 
13 28.5209 25.8836 31.6019 28.7911 30.0210 31.6353 33.3894 28.3782 27.0 
14 66.3458 70.9850 66.2665 68.8012 68.1128 68.4882 67.9026 70.5389 70.8 
15 11.7923 14.7299 11.9394 13.5804 15.8978 14.0566 16.5573 13.2236 16.9 




Table 8.10. Calculated and experimental 1H shifts (in ppm) for 3a-3h 
Pos 1H Corrected Calculated 1H Experimental 
 3a 3b 3c 3d 3e 3f 3g 3h 3 
3a 2.24118 2.32356 2.21215 2.21711 2.43008 2.71651 2.37370 2.40351 2.59 
3b 2.85131 2.27272 2.82266 2.74012 2.63130 2.14915 2.61124 2.39277 2.89 
4a 1.58321 1.84278 1.54421 1.51062 1.69001 2.14112 1.67881 1.55331 1.97 
4b 1.93602 1.56523 1.86087 2.19957 1.99269 1.47990 1.94527 2.10620 2.15 
5 4.06621 3.42274 4.08286 3.89963 3.31483 3.84875 3.26179 3.51250 3.75 
6 4.68910 4.58166 4.56222 4.60155 4.61615 4.82453 4.46592 4.56429 5.33 
9 5.73692 5.78409 5.48174 5.63899 5.66159 5.87600 5.39268 5.60685 6.03 
10 6.96738 7.20019 6.44755 6.93989 6.77516 7.08141 6.25303 6.93196 6.71 
11 4.51661 4.13061 3.80385 4.40007 4.44166 4.16045 3.75160 4.38619 4.65 
12a 1.79384 1.36831 1.59604 1.89223 1.78962 1.64688 1.61564 1.97798 1.61 
12b 1.85621 1.64542 1.72885 1.74824 1.82915 1.70530 1.73114 1.56171 1.86 
13a 1.37852 1.80335 1.51738 1.42086 1.38660 1.62702 1.54376 1.42343 1.79 
13b 1.87734 1.45117 1.53458 1.92317 1.88175 1.58431 1.56331 2.01198 1.95 
14 4.50477 4.57271 4.24962 4.62705 4.47158 4.52258 4.24105 4.75683 4.96 
15 2.24118 2.32356 2.21215 2.21711 2.43008 2.71651 2.37370 2.40351 1.25 
16 2.85131 2.27272 2.82266 2.74012 2.63130 2.14915 2.61124 2.39277 1.19 
 
 
Table 8.11. Average values of the correlation coefficients for 3a-3h. The “all” refers to 13C 
and 1H results combined using the geometric mean. 
 










Table 8.12. Calculated and experimental 13C shifts (in ppm) for 4a-4h 
 
Pos 13C Corrected Calculated 13C Experimental 
 4a 4b 4c 4d 4e 4f 4g 4h 4 
2 172.2573 175.4740 172.8254 174.2174 173.1978 174.4660 173.8394 176.7563 172.6 
3 28.1900 33.5176 29.3619 29.0701 33.3916 28.9982 34.2576 33.3917 28.7 
4 27.5844 31.0646 28.1599 26.9320 30.6834 26.2397 31.3662 29.4281 27.0 
5 67.8304 71.5647 67.7141 71.6952 74.6114 72.4949 75.3142 71.8438 69.4 
6 72.2884 71.9947 72.9844 74.2143 74.4348 72.9794 75.6235 73.6436 73.3 
8 162.3586 164.0159 163.0119 165.3478 162.6629 165.4222 163.4379 165.5283 164.7 
9 116.8780 117.5679 121.5236 119.0676 117.9121 117.4929 122.2869 120.1752 119.8 
10 153.8496 154.1857 152.1686 156.5895 153.2789 156.9683 152.2059 157.4176 150.7 
11 68.9227 71.1433 73.0605 71.2083 69.9946 71.7948 74.2672 72.0189 69.4 
12 28.9562 31.8610 32.4610 31.8244 30.4184 35.3587 33.9914 32.2089 28.8 
13 29.2728 26.6092 32.3606 29.5440 30.7302 32.3947 34.1070 29.1184 28.0 
14 67.0939 71.7331 67.0183 69.5540 68.8447 69.2402 68.6373 71.2877 69.6 
15 12.5459 15.4499 12.7020 14.3333 16.5985 14.8195 17.2665 13.9608 14.5 




Table 8.13. Calculated and experimental 1H shifts (in ppm) for 4a-4h 
 
Pos 1H Corrected Calculated 1H Experimental 
 4a 4b 4c 4d 4e 4f 4g 4h 4 
3a 2.30034 2.37906 2.26870 2.27614 2.48238 2.76992 2.42321 2.45854 2.36 
3b 2.90414 2.32852 2.87316 2.79356 2.68269 2.20662 2.65999 2.44789 2.72 
4a 1.99834 1.62527 1.92091 2.25879 2.04696 1.54216 1.99614 2.16369 2.07 
4b 1.64918 1.90116 1.60738 1.57721 1.74565 2.19865 1.73054 1.61537 1.81 
5 4.10646 3.47167 4.12085 3.94065 3.36315 3.89406 3.30846 3.55836 4.05 
6 4.72290 4.62364 4.59546 4.63507 4.65861 4.86287 4.50874 4.60146 5.04 
9 5.75987 5.81887 5.50585 5.66140 5.69934 5.90681 5.43255 5.63540 5.97 
10 6.97758 7.22649 6.46208 6.94839 6.80789 7.10360 6.29016 6.94955 6.82 
11 4.55219 4.17530 3.84461 4.43574 4.48490 4.20354 3.79671 4.42483 4.62 
12a 1.85763 1.42953 1.65870 1.95474 1.84480 1.70794 1.66757 2.03653 1.88 
12b 1.91936 1.70499 1.79019 1.81228 1.88416 1.76595 1.78269 1.62370 1.88 
13a 1.94027 1.51189 1.59785 1.98535 1.93652 1.64583 1.61540 2.07024 1.81 
13b 1.44661 1.86196 1.58082 1.48841 1.44361 1.68822 1.59592 1.48656 1.54 
14 4.54047 4.61475 4.28596 4.66030 4.51469 4.56307 4.28460 4.79240 4.84 
15 2.30034 2.37906 2.26870 2.27614 2.48238 2.76992 2.42321 2.45854 1.31 
16 2.90414 2.32852 2.87316 2.79356 2.68269 2.20662 2.65999 2.44789 1.15 
 
Table 8.14. Average values of the correlation coefficients for 4a-4h 




















Table 8.15. 1H NMR spectrum comparison of literature acremodiol and compound 4 
(acremodiol C) 
 
Pos. Literature90* Acremodiol C# 
3 2.72, 2.66 (2 dd, 1H, J = 3.0, 11.3 Hz) 
2.34, 2.28 (2 dd, 1H, J = 3.6, 6.7 Hz) 
2.71, 2.67 (2 dd, 1H, J = 2.7, 11.0 Hz) 
2.33, 2.28 (2 dd, 1H, J = 3.1, 7.2 Hz) 
4 1.78 (m, 1H) 
1.64/1.43 (m, 1H) 
1.79 (m, 1H) 
1.65/1.43 (m, 1H) 
5 3.80 (m, 1H) 3.81 (dt, 1H, J = 3.4, 7.2 Hz) 
6 4.83 (dq, 1H, J = 3.0, 6.7 Hz) 4.83 (qd, 1H, J = 2.8, 6.5 Hz) 
9 5.78 (dd, 1H, J = 2.2, 15.8 Hz) 5.74 (dd, 1H, J = 2.3, 15.7 Hz) 
10 6.83 (dd, 1H, J = 3.0, 15.8 Hz) 6.83 (dd, 1H, J = 2.5, 15.8) 
11 4.47 (m, 1H) 4.46 (m, 1H) 
12 1.72 (m, 2H) 1.71 (m, 2H) 
13 1.64/1.43 (m, 2H) 1.65/1.43 (m, 2H) 
14 4.65 (m, 1H) 4.65 (m, 1H) 
15 1.17 (d, 3H, J = 6.0 Hz) 1.17 (d, 3H, J = 6.6 Hz) 
16 1.07 (d, 3H, J = 6.0 Hz) 1.07 (d, 3H, J = 6.4 Hz) 
* DMSO-d6 , 300 MHz 
# DMSO-d6 , 400 MHz 
 











































Table 8.17. DP4+ Analysis 
 
 1 
 1a (RRR) 1b (RRS) 1c (RSR) 1d (RSS) 
DP4+ 
(H) 
95.41% 4.59% 0.00% 0.00% 
DP4+ 
(C) 




96.78% 3.22% 0.00% 0.00% 
 2 
 2a (RRR) 2b (RRS) 2c (RSR) 2d (RSS) 
DP4+ 
(H) 
72.45% 0.02% 27.53% 0.00% 
DP4+ 
(C) 

























14.26% 0.01% 0.01% 33.06% 33.23% 1.30% 0.01% 18.13% 
DP4+ 
(C) 

























88.36% 0.00% 0.00% 3.35% 7.74% 0.00% 0.00% 0.55% 
DP4+ 
(C) 
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